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CHAPTER 1: General Introduction 
Introduction 
Leishmaniasis is a zoonotic disease endemic in tropical and sub-tropical regions of the 
world. It is caused by intracellular protozoan parasites of the genus Leishmania, which are 
transmitted to the host through the bite of an infected female sand fly. The resulting disease 
depends on the species of Leishmania involved and the type of immune response mounted by 
the host, and it is classically subdivided into three forms: visceral, cutaneous and 
mucocutaneous (reviewed in (109,180,323)). For example, Leishmania infantum, 
Leishmania donovani and Leishmania chagasi are responsible for the visceral form of the 
disease (also referred as Kala Azar); infection with Leishmania major, Leishmania mexicana 
and Leishmania amazonensis results in cutaneous leishmaniasis and Leishmania braziliensis 
is the main etiologic agent of mucocutaneous leishmaniasis (or espundia). However, there are 
some exceptions and Leishmania species usually responsible for visceral disease can 
sometimes be isolated from cutaneous lesions and vice-versa (16,48, 320, 325,436,445). 
During visceral leishmaniasis, Leishmania parasites reside within phagocytes of the 
spleen, lymph nodes, liver and bone marrow, subsequently resulting in splenomegaly, 
lymphadenopathy, hepatomegaly, pancytopenia, hypoalbuminemia and cachexia (211). This 
leads to multi-organ failure, which is often fatal if left untreated. Five percent of the patients 
recovering from visceral leishmaniasis also develop cutaneous lesions, referred to as post-
Kala Azar dermal leishmaniasis (180). Cutaneous leishmaniasis causes lesions of varying 
severity, ranging from a self-limiting ulcer to diffuse skin lesions that may persist for months 
before healing and possibly leaving a permanent scar (180). Mucocutaneous leishmaniasis 
usually results from the metastasis of a previous cutaneous lesion that may have healed years 
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before (reviewed in (322)). However, it is sometimes secondary to a cutaneous lesion that 
extends to adjacent mucous membranes by contiguous spread. The mucosae involved during 
mucocutaneous leishmaniasis include those of the mouth, palate, naso-pharynx, larynx and 
occasionally trachea. The associated lesions are usually severely disfiguring and can be life 
threatening. 
The widespread distribution and the increased incidence of human leishmaniasis has 
hampered the economic development and productibility of several regions of the world 
(144). The disease is currently endemic in a total of 88 countries within Africa, Asia, Europe, 
North America and South America (582). It affects 12 million people around the world and 
350 million are at risk (144). A case of leishmaniasis was also recently described in Australia 
(469). Within the United States leishmaniasis is only occasionally diagnosed, usually in 
people coming back from endemic areas, including soldiers that have served in the Middle 
East (271,320). The first autochthonous case of leishamaniasis in the U.S. has been reported 
in 1940, in a 26 year-old male from Chicago (50). The patient initially developed the muco­
cutaneous form of the disease with subsequent involvement of the bone-marrow. In addition, 
human cutaneous leishmaniasis due to L. mexicana is endemic in Texas (256, 338) and 
sporadic cases of canine visceral leishmaniasis have been documented throughout the United 
States (151, 162,471,518,542). 
There are approximately 1.5 to 2 million new cases of leishmaniasis every year, with 
cutaneous leishmaniasis representing 50 to 75% of them (582). In addition, there is an 
increased incidence of leishmaniasis in immunosuppressed patients infected with HIV (109, 
582). Currently, there is no mti-Leishmania vaccine available and treatment of the disease 
involves aggressive, long lasting chemotherapy that is usually expensive and associated with 
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adverse side effects (54,124, 582). More studies are required before efficient and safe 
prophylactic and/or therapeutic strategies to control leishmaniasis are available. 
The susceptibility of humans to leishmaniasis has been shown to correlate with poor cell-
mediated immunity. In particular, the immune response of infected patients is usually of a 
mixed T helper 1 (Thl) and T helper 2 (Th2) phenotype, and often characterized by the 
production of low to undetectable levels of IFN-y (64, 81,123,432,465). As in humans, 
experimental murine leishmaniasis can have different outcomes depending on the parasite 
strain/species and the genetic background of the host (5, 39,60,108,114, 176,237,463). 
Experimental infection of mice with various Leishmania species has led to an understanding 
of some of the immune mechanisms necessary to control these intracellular protozoa. In 
particular, murine studies of cutaneous leishmaniasis have highlighted some of the immune 
factors correlating with susceptibility and resistance to the disease (reviewed (304)). For 
example, the outcome of murine cutaneous leishmaniasis caused by L. major is determined 
by the phenotype of the CD4+ T cell response: Thl CD4+ T cells producing IFN-y promote 
resistance while Th2 CD4+ T cells producing IL-4 induce susceptibility (reviewed in (455) 
and (480)). Upon infection with L. major, BALB/c mice mount a Th2 response characterized 
by the production of high levels of IL-4; these mice subsequently develop progressive 
cutaneous lesions and succumb to infection. In contrast, C3H and C57BL/6 mice are able to 
control a L. major infection by mounting a protective Thl immune response characterized by 
the production of IL-12 and IFN-y. This resistant phenotype requires a sustained source of 
IL-12 and the expression of IL-12R|32 and T-bet, a Thl associated transcription factor (214, 
218, 234,418,546). This correlates with lesion resolution and very low parasite loads 
(reviewed in (455)). Furthermore, several studies using L. mexicana infection in C57BL/6 
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mice have illustrated how the chronic disease associated with the infection by this pathogen 
is a result of a balance between Thl and Th2 immune effector functions. In this system, the 
inhibition of the Thl signaling pathways through STAT-4 leads to lesion progression (80). 
The infection of IL-4 deficient or STAT-6 deficient mice, animals in which Th2 signaling 
pathways are compromised, results in lesion resolution with low parasite loads and higher 
amounts of IFN-y in recall responses (502,536). However, studies using C3H and C57BL/6 
mice infected with L. amazonensis, a member of the L. mexicana complex of parasites, 
demonstrate that the chronic cutaneous lesions containing up to 10* parasites persist even 
with exogenous administration of the Thl-promoting cytokine IL-12 and IFN-y (41,236). 
This refractoriness to IL-12 correlates with low levels of IL-12 receptor |32 expression on the 
CD4+ T cell population, which remains low even in the absence of the Th2 cytokine IL-4 
(236). These studies suggest that the susceptibility of these mice to L. amazonensis is 
probably multifactorial and results, in part, from an inability to develop an effective Thl 
response, a phenotype that is independent of the presence or absence of IL-4. Therefore, this 
murine model of cutaneous leishmaniasis, in addition to visceral diseases caused by L. 
donovani and L. chagasi in mice, is an experimental system in which Thl responses are 
limited without expansion of Th2 cells (248,586). 
Our laboratory is studying the immune response of C3HeB/FeJ mice infected with L. 
amazonensis. The main focus of our research is to characterize and overcome the immune 
defects associated with the impaired Thl response of L. amazonensis-infected mice. The 
central hypothesis of my work is that a Thl response will provide protection to a L. 
amazonensis infection. The data presented here summarize some of our studies aimed at 
promoting resistance to a L. amazonensis infection. In particular, we have attempted to 
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induce a Thl response in C3HeB/FeJ mice either before or during a L. amazonensis 
infection, and we have subsequently followed the outcome of the disease. We have 
characterized the results and analyzed them in the context of the available Leishmania 
literature: these studies have helped us to understand some of the immune factors necessary, 
or not, for resistance to a L. amazonensis challenge and are relevant to future vaccine or 
immunotherapy strategies. 
Dissertation organization 
The objective of the first study was to promote a Thl immune response in mice 
chronically infected with L. amazonensis. Dendritic cells are the main antigen-presenting 
cells in vitro and in vivo and their potential as prophylactic vaccine adjuvants has been 
exploited to promote an efficient immune response before infection with L. major (53,157, 
574). However, DC-based vaccines have not been tried therapeutically in mice with 
established cutaneous lesions. Our hypothesis was that administration of antigen-pulsed bone 
marrow-derived dendritic cells (BM-DC) and the Thl promoting cytokine IL-12 would 
promote lesion resolution in C3HeB/FeJ mice chronically infected with L. amazonensis. 
The objective of the second study was to test if the Thl response induced in naïve mice 
vaccinated with L. amazonensis antigen-pulsed BM-DC and IL-12 would promote resistance 
to L. amazonensis infection. Protection to a L. amazonensis challenge has been achieved in 
mice by giving parasite Ag, DNA or by adoptively transferring a L. amazonensis-specific 
Thl CD4+ T cell line before the infection (56,82,233,431). This was associated with an 
increase in IFN-y production within the draining lymph node (DLN), suggesting a Thl 
phenotype of the local immune response. Furthermore, Ji et al. showed that CD4+ T cells 
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from the DLN of protected mice had increased expression of mRNA levels for IL-12R(32, 
further supporting that a Thl response could provide protection to L. amazonensis infection 
(233). Therefore, we hypothesized that mice vaccinated with L. amazonensis-pulsed BM-DC 
and IL-12 would resist a subsequent L. amazonensis infection. 
The objective of the third study was to determine if the Thl response of C3HeB/FeJ mice 
that have healed a previous L. major infection can adequately promote protection to a 
subsequent L. amazonensis infection. While the immune response to L. major infection is 
used as a model in this experimental system of murine cutaneous leishmaniasis, it is not 
known if the Thl response elicited by L. major in vivo would provide protection to a 
subsequent L. amazonensis infection. Therefore, it is possible that the immune response 
necessary to promote resistance to L. amazonensis may not be the same as that for L. major. 
Variable degrees of cross-protection between different Leishmania species have been 
previously described (11,14,15,42, 82, 111, 115,161,167,221,222, 280,282,283, 351, 
395,422,431, 526, 571). In particular, one mouse study has reported efficient cross-
protection between L. major and L. amazonensis after co-infection (571). However, cross-
protection was achieved using an avirulent strain of L. major and the associated immune 
response and parasite quantification were not determined. Therefore, we have studied the 
outcome of a L. amazonensis infection in mice sequentially infected with L. major and L. 
amazonensis. We have characterized the associated immune response and parasite loads. 
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Literature review 
L History 
There is evidence that leishmaniasis has a long history as designs of human faces 
reminiscent of the ones of patients with cutaneous and mucocutaneous leishmaniasis were 
found on pottery from 400-900 A.D (144,279). Later, the Bedouin in the desert of Arabia 
described a chronic sore affecting the exposed part of their bodies, called "A1 Okht" or the 
little sister (reviewed in (426)). It is thought that this disease corresponded to leishmaniasis. 
It is only in 1756 that Russell first reported a description of this chronic sore. In 1885 and 
1898, Cunningham and Borovsky, respectively, described organisms in the lesions of patients 
with such disease. In 1903, Wright called these organisms Helcosoma tropicum. At the same 
time, Leishman and Donovan described ovoid bodies in the spleen of human patients in 
India. These were first called Piroplasma donovani by Laveran and Mesnil and then later 
renamed Leishmania donovani by Ross. In 1906, the organism described by Wright was 
named Leishmania tropica (reviewed in (426)). 
2. Leishmania parasites 
Leishmania are intracellular protozoa belonging to the family of Trypanosomatidae 
(Table 1). There are approximately 20 different species of Leishmania parasites and each of 
them is generally responsible for a specific clinical form of the disease (136). However, some 
species usually causing cutaneous disease have been isolated from patients with visceral 
leishmaniasis and vice versa (16,48,320, 325,436,445). For example, L. amazonensis (a 
member of the L. mexicana complex of parasites) usually causes localized cutaneous 
leishmaniasis, but also occasionally diffuse cutaneous leishmaniasis and mucocutaneous 
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leishmaniasis (38,279,498). In addition, it has been recovered from people with visceral 
leishmaniasis (37, 38). 
Leishmania spp. are digenetic parasites, i.e. they adopt two different morphologies in 
their host and vector. The insect vectors harbor the promastigote forms of the parasite, which 
are long, slender and possess an anterior flagellum. In contrast, within the host cells, the 
promastigotes transform into a round, aflagellated form termed amastigotes (reviewed in 
(198)). 
The genome of Leishmania spp. is subdivided into kinetoplastic (i.e. the equivalent of 
mammalian mitochondria) and nuclear genomes. It is composed of 36 chromosomes and the 
genome size is 35 Mb (588). The difference between Leishmania spp. at the 
deoxyribonucleic acid sequence level is estimated to be approximately 15% (114). 
Table 1. Taxonomy of Leishmania parasites (adapted from Dedet et al. (136)). 
Kingdom: Protista 
Subkingdom: Protozoa 
Phylum: Sarcomastigophora 
Subphylum: Mastigophora 
Class: Zoomastigophora 
Order: Kinetoplastida 
Suborder: Trypanosomatina 
Family: Trypanosomatidae 
Section: Salivaria 
Genus: Leishmania 
Sub-genus: Leishmania (Suprapylaria) 
Vianna (Peripylaria) 
Species: major, amazonensis, mexicana, donovani, chagasi, etc. 
3. Vectors 
The main vectors of leishmaniasis belong to the family of Psychodidae and subfamily of 
Phlebotominae (sand flies). Natural transmission of leishmaniasis generally occurs through 
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the bite of an infected female sand fly, either of the genus Phlebotomus (in the Old World) or 
Lutzomyia (in the New World), during its bloodmeal. A link between leishmaniasis and its 
sand fly vector was first observed in 1764 by Cosme (210). However, the first evidence of 
experimental transmission of leishmaniasis through the bite of a sand fly was reported in 
1931 (521). There is evidence that approximately 30 different species of sand flies can act as 
vectors of leishmaniasis (258). In general, each species of sand fly can only transmit some 
specific Leishmania species (reviewed in (479) and (259)). This is referred to as vectorial 
competence and may result from different structures of the lipophosphoglycan (LPG) 
molecules on promastigotes between Leishmania (430). 
Lutzomyia flaviscutellata is considered as the main vector of L. amazonensis. It is a 
nocturnal feeder, abundant in forests that are rarely frequented by man (279). Furthermore, 
there is evidence that Lutzomyia olmeca nociva may also be transmitting L. amazonensis 
(258). In addition, more recently, Lutzomyia nuneztovari anglesi has been reported as a 
vector for L. amazonensis (324). 
Females sand flies require a bloodmeal every 4 to 5 days (244). The blood meal volume 
of a sand fly is estimated around 100-300 nl and the number of transmitted parasites 
evaluated between 25 and 1000 (147,480). 
Although sand flies may not always be required for the transmission of leishmaniasis (see 
below), passage through the sand fly vector is necessary for the parasite cycle to be 
completed. Indeed, the sand fly digestive tract is where the transformation of the ingested 
amastigotes into infective metacyclic promastigotes, takes place (reviewed in (482)). When a 
female sand fly takes its bloodmeal on an infected host, the ingesta containing Leishmania 
amastigotes reaches the midgut where the bloodmeal is confined within a structure called the 
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peritrophic membrane. It is composed of a network of chitin that may protect the parasite 
from digestive enzymes early after the bloodmeal. In addition, it may also later interfere with 
promastigote development and both Leishmania and sand fly derived chitinases are necessary 
for the parasite to escape the peritrophic membrane (reviewed in (482)). The transformation 
of amastigotes into promastigotes takes 12 to 18h (reviewed in (482)). However, it takes 
approximately 6 to 7 days for the complete differentiation of promastigotes towards their 
metacyclic stage, i.e. the infective form that will be inoculated into the host (487,488). Based 
on the location within the gut where promastigotes develop, Leishmania parasites have been 
subdivided into suprapylarian (promastigote development restricted to the midgut and 
foregut) or peripylarian (development of promastigotes within the hindgut) (reviewed in 
(136)). In both groups however, the metacyclogenesis involves a sequential transition of 
promastigotes through different morphological stages, i.e. procyclic (short, ovoid, slightly 
motile), nectomonad (long, slender, highly motile), haptomonads (occasionally dividing) and 
finally metacyclic (unattached, elongated flagellum, thinner, highly motile, never seen 
dividing) (reviewed in (479)). During this transition, the promastigotes migrate toward the 
foregut and proboscis (mouth parts). Ultrastructural studies have shown that Leishmania spp. 
promastigotes, including L. amazonensis, intimately attach to the microvilli of the midgut 
epithelial cells of the sand fly and this may allow the parasites to resist gut peristaltis (261, 
357). Upon feeding on the host, the infected sand fly will inoculate metacyclic promastigotes. 
Experimentally, the isolation of metacyclic L. major promastigotes is achievable as these 
express different cell surface carbohydrates, which results in the loss of their ability to 
agglutinate in the presence of peanut agglutinin (484). 
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4. Saliva 
Many studies have characterized the composition of sand fly saliva. Most of the 
described pharmacologically active compounds from sand fly saliva are from Phlebotomus 
papatasi (vector of L. major) and Lutzomyia longipalpis (vector of L. chagasi). The saliva 
from these sand flies has been shown to contain an array of immunomodulatory molecules 
that have a wide range of actions, including vasodilation, inhibition of blood clotting, 
inhibition of platelet aggregation and downregulation of the innate & adaptive immunity 
(reviewed in (244) and Table 2). The vasodilation and inhibition of platelet aggregation 
inhibits the rapid formation of a blood clot and allow the parasite to be exposed to certain 
serum constituents such as the complement components and natural anti-leishmanial IgM, 
which Leishmania promastigotes use for their subsequent uptake by phagocytes (see 
complement section). The downregulation of the immune response includes the inhibition of 
IL-12, IFN-y and nitric oxide, all of which are important mediators of the protective Thl 
response necessary to heal Leishmania infection. In addition, a recent study has reported that 
the saliva from Lu. longipalpis could inhibit both the classical and alternative complement 
pathways (95). 
Clinically, it has been suggested that qualitative differences within the sand fly saliva 
may have an impact on the severity of the resulting infection. Indeed, Warburg et al. have 
shown that Lu. longipalpis from Costa-Rica produce smaller amounts of maxadilan, a potent 
vasodilator from the saliva, than the Lu. longipalpis vectors from Brazil (579). Interestingly, 
L. chagasi infection has a different outcome in each of these countries: it results in the 
cutaneous disease in Costa-Rica while it causes the visceral form of leihmaniasis in Brazil 
(579). As the parasite isolates from both countries appear identical, this suggests that 
vectorial differences between the Lu. longipalpis from both countries influence the outcome 
of L. chagasi infection. It is also possible that host differences may have accounted for the 
different clinical forms of L. chagasi infection observed in those countries. 
During experimental murine studies, the co-injection of salivary gland homogenates, 
extracts or sonicates (referred to as SGH below) with the parasite inoculum has been shown 
to exacerbate the infection, i.e. to increase lesion size and parasite numbers, in comparison to 
the mice injected with parasites alone (45,57, 307, 331,403,499, 556). This increased 
severity of infection was shown to require functional lymphocytes as SGH did not exacerbate 
the disease in SCID mice (45). When L. major or L. braziliensis were co-injected with SGH, 
the exacerbated disease was associated with an increased IL-4 production in the draining 
lymph node (45, 307, 331). In addition, a decrease in IFN-y, IL-12 and iNOS mRNA but not 
in IL-10 and TGF-|3 mRNA were observed in the draining lymph node of mice infected with 
L. major and the SGH (331). Moreover, the exacerbative effect of the SGH was abrogated in 
mice treated with neutralizing antibodies to IL-4 or in IL-4 deficient mice (45, 307). 
Altogether, these data suggested that saliva could induce a Th2 response, resulting in an 
enhanced host susceptibility. Exacerbation of the disease by sand fly saliva was not observed 
in one mouse study (93). Similarly, co-injection of Leishmania parasites with saliva does not 
seem to affect the course of experimental canine leishmaniasis (416). The reasons for these 
discrepancies are currently unknown. 
The specific effect of the saliva from Lu. flaviscutellata, the vector for L. amazonensis, 
on subsequent L. amazonensis infection remains unknown, as rearing Lu. flaviscutellata in 
the laboratory is difficult. However, it has been shown that mice co-injected with Lu. 
longipalpis SGH and L. amazonensis had increased lesion size in comparison to the controls 
(403,553). This was associated with an enhanced production of IL-4 and IL-10 in the 
draining lymph node; furthermore, the levels of IL-10 mRNA were increased at the lesion 
site (403). Although Lu. longipalpis is not the vector for L. amazonensis, it can transmit L. 
amazonensis under experimental conditions (260). In addition, the geographic distribution of 
Lu. longipalpis overlaps with the one of Lu. flaviscutellata (69). Therefore, it is conceivable 
that saliva from bites of Lu. longipalpis could modulate a subsequent L. amazonensis 
infection in those areas of the world. 
Although the injection of SGH did exacerbate the disease, it remained to be determined if 
sand flies themselves inoculate a substance that would similarly affect the infection. An 
initial study showed that the subcutaneous injection of L. major promastigotes at a cutaneous 
location exposed to the bites of uninfected L. longipalpis one hour earlier resulted in 
increased lesion size in comparison to controls which had not been previously bitten by sand 
flies (553). This confirmed the available data and indicated that during their bloodmeal, sand 
flies also inject a material that is able to exacerbate the infection. However, more recently, 
Belkaid et al have shown that the exacerbation of dermal lesions due to the co-injection of L. 
major and P. papatasi SGH was abrogated in mice pre-exposed with SGH two weeks earlier 
and this correlated with the presence of anti-saliva antibodies in pre-exposed mice (45). The 
reasons for the discrepancies between these results, i.e. lesion exacerbation or not after saliva 
exposure, are unknown; however, the source of SGH was different and when saliva from L. 
major vector sand fly (P. papatasi) was used, it is a lack of exacerbation that was observed. 
Therefore, this suggested that pre-exposure to saliva may have some protective effects. This 
was later supported by a study demonstrating that pre-exposure of mice to the bites of 
uninfected P. papatasi resulted in an increased protection to a subsequent L. major challenge 
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through the bite of infected sand flies (245). This was accompanied by a strong DTH 
response and an infiltrate of IFN-y and IL-12 producing cells at the site of infection. Of note, 
the bites of infected sand flies did not induce an enhanced IL-4 production, suggesting that 
salivary secretions do not promote IL-4, which may be an artifact of whole salivary glands 
homogenate preparation used in the co-injection studies. In addition, these results are 
consistent with what happens in the field: indeed, people living in areas endemic for 
leishmaniasis are known to show attenuated infections, while tourists tend to develop more 
severe disease. Finally, the protection obtained after pre-exposure to saliva indicated that 
immunogenic salivary molecules might be used as components of anti-leishmanial vaccine. 
One such molecule, a 15 kD protein named SP15 has been isolated from salivary glands of P. 
papatasi and used as a vaccine to successfully confer protection to mice subsequently 
infected with L. major (567). Similarly, vaccination against the potent salivary vasodilator 
maxadilan was shown to provide increased resistance to L. major infection (362). 
Table 2. Immunomodulatory molecules from sand fly saliva. 
Molecule Sand fly Activity 
Apyrase Lu. longipalpis 
P. papatasi 
Maxadilan Lu. longipalpis 
Adenosine & AMP Lu. longipalpis 
P. papatasi 
Hydrolyzes ATP and ADP to AMP which 
inhibits platelet aggregation. 
Vasodilation, inhibition of T cell proliferation 
and delayed type hypersensitivity response. 
Anti-platelet aggregation, vasodilation, 
inhibition of IL-12, IFN-y and TNF-a, 
downregulation of nitric oxide synthase gene, 
enhancement of IL-10. 
5' nucleotidase Lu. longipalpis Anti-platelet aggregation and vasodilation. 
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Table 2 (Continued) 
Adenosine deaminase Lu. longipalpis Production of inosine which inhibit IL-12, 
IFN-y, TNF- a and nitric oxide. 
This table has been modified from Kamhawi, 2000, Microbes and Infection. 
5. Atypical transmission 
Although the transmission of leishmaniasis occurs mainly through the bite of an infected 
sand fly, other marginal ways of transmission have been reported. As parasites can be found 
in the blood from both asymptomatic and symptomatic patients (50,110,297, 326,407), 
transmission through the use of contaminated syringes (125) or blood transfer is possible 
(183,276). It appears that blood monocytes are the main source of Leishmania parasites in 
blood samples and these remain infective even after storage in blood banks (139,183). In 
addition, congenital transmission has been described (153, 316,406,595). However, 
infection of the placenta does not always result in vertical transmission as observed in dogs 
infected with L. chagasi (19). Animal to animal propagation of the disease has also been 
reported through direct contacts (281,406). The fact that Leishmania parasites can be 
detected in the nasal secretion of dogs suggests that direct contacts may be a potential, 
although probably unusual, way of transmission within reservoir hosts (69). Finally, 
mechanical transmission via the stable fly Stomoxys calcitrans has been achieved 
experimentally (284). 
Hyaluronidase Lu. longipalpis Creates gaps in the extracellular matrix and 
P. papatasi promote diffusion. 
Unknown protein 
(10000-30000 Da) 
Lu. longipalpis Inhibition of the classical and alternative 
complement pathways. 
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6. Reservoirs 
Depending on the Leishmania species and the geographic area of interest, the main 
reservoirs include small rodents (e.g. rats, gerbils, squirrels), marsupials, wild canids (e.g. 
wolves, foxes), domestic dogs and humans (reviewed in (69) and (29)). Forest rodents and 
marsupials are reservoirs for L. amazonensis, with the rodent Proechimys guyannensis being 
the primary host reservoir (69, 279). The reservoirs for L. mexicana in Texas appear to be the 
southern plain woodrats Neotoma micropus and Neotoma floridana (256, 339). In addition, 
L. mexicana has also been cultured from Neotoma albigula in Arizona (257). 
While dogs have been incriminated as reservoir hosts of visceral leishmaniasis (reviewed 
in (360)), there is only inconclusive evidence that they may have a role as reservoir in the 
transmission of cutaneous leishmaniasis (reviewed in (457)). Programs aimed at eradicating 
infected dogs have taken place in geographic areas where visceral leishmaniasis is endemic 
(28,119,145, 360,415). However, the culling of infected dogs is controversial for ethical, 
emotional and economical reasons. Furthermore, the epidemiological studies that have 
analyzed the effect of culling on the resulting incidence of human leishmaniasis have 
provided conflicting results (28,119,145, 360,415). There are several hypotheses as to why 
the culling of infected dogs did not consistently reduce the incidence of human cases. For 
example, all asymptomatic dogs may not have been eradicated. However, whether these dogs 
are infective to sand flies remains contradictory due to equivocal results (17, 360,560). Also, 
other sylvatic reservoirs probably persisted in the environment, keeping the parasite cycle 
active. 
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In conclusion, it is likely that future eradicating program will require a combination of 
better diagnostic tools to identify infected dogs, the elimination of other potential reservoirs 
and strategies aimed at controlling the vector population (55, 360). 
7. Virulence factors 
7.1. Phosphoglycans 
A variety of phosphoglycans (PGs), i.e. glycoconjugates, are expressed by Leishmania 
spp. (reviewed in (479)). Some of the PGs, such as the lipophosphoglycan (LPG) and 
proteophosphoglycan (PPG) are attached to the parasite surface through 
glycosylphosphatidylinositol (GPI) lipid anchors. In contrast, other PGs are secreted, 
including the secreted proteophosphoglycan (sPPG) and a secreted acid phosphatase (sAP). 
Phosphoglycans in general act as virulence factors: they can inhibit the production of the Thl 
promoting cytokine IL-12 by macrophages and they are notably responsible for the resistance 
to the oxidative burst (428, 532). In particular, virulence properties have been attributed to 
specific PGs, and this is summarized below. 
7.I.A. Lipophosphoglycans 
The lipophosphoglycans (LPG) molecules of Leishmania spp. are mainly expressed on 
promastigotes and have multiple functions that are crucial for the survival and/or uptake of 
the parasites within both their vectors and hosts (reviewed in (563)). LPG molecules have 4 
domains, i.e. a phophatidylinositol lipid anchor, a glycan core, a repeating saccharide-
phosphate region and an oligosaccharide cap. It is present on the entire surface of 
promastigotes, including the flagellum. Although the flagellum is dispensable for 
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macrophage infection, it is indispensable for survival within the sand fly (126). In particular, 
the LPG molecules play a role in attachment to the gut epithelial cells from the sand fly 
(reviewed (479), (482) and (486)). Furthermore, it does promote parasite retention within the 
sand fly vector (486). In addition, the LPG molecules undergo structural changes during 
metacyclogenesis (333). These include elongation due to increased numbers of 
phosphorylated saccharides and changes in the nature of the terminal sugars, i.e. these are 
galactose and arabinopyranose on procyclic and metacyclic promastigotes, respectively. 
These changes explain the loss of PNA agglutinability by metacyclic promastigotes (484). 
Moreover, the modifications in the LPG molecules during metacyclogenesis result in a loss 
of binding to the sand fly gut epithelial cells (482). 
In addition to its importance within the sand fly vector, LPG also acts as a virulence 
factor in the host (reviewed in (563)). Indeed, it can mediate the binding of both 
promastigotes and amastigotes to phagocytes (251,252, 369,551). In addition, using LPG-
deficient parasites, it has been shown that LPG does confer intracellular survival (200, 341). 
Such enhanced viability within host cells may be mediated by the ability of LPG to protect 
the parasites from oxidative damage by scavenging oxygen radicals (99, 341,531). 
Furthermore, LPG can downregulate macrophage functions such as pro-inflammatory 
cytokine production and chemotaxis (160). Similarly, LPG can inhibit signal transduction, 
e.g. protein kinase C activity, within macrophages (142, 143). 
In support of these studies, LPG deficient-L. major parasites are highly attenuated both in 
vitro and in vivo (530,531). In contrast, LPG deficient-L. mexicana are as infective and 
virulent as wild type control, suggesting that LPG does not act as a virulence factor for L. 
mexicana (226). 
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7.1. B. Proteophosphoglycans 
The proteophospoglycans from L. mexicana can activate complement via the mannan 
binding lectin pathway (424). Furthermore, it has been suggested that there may be a 
correlation between the interaction of PPG with the complement and the chronic lesions 
associated with L. mexicana infection. It is thought that PPG released at the site of infection 
may deplete the lesion of complement. This depletion, which is consistent with the finding 
that tissue-derived L. mexicana amastigotes do not have detectable C3 on their surface (423), 
would prevent complement-mediated lysis of the amastigotes. 
7.2. Glycoprotein 63 (gp63) 
The zinc metalloproteinase gp63, also referred as leishmanolysin, is a GPI-anchored 
protein present at the surface of several Leishmania species (68,117, 301). Its expression 
increases during metacyclogenesis (239, 278). Although the development gp63-deficient 
parasites within sand flies is not altered (239), gp63 plays a role in the attachment and 
subsequent uptake of Leishamania parasites to phagocytes (311,336,476). In addition, gp63 
promotes resistance to complement-mediated lysis (74,239). Finally, gp63 is able to degrade 
components of the extra-cellular matrix and to enhance the migration of Leishmania parasites 
within the extra-cellular matrix in vitro, further supporting a role for gp63 in the pathogenesis 
of leishmaniasis (337). 
7.3. Cysteine proteinases 
Cysteine proteinases (CPs) are enzymes common to several Leishmania species, and in 
particular L. mexicana and L. amazonensis (reviewed in (371)). They are not essential for 
parasite growth but act as potent virulence factors (130, 371, 372). L. mexicana has 3 types of 
CPs encoded by the cpa, cpb and cpc genes. Their expression is stage specific: it is increased 
on metacyclic promastigotes with maximal expression in amastigotes (121,371,464). In 
particular, the CPs are mostly localized to the megasomes, i.e. the lysosome-like organelles 
of L. mexicana and L. amazonensis amastigotes (227, 564). In vivo, mice infected with L. 
mexicana promastigotes deficient in one or several of the CPs could control their infection 
and the associated immune response was of the Thl phenotype (13,79,159, 372). 
Furthermore, mice that had controlled a challenge of CPs deficient parasite could resist a 
challenge with wild-type virulent organisms (13). Similarly, immunization of mice with CPs 
from L. amazonensis provided some degree of protection towards a subsequent L. 
amazonensis infection (56). Therefore, this suggested that CPs or CPs deficient parasites 
could potentially be used in vaccine strategies (371). Finally, the degradation of MHC class 
II molecules by L. amazonensis parasites is likely mediated by CPs, thereby suggesting that 
CPs may interfere with adequate parasite-antigen presentation during the course of a 
Leishmania infection (133). This further supports a role for these proteinases as virulence 
factors in vivo. 
7.4. LACK genes 
The early production of IL-4 in susceptible BALB/c mice infected with L. major is 
mediated by a specific subset of CD4+ T cells recognizing the Leishmania homologue of 
mammalian receptor for activated C kinase (LACK) antigen (293). L. major contains four 
copies of the LACK gene in its genome and attempts at generating parasites lacking LACK 
have failed, suggesting that LACK is necessary for parasite viability (254). In addition, L. 
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major containing a single LACK gene showed attenuated virulence, and this was reversed if 
these parasites were complemented with an additional copy of the LACK gene (254). 
Altogether, this suggests that LACK can be considered as a virulence factor of Leishmania 
spp. 
8. Complement activation and subversion 
Upon contact with host blood, promastigotes come into contact with opsonins such as 
natural antibodies and complement components that subsequently trigger the activation of the 
complement cascade (reviewed in (147)). The relationship between Leishmania and the 
complement system are paradoxical as they serve both the host and the parasites (reviewed in 
(365)). 
Complement activation is one of the most effective host defense mechanism against 
infection and both the classical and alternative complement pathways can be activated by 
Leishmania parasites (148, 366,367). The classical pathway of complement activation is the 
main mechanism of Leishmania opsonization in the serum of mammals. It is activated very 
rapidly, with maximum binding reached after 2 to 3 min (148). As a result, C3b is deposited 
on the promastigote surface and acts as the C5 convertase, which will lead to the assembly of 
the membrane attack complex and the subsequent lysis of the parasites. While the alternative 
pathway of complement activation is activated simultaneously, it is slower. However, after a 
few minutes, it is the only complement pathway detectable (148). As a result of complement 
activation, 90% of the inoculated promastigotes are killed 2.5 min after serum contact (148). 
Therefore, it is crucial for Leishmania parasites to rapidly enter host phagocytes to avoid 
complement lysis. To do so, Leishmania spp. have exploited the complement system. For 
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example, C3-opsonized promastigotes adhere to CR1 on erythrocytes or to platelets in 
primate or non-primate mammals (including dog, rabbit, guinea-pig, hamster and mouse), 
respectively (149, 150). This phenomenon has been referred to as immune adherence and its 
purpose is to enhance the uptake of opsonized parasites by professional phagocytes (147, 
396). In addition, the activation of complement by Leishmania parasites was required for 
macrophage chemotaxis to occur (70). This migration of macrophages towards the products 
of complement activation may enhance the killing of Leishmania but alternatively could 
serve as a source of reservoir cells for the parasites. In addition, studies have suggested that 
macrophages can produce sufficient amounts of complement components to opsonize 
Leishmania parasites and subsequently promote their uptake by phagocytic cells (61,589). 
Therefore, Leishmania parasites are able to exploit the host defense mechanisms to enter host 
cells. 
Furthermore, Leishmania parasites have also evolved ways to resist complement 
activation: for example, the infective metacyclic promastigotes are more resistant to 
complement-mediated lysis than the non-infective log-phase promastigotes (148)(also go see 
Sacks Science paper where he discovers the metacyclics). Increased resistance of metacyclic 
promastigotes to complement-mediated lysis correlates with modifications of the LPG 
molecules (444). In addition, a role for the zinc metalloproteinase gp63 expressed by 
promastigotes was incriminated in resistance of L. amazonensis to complement, as gp63 is 
the major binding site for C3 on promastigotes and the presence of proteolytically active 
gp63 correlated with increased conversion of C3b to a form antigenically similar to its 
inactive form iC3b, resulting in a decreased complement-mediated lysis (74,474). However, 
using gp63 deficient L. amazonensis transfected with proteolytically active or inactive gp63, 
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Brittingham et al.showed that gp63 was not necessary for complement fixation (74). In 
addition, it was recently reported that complement resistance by L. amazonensis was gp63 
independent (405). Furthermore, resistance of L. amazonensis to complement-mediated lysis 
was shown to occur after C3b deposition and results from the inhibition of late events from 
the complement cascade, possibly the limitation of C9 to access the parasite surface (404). 
Finally, complement components may also promote parasite survival within host cells. 
Indeed, complement-opsonized L. major promastigotes displayed an increased intra-cellular 
survival in comparison to non-opsonized control (368). In contrast, L. amazonensis 
promastigotes appear to survive efficiently within macrophages even in the absence of 
complement (369). 
9. Uptake by host cells 
Although Leishmania spp. can be taken up by a variety of cell types, including dendritic 
cells (113, 355,442, 573), neutrophils (291,420,473), eosinophils (182,421,429,435) and 
fibroblasts (63, 101, 137,510), macrophages are the main host cells for the parasites 
(reviewed in (369)). As a result, the uptake of Leishmania by phagocytes has mainly been 
studied in macrophages. Most of the data available about the uptake of either promastigotes 
or amastigotes have been consistent with receptor-mediated endocytosis (194, 315,369). In 
addition, amastigotes have been shown to directly adhere to proteoglycans present on the 
surface of mamalian cells (314). Below is a summary of the several receptors that have been 
shown to promote the uptake of Leishmania parasites. 
9.1. Complement receptors 
As mentioned earlier, the opsonization of Leishmania promastigotes by components of 
the complement can enhance attachment and subsequently facilitate their uptake by 
phagocytes (149, 367, 369). Among the complement receptors (CR), CRI, CR3 (Mac-1) and 
CR4 have all been shown to play a role in binding and uptake of Leishmania. 
Immune adherence, i.e. the adhesion of C3-opsonized promastigotes to CR1 on 
erythrocytes, is one of the earliest events that occur after infection and it may facilitate 
parasite uptake by phagocytes (147, 149). In addition, while L. major can bind CR1 on 
macrophages, antibodies to CR1 could not inhibit the phagocytosis of serum-opsonized 
promastigotes (128,470). Finally, the binding of L. amazonensis to macrophages does not 
seem to involve CR1 as the blocking of this receptor did not affect parasite binding (369). 
Altogether, this data suggest that, in general, CR1 may just play a minor role in facilitating 
parasite entry into macrophages. 
Multiple studies have reported the binding of Leishmania spp. promastigotes and 
amastigotes to CR3 on macrophages (61,194,250,370,470,585). CR3 preferentially binds 
the iC3b form of the C3 molecule that may be present on the surface of opsonized parasites 
(369). In addition, ligands for CR3 on promastigotes include the zinc metalloproteinase gp63 
and the Leishmania LPG (364,475-477,551). A role for gp63 in binding and subsequent 
phagocytosis by macrophages was further supported by studies using blocking antibodies 
(476) and after transfection of gp63-deficient parasite with gp63 (311, 336). The 
phagocytosis of L. major by Langerhans cells was also shown to involve CR3 and the uptake 
was blocked by anti-CR3 antibodies (62). Although L. amazonensis promastigotes were 
shown to bind CR3 (370), their enhanced binding to macrophages in the presence of 
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complement is minimal (369). In addition, it appears that L. amazonensis amastigotes do not 
bind CR3 (369). Finally, the uptake of both L. amazonensis promastigotes and amastigotes 
by dendritic cells has been described (442). Pre-incubation of the parasites with immune 
serum, but not C3, enhanced the uptake of parasites by DC, and this was more pronounced 
when amastigotes were used. 
While both L. major and L. amazonensis promastigotes can adhere to CR4, the role of 
this receptor is minor in comparison to the one of CR3 (370). 
9.2. Fc receptor (FcR) 
The cell surface of phagocytes contains a variety of Fc receptors that can bind the Fc 
portion of immunoglobulins. Upon ligand binding, these receptors will positively or 
negatively activate the cells, depending on the type of signaling motifs present in their 
cytoplasmic tail (433). There is evidence that Fc receptors play a role in the uptake of 
Leishmania parasites (194,209, 369,423). Promastigotes are unlikely to interact with 
abundant Leishmania-specific antibodies. In contrast, the surface of tissue-derived 
amastigotes isolated from lesions of Leishmania-infectzd mice, are coated with antibodies of 
different isotypes (194,246,423). As a result, the binding and uptake through the Fc receptor 
may be particularly relevant for amastigotes entry into host cells. Indeed, the phagocytosis of 
amastigote by macrophages, dendritic cells or fibroblastoid cell lines was enhanced when 
previously opsonized with immunoglobulins (194,423,442). Although the ligation of FcR 
generally induces a respiratory burst, it appears that Leishmania parasites taken up through 
FcR can survive for several days intracellular^ (194,590). This suggests that Leishmania 
has evolved ways to counteract or resist the detrimental effects of the respiratory burst. For 
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example, it has been reported that the uptake of amastigotes by macrophages through their 
FcyR triggered the production of IL-10, which in turn contributed to the enhanced 
intracellular parasite growth (246). The subversion of the FcyR signaling pathways by 
Leishmania parasites to their advantage is further supported by studies showing that mice 
lacking FcyR develop only minimal lesions when infected with L. amazonensis and L. pifanoi 
(262). 
9.3. Lectin-like receptors 
Macrophages and/or dendritic cells express a series of lectin-like receptor on their 
surface, including the mannose fucose receptor (MFR), the receptor for advanced 
glycosylation end-products and/or dendritic cell- specific ICAM 3 grabbing nonintegrin (DC-
SIGN), all of which have been incriminated in the binding and uptake of Leishmania 
parasites. 
9.4. Mannose Fucose Receptor 
Several studies have reported a role for the MFR in the binding and uptake of 
promastigotes from different Leishmania spp. (61,584,585). In contrast, the MFR does not 
seem to be used by L. major and L. amazonensis amastigotes, supporting the fact that 
promastigotes and amastigotes may use different sets of receptors to enter host cells (194, 
369). 
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9.5. DC-SIGN 
DC-SIGN is a C-type lectin expressed on the surface of dendritic cells; it has been 
involved in the recognition and binding of several pathogens (569). In particular, the binding 
and uptake of L. infantum and L. pifanoi promastigotes and amastigotes can be mediated by 
DC-SIGN (113,116). In contrast, DC-SIGN does not appear to be an important receptor for 
L. major uptake (113). Finally, while L. mexicana LPG could interact with a DC-SIGN 
chimeric molecule (24), there is recent evidence that the binding of L. infantum, L. pifanoi 
and L. donovani to DC-SIGN is LPG independent (113). 
9.6. Fibronectin receptor 
There is evidence that the binding and uptake of Leishmania spp. by macrophages 
involve the fibronectin receptor (73,462,591). In particular, gp63 harbors a region 
antigenically similar to a region from fibronectin and thereby mediate the binding to the 
fibronectin receptor (73,462). However, this adhesion was enhanced in the presence of 
complement, suggesting that the fibronectin receptor may cooperate with complement 
receptors to mediate parasite uptake (73). 
10. The parasitophorous vacuole (PV) 
Within host phagocytes, Leishmania parasites reside within vacuoles termed 
parasitophorous vacuoles (PV). These vacuoles have mainly been characterized in 
macrophages (reviewed in (23)). The PV in which parasites from the L. mexicana complex 
reside rapidly expand to form large vacuoles (22,120,449). There is evidence that this 
expansion of the PV is mediated by proteophosphoglycans (PPG) secreted by intracellular 
amastigotes (425). In general, the PV have characteristics of the late endosomal-lysosomal 
compartments, as they contain phosphatases, hydrolases, express lysosomal-associated 
membrane proteins (LAMPs) and the vesicular proton-ATPase (22,102,120,286,478). As a 
result, the PV represent an acidic compartment characterized by a pH reaching 4.7 to 5.2 
early after infection and it is likely that Leishmania spp. have evolved ways to resist in such 
acidic environment (22). In addition, there have been several reports of the localization of 
MHC class II molecules within the PV, suggesting that Leishmania parasites may interfere 
with antigen presentation (20,21,285,286). 
More recently, the characteristics of the PV from Leishmania-infected DC have been 
described. In general, the PV from L. amazonensis-infected DC are very similar to the ones 
from macrophages infected with the same parasite. Indeed, they were also acidic, expressed 
molecules typical of late endosomes/lysosomes, and contained both MHC calls II and H-2M 
molecules (442). However, in contrast to the PV of infected macrophages, the ones from DC 
were poor in cathepsins B, H, L & D, and lesser number of PV expressed rab7p, a protein 
involved in the fusion of late endosomes/lysososmes. In addition, the enlargement of the PV 
was less pronounced in DC than in (442). 
11. Immune evasion 
11.1. Evading MHC class II presentation 
In vitro studies using both macrophages and dendritic cells have shown that Leishmania 
parasites, and in particular L. mexicana and L. amazonensis, can internalize MHC class II 
molecules and H2M, an enzyme that catalyzes the formation of MHC class II-peptide 
complexes (21,133,442). Intracellularly, these are localized within the megasomes, i.e. the 
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lysosome-like organelles of Leishmania amastigotes. In addition, there is evidence that 
MHC class II molecules and most likely H2M are degraded by parasitic cysteine proteinases 
(21, 133). Altogether, this suggests that Leishmania spp. may have evolved ways of evading 
the MHC class II pathway of antigen presentation, which could explain the poor immune 
response elicited by L. mexicana and/or L. amazonensis. However, the surface expression of 
MHC class II molecules on the surface of infected macrophages appeared normal, indicating 
that the sequestration of MHC class II molecules by intacellular amastigotes may not be 
biologically relevant (21,285,443). This was further supported by a recent study using L. 
mexicana showing that although H2M colocalized with the vacuoles containing parasites, the 
antigen presenting activity of infected macrophages was only minimally reduced (51). 
11.2. Apoptotic mimicry 
A recent study has shown that the surface membrane of L. amazonensis amastigotes 
express phosphatidylserine, a lipid typically exposed within the membrane of apoptotic cells 
(131). During the in vivo steady state, the elimination of apoptotic cells by macrophages does 
not elicit an overt inflammatory response as these cells are recognized as self. Similarly, de 
Freitas Balanco et al. suggest that L. amazonensis amastigotes use their expression of 
phosphatidylserine as a Trojan horse, to facilitate their entry into host cells, i.e. macrophages. 
Indeed, the blocking of phosphatidylserine reduced L. amazonensis infectivity in vitro and in 
vivo, and decreased the production of nitric oxide and TGF-|3 by macrophages (131). 
12. Experimental leishmaniasis 
Experimental studies of leishmaniasis have been performed in several animal species 
including non-human primates, dogs, hamsters and mice (reviewed in (217)). In particular, 
due to their small size, their affordable cost, the diversity of the available genetic 
backgrounds and the possibility to have animals deficient in certain specific gene/molecules, 
inbred strains of mice have emerged as the most commonly used animal models of 
leishmaniasis. The factors that influence the outcome of a Leishmania spp. infection in mice 
are multiple and notably include the genetic background of the host, of the inoculating dose 
of parasites used, the anatomic location of the primary infection and/or the gender. 
Inbred strains of mice have helped uncover some of the immune mechanisms associated 
with resistance and/or susceptibility with the disease. For example, after a L. major infection, 
BALB/c mice mount a Th2 response and subsequently develop progressive, eventually fatal 
lesions. In contrast, C3H, C57BL/6 or C57BL/10 mice are resistant to L. major,; this 
correlates with a strong Thl immune response (reviewed in (480)). However, when these 
same mice are infected with L. amazonensis, they develop chronic cutaneous lesions (5,236, 
525). The susceptibility of these mice to L. amazonensis does not result from a strong Th2 
response; instead, the associated immune response of the mixed Thl/Th2 phenotype. In 
addition, using genetically defined inbred strains of mice has allowed the identification of 
specific genes linked to disease control or susceptibility; these include Scl-1, Scl-2, MHC 
and Nrampl/Lsh/Bcg genes (reviewed in (59)). 
The absolute numbers of Leishmania promastigotes used to experimentally inoculate 
mice also have an impact on the subsequent clinical outcome of the disease. The inoculating 
dose can be classified as to a "high dose challenge" (usually in the order of 10s parasites or 
more) and a "low dose challenge" (usually 104 parasites or less). For example, CBA mice 
develop non-healing and self-healing lesions when infected with high and low doses of L. 
major, respectively (440). In addition, while BALB/c mice infected with high doses of L. 
major display progressive lesions, they develop minimal footpad swelling when challenged 
with low doses of parasites (72,122, 329). A similar correlation between the infecting dose 
and the resulting footpad swelling has been described in BALB/c mice infected with L. 
amazonensis (122). However, while BALB/c mice inoculated with as low as 10 L. major can 
later resist a higher dose challenge, BALB/c mice immunized with 10 L. amazonensis 
promastigotes can not control a subsequent infection composed of 1000 L. amazonensis 
parasites (72, 122). 
Several studies have reported that the clinical presentation of the disease varies 
depending on the anatomical site of infection, and this seems to be partly dependent upon the 
host strain (361). In general, mice are more susceptible to L. major when infected at the base 
of the tail than when they are challenged in the ear or the footpad (33,267,439). In contrast, 
the opposite effect was observed in SWR mice infected with L. major, i.e. the disease was 
less severe when mice were infected in the footpad than at the base of the tail (392). 
Finally, it has been reported that the host gender may influence the pathogenesis of 
leishmaniasis. In particular, the gender effect appears to be dependent upon the species 
and/or strain of the host. Indeed, the disease associated with the infection of hamsters with L. 
panamensis or L. guyanensis is more severe in males (i.e. larger lesion size, higher parasite 
load and increased spreading to distant cutaneous sites) than in females (559). In contrast, the 
opposite trend is observed in B10.129 mice infected with L. major, i.e. males are more 
resistant than females (166). However, in BALB/c mice, both genders are equally susceptible 
to L. major (166). 
13. The Immune Response of infected mice 
13.1. The CD4+ T cell response and associated cytokines 
The CD4+ T cell compartment of both mice and humans has been subdivided into two 
subsets, i.e. T helper 1 (Thl) and T helper 2 (Th2), based on their cytokine production 
profiles (reviewed in (303)). Thl responses are characterized by the production of IFN-y and 
IL-12 while Th2 responses are associated with the secretion of IL-4, IL-10 and/or IL-13. A 
critical role for each of these responses has been highlighted in murine studies of L. major 
infection, as Thl and Th2 CD4+ T cells promote resistance and susceptibility to the disease, 
respectively. 
13.1.A. Leishmania major 
Among all the Leishmania species, L. major is the most studied. The immune response 
associated with L. major infection is very well characterized and has led to an understanding 
of some of the immune mechanisms necessary to control these intracellular protozoa 
(reviewed in (455) and (480). Most strains of mice (C57BL/6, C3H, CBA, 129Sv/Ev) are 
resistant to an infection with L. major, this is characterized by the development of a transient 
lesion that subsequently heal. In contrast, BALB/c mice are highly susceptible to a similar 
infection and develop progressive lesions. As mentioned above, studies from the late 1980s 
have shown that resistance to L. major infection correlated with the expansion of Thl CD4+ 
T cells while Th2 CD4+ T cells promoted susceptibility (205,515). 
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13.1.A.1. IFN-y 
The production of IFN-y, characteristic of Thl immune responses, appears critical for 
lesion resolution. In particular, IFN-y produced by Thl cells signals through STAT-1 and 
induces the expression of T-bet, a Thl specific transcription factor (3). While draining lymph 
node cells from resistant mice produce large amounts of IFN-y in response to antigen 
stimulation in vitro, the ones from susceptible mice only secrete low to undetectable levels of 
IFN-y (206,491, 513). The primary source of IFN-y is the CD4+ T cell population (206). In 
addition, resistant mice deficient in IFN-y production or treated with antibodies against IFN-y 
mount a Th2 response and cannot control the disease (49,104,204,292,294,490,513,543, 
578). In particular, the timing of the administration of anti-IFN-y antibodies was critical since 
it was only effective when given at the time of infection, suggesting that the levels of IFN-y 
at the time of infection were critical to determine the phenotype of the subsequent immune 
response, i.e. Thl vs Th2 (49, 513). In addition, mice will subsequently heal if the antibody 
treatment is abrogated (219). Furthermore, regardless of the production of IFN-y, several 
studies have shown that the IFN-y signaling pathway needed to be intact for lesion resolution 
to occur. First, mice lacking the IFN-y receptor developed progressive lesions after L. major 
infection, despite the presence of IFN-y-producing CD4+ T cells (269,468,543). Second, 
genetically resistant mice lacking STAT1 were unable to mount a Thl response and 
subsequently became susceptible to L. major infection (468). Similarly, mice lacking T-bet 
developed non-healing lesions after a L. major challenge and this susceptibility correlated 
with the presence of CD4+ T cells producing predominantly Th2 cytokines (546). 
Finally, while susceptible mice given exogenous IFN-y or infected with Leishmania 
parasites expressing IFN-y did initially develop smaller lesions, they still produced Th2 
cytokines and display progressive disease (313,513,558). This suggests that IFN-y alone is 
not able to promote protection and that other Thl specific factors may be required to reverse 
the Th2 response of naturally susceptible mice. 
13.1.A.2. IL-12 
Interleukin 12 is produced by different cell types including dendritic cells, macrophages, 
B cells and polymorphonuclear neutrophils (reviewed in (163) and (561)); it signals through 
STAT-4, promotes the production of IFN-y and favours Thl differentiation of the CD4+ T 
cells (reviewed in (163) and (561)). The bioactive IL-12, i.e. IL-12p70, is a heterodimeric 
cytokine composed of 2 subunits: IL-12p40 and IL-12p35. Its receptor is also composed of 2 
subunits, i.e. IL-12Rpl and IL-12R|32. While IL-12R|31 is mainly responsible for the binding 
of IL-12, IL-12RJ32 is necessary for the signal transduction triggered by IL-12 (reviewed in 
(163) and (561)). In addition, IL-12R|32 expression is induced by T-bet and is a marker of 
Thl responses as Th2 cells lose its expression (3, 373, 545). As a result, IL-12 
responsiveness has been considered as a major component of protective responses towards 
Leishmania infection (214, 234). 
The role of IL-12 in the protective response to L. major has been highlighted by studies 
showing that its exogenous administration to susceptible mice at the time of infection, but not 
later, was associated with enhanced protection, e.g. smaller lesion size and parasite burdens 
(207,295,418,544). This was associated with an enhanced Thl response as determined by 
an increased production of IFN-y and decreased IL-10 and IL-4 expression (207,544,578). 
Furthermore, while the protective response was IFN-y-dependent, the suppression ofIL-10 
and IL-4 were IFN-y-independent, suggesting that IL-12 can suppress Th2 responses 
independently of IFN-y (207,294, 578). Conversely, the administration of monoclonal 
antibodies against IL-12 to resistant mice during the acute phase of disease resulted in an 
inhibition of pro-inflammatory chemokine expression, increased IL-4 production, decreased 
secretion of IFN-y and the development of large lesions (204,219,544,599). However, if the 
duration of anti-IL-12 treatment was only transient, a switch for a Th2 to a Thl response was 
observed and the mice subsequently healed (218,219). This reversal of the phenotype of the 
immune response could be explained by the maintenance of a state of IL-12 responsiveness 
by the CD4+ T cells. Indeed, in contrast to BALB/c controls, the CD4+ T cells from anti-IL-
12 treated resistant mice had maintained their expression of both IL-12 receptor (218). In 
addition, studies using mice lacking either the p40 or the p35 subunit of IL-12 have further 
supported the crucial role of IL-12 during L. major infection (329, 330,417,418). 
Furthermore, it has been demonstrated that a sustained production of IL-12 was necessary to 
maintain a protective Thl immune response, notably by preventing the loss of Thl cells (417, 
418,541). 
While IL-12 is critical during the protective immune response toward L. major, an intact 
IL-12 signaling pathway is crucial as well. The relative expression of the IL-12R subunits 
after L. major infection was shown to correlate with the outcome of the disease (214,234). In 
addition, STAT-4 or IL-12R|32 deficient mice were shown to develop large, non-healing 
lesions when infected with L. major, this susceptibility correlated with an impaired IFN-y 
production in the draining lymph node (96,537). Finally, while the expression of IL-12R|32 
appear necessary for the control of the disease, it is not sufficient as demonstrated by the fact 
that BALB/c mice bearing a transgenic IL-12R(32 gene were unable to control a L. major 
challenge (399). 
13.1.A.3. IL-4 
In contrast to resistant strains of mice, susceptible mice produce a rapid burst of IL-4 
after a L. major infection (292,294,295,513). The early production of IL-4 of susceptible 
mice ensures the differentiation of CD4+ T cells towards a Th2 phenotype, downregulates the 
expression of IL-12R|32 and thereby induces a state of IL-12 unresponsiveness (213,214, 
295, 545). CD4+ T cells have been shown to be the main source of IL-4 in susceptible mice 
(206). In particular, the early IL-4 response of susceptible mice is elicited by a population of 
CD4+ T cells expressing the V(34-Va8 TCR chains that recognize the I-Ad-restricted epitope 
LACK, i.e. the Leishmania homolog of mammalian receptor for activated protein kinase C 
(RACK1) (293). Interestingly, V|34-Va8 CD4+ T cells are also the source of IL-4 in resistant 
mice treated with either anti-IL-12 or anti-IFN-y antibodies (292). 
The induction of a resistant phenotype in susceptible mice infected with L. major can be 
easily achieved by either giving exogenous Thl cytokines or by blocking the early source of 
IL-4. For example, BALB/c mice that were either V(34 deficient or rendered tolerant to 
LACK antigen developed a stronger Thl response that mediated disease control (213,240). 
In addition, treatment of susceptible mice with anti-IL-4 at the time of infection allowed the 
development of a protective Thl response and disease control (104,105,205, 313,490). 
Similarly, the prevention of the early burst of IL-4 can be induced by exogenous 
administration of IL-12 or IFN-y at the time of infection (295). It is critical that the IL-12 or 
the anti-IL-4 treatments are given at early timepoints after infection to effectively prevent the 
early peak of IL-4 (295). However, if the infective inoculum contains only 103 parasites, the 
anti-IL-4 treatment remains effective as long as 6 months post-infection (565). 
Resistant mice have an inherent tendency to develop a Thl response and the outcome of 
disease cannot be reversed by exogenous administration of IL-4 like in BALB/c mice, unless 
the source of IL-4 is persistent, as in IL-4 transgenic mice (105,298, 313,492). 
To further assess the role of IL-4 during a L. major infection, studies have been 
performed in IL-4 or IL-4R deficient mice. These have provided conflicting results, as both 
resistance and susceptibility have been reported in these mice after L. major infection (269, 
273,353,400,402). However, it appears that these discrepancies may result from differences 
in the strain of L. major used (402). Furthermore, the definition of "resistance" is not similar 
among authors and it is not uncommon in experimental systems using BALB/c mice to 
consider resistance as the absence of progressive disease. 
Paradoxically, while IL-4 has been shown to be a major cytokine driving Th2 responses, 
it may also promote Thl development. First, it has been shown that IL-4 can enhance the 
production of bioactive IL-12 by dendritic cells (58,216). Second, the administration of IL-4 
to BALB/c mice during the initial activation of dendritic cells, i.e. before T cell activation, 
induced resistance to L. major infection (58). This protective effect was associated with a 
Thl response, correlated with an enhanced production of IL-12 by dendritic cells within the 
draining lymph node, and was abrogated by anti-IL-12 (58). Finally, when susceptible and 
resistant mice, in which the IL-4 gene was linked to green fluorescent protein, were infected 
with L. major, both strains displayed similar percentages of IL-4 expressing-cells, further 
supporting that IL-4 could have implications in both Thl and Th2 development (540). 
In conclusion, while IL-4 may be required for the induction of both Thl and Th2 
responses, the early burst of IL-4 is only observed in susceptible, but not resistant, mice 
infected with L. major. Therefore, the modulation of the IL-4 response to promote healing 
has only relevancy in the BALB/c model of leishmaniasis. 
13.1.A.5. IL-13 
Interleukin 13 is a cytokine with similar properties to IL-4 (reviewed in (592)). It also 
uses the IL-4Ra chain and STAT-6 for signaling. As a result, while IL-4 deficient mice 
retain normal IL-13 functions, IL-4Ra deficient mice have a defective IL-4 and IL-13 
signaling. The role of IL-13 during L. major infection has been studied in mice lacking IL-4, 
IL-4R or STAT6 or in mice given anti-IL13, and the results are somewhat controversial. 
Most studies have suggested that in susceptible mice, IL-13 has a deleterious effect on the 
disease outcome and that it may act synergistically with IL-4 (141, 328,402). However, other 
studies have failed to attribute a detrimental role for IL-13 during L. major infection (274, 
353). These discrepancies may result from the use of different strains of L. major and/or from 
different inoculating dose of parasites. 
13.1.A.6. IL-10 
Interleukin 10 is classified among the Th2 cytokines. However, only at early timepoints 
after L. major infection do susceptible mice produce significantly more IL-10 than resistant 
mice (103, 524). Although CD4+ T cells represent the main source IL-10 in susceptible mice 
(103,206), macrophages can also produce IL-10 and in vitro studies have shown that this 
cytokine can enhanced the intracellular survival of L. major (246,572). In addition, 
transgenic mice from a resistant background, in which the IL-10 gene was under the MHC 
class II promoter, developed progressive lesions when infected with L. major, indicating a 
deleterious role for this cytokine (185). It is interesting to notice that when the IL-10 
transgene was under the IL-2 promoter, the course of the disease was not altered (195). It is 
likely that IL-2 is not abundant during a chronic infection and that the levels of IL-10 
secreted by these mice may not have been high enough to modulate the outcome of disease. 
In addition, there is further evidence that IL-10 plays an immunomodulatory role during a L. 
major infection. Indeed, susceptible mice lacking IL-10 or in which the IL-10 signaling is 
blocked are able to control the disease (246,401). In contrast, one study has reported 
susceptible mice given anti-IL-10 before L. major infection still developed a Th2 response 
and progressive lesions (103). However, it is possible that the exogenous administration of 
anti-IL10 antibodies may not have been as efficient as knocking-out the IL-10 gene, thereby 
explaining these conflicting results. 
Altogether, these data suggest that the production of IL-10 can be detrimental for the host 
during a L. major infection. 
13.1.B. Leishmania donovani and Leishmania chagasi 
BALB/c mice and C3H mice are considered susceptible and resistant, respectively, to the 
infection with the visceralizing species L. donovani and L. chagasi (586,587). However, 
spontaneous resolution is the natural outcome in both strains of mice and the only difference 
relies in an initially higher parasite burden within the liver of BALB/c mice while the splenic 
parasite load remains low during the course of infection in both strains of mice (586,587). 
While the susceptibility to the visceral disease of mice does not correlate with the expansion 
of Th2 cells, the induction of a Th2 response could exacerbate the course of L. donovani 
infection (248, 385,586). In these mice however, the administration of exogenous IL-12 or 
IFN-y could reverse the susceptible phenotype (385). In addition, there is evidence that the 
production of IFN-y is critical for protection (247,248, 390, 391,533, 586). For example, 
IFN-y deficient mice have an exacerbated disease, which is eventually controlled during later 
stages of the disease and this correlated with an enhanced production of TNF-a (552). 
Furthermore, the enhanced susceptibility of mice lacking IFN-y could be reversed by 
exogenous administration of IL-12; this curative effect was also TNF-a mediated (552). The 
neutralization of IL-12 led to an increased parasite burden in the liver and spleen of 
susceptible but not resistant mice (154). 
Several studies have reported that the limitation of the antigen-specific responses, e.g. 
IFN-y production, during visceral disease was mediated by macrophages (169, 384,586). In 
particular, in susceptible mice infected with L. chagasi, the impaired production of IFN-y 
within hepatic granulomas and was mediated by TGF-fJ (586,587). TGF-(3 is an 
immunomodulatory cytokine that has been shown to block Thl differentiation by inhibiting 
T-bet and IL-12R02 expression, although the effect of TGF-(3 on IL-12R(32 expression has 
been recently challenged (177,178). As TGF-|3 levels are high in the hepatic granulomas 
from BALB/c but not from C3H mice, it suggests that this cytokine may be a strong 
immunomodulator in BALB/c mice while it is likely innocuous in C3H mice. 
Whereas there was no evidence of an immunomodulatory role for IL-10 during L. 
chagasi infection, studies have reported such a role in mice infected with L. donovani (383, 
386,587). Indeed, IL-10 deficient mice or mice given anti-IL-10R were able to control the 
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infection faster than wild-type controls and this was associated with an enhanced Thl 
response (383, 386). Finally, IL-10 transgenic mice infected with L. donovani have been 
shown to develop higher, uncontrolled, parasite burdens, further supporting a detrimental role 
for IL-10 during a L. donovani infection (386). 
13.1.C. Leishmania mexicana 
Most inbred strains of mice are susceptible to L. mexicana infection. In contrast to what 
is observed in mice susceptible to L. major, the susceptibility to L. mexicana is not associated 
with an early burst of IL-4 (188). However, experimental murine studies using L. mexicana 
have illustrated how the associated cutaneous disease is also a result of a balance between 
Thl and Th2 immune effector functions. In this system, the inhibition of the Thl signaling 
pathways through STAT-4, IFN-y or iNOS lead to lesion progression (80). In addition, mice 
in which Th2 signaling pathways are compromised, i.e. lacking STAT-6, IL-4, IL-4Ra, IL-
13 or both IL-4 and IL-13, did not develop lesions after L. mexicana infection and such 
protection was characterized by higher amounts of IFN-y produced in recall responses (12, 
466,502,536). Although there is conflicting data about the role of IL-13 during L. mexicana 
infection, it appears that while IL-13 deficient mice develop similar lesions than wild-type 
mice during the early stage of disease, they ultimately heal with time (12,466). The lack of 
IL-10 did not modify the course of the disease, unless IL-4 was absent too (412). Finally, the 
role of IL-12 during L. mexicana infection has also been controversial. While it was 
suggested that the susceptibility to L. mexicana resulted from an inability to produce IL-12, 
the course of disease was similar between IL-12p40 deficient mice and wild-type controls 
(80,466). Altogether, this suggested a new IL-12p40 independent but STAT-4 dependent 
pathway of controlling L. mexicana infection (80). However, another study has reported that 
although IL-12p40 is not required for the early control of a L. mexicana infection, it was 
critical for controlling the late stages of infection (7). The discrepancies between those 
studies may result from differences strains of parasite strains or inoculum doses used. 
13.1.D. Leishmania amazonensis 
L. amazonensis induces non-healing lesions in mice that are both susceptible (e.g. 
BALB/c) and resistant (e.g. C3H, C57BL/6 or C57BL/10) to L. major. Susceptibility does 
not correlate with the expansion of Th2 cells but rather with a mixed Thl/Th2 immune 
response, characterized by the production of low to undetectable levels of both IFN-y and IL-
4 (5, 232,236). While BALB/c mice infected with L. amazonensis develop uncontrolled 
disease, C3H, C57BL/6 and C57BL/10 mice develop a single chronic cutaneous lesion (5, 
233,235,413,446). Furthermore, it is important to notice that although C3H, C57BL/6 and 
C57BL/10 mice are susceptible to L. amazonensis infection, the resulting lesions are not 
progressive but rather persistent over time. Indeed, their lesions reach a plateau at 
approximately 8 to 10 weeks post-infection and persist as such over time. This suggests that 
despite their overall susceptible phenotype, these mice are able to partially control the 
infection. This was further supported by a study in which C57BL/10 mice had their draining 
lymph node surgically removed before infection with L. amazonensis (454). These mice 
developed progressive lesions with occasional spreading to other cutaneous locations and/or 
death, in comparison to the sham-operated control mice. 
Attempts at modulating the immune response before or during the course of L. 
amazonensis infection have generally been unsuccessful. In BALB/c mice, which are 
generally very sensitive to the modulation of the Thl/Th2 cytokine balance, as mentioned 
earlier, the injection of anti-IL-4 or anti-TGF-(3 induced a Thl response and subsequent 
control of the disease (5,40). Despite this apparent healing response, the infected feet of 
these mice were still swollen and/or contained high parasite loads (5,40). In addition, the 
lack of IL-10 or the exogenous administration of IFN-y to BALB/c mice did not alter the 
course of disease (41,412). In C3H, C57BL/6 and C57BL/10 mice, the manipulation of the T 
helper response has not been successful either. Indeed, such mice lacking IL-10, IL-4 or 
given anti-IL-4 still developed chronic cutaneous lesions after a L. amazonensis challenge (5, 
233,235,236). In addition, mice remained susceptible after exogenous administration of IL-
12 (236). This refractoriness to IL-12 correlated with low levels of IL-12R(32 expression on 
the CD4+ T cell population, which remained low even in the absence of IL-4 (233,236). 
Furthermore, it has been suggested that IL-12 production may be limited during L. 
amazonensis infection (236,446). Finally, while TGF-|3 seems to limit the production of 
IFN-y during the infection of C3H mice with L. chagasi, this does not seem to play a major 
role in L. amazonensis-infected C3H, as anti-TGF-p did not affect the percentage of IFN-y 
producing cells in these mice (236). Altogether, these studies suggest that the susceptibility 
of these mice to L. amazonensis is probably multifactorial and results, in part, from an 
inability to develop an effective Thl response. Therefore, the murine model of cutaneous 
leishmaniasis caused by L. amazonensis is, in addition to visceral diseases caused by L. 
donovani and L. chagasi in mice, an experimental system in which Thl responses are limited 
without expansion of Th2 cells (248, 586). 
13.2. CD4+ CD25+ regulatory T cells 
CD4+ CD25+ regulatory T cells (Treg), which represent 5 to 10% of the peripheral CD4+ 
T cells, have the ability to suppress immune responses, i.e. T cell proliferation and/or 
activation (reviewed in (453) and (519)). These cells can inhibit both Thl and Th2 responses 
and it has been suggested that they can do so either through the production of IL-10 and/or 
TGF-(3 or by cell to cell contact (186,238,393,554). It has been shown that their 
suppressive effect on cell proliferation results from the inhibition of IL-2 production by the 
other lymphocytes (554). 
Recent studies have suggested that Treg cells play a role in both susceptible and resistant 
mice during L. major infection. For example, the depletion of Treg cells before the infection 
of BALB/c mice with L. major resulted in an enhanced early burst of IL-4 and exacerbated 
disease (27). In addition, adoptive transfer studies in SCID mice have further supported a 
protective role for Treg cells during L. major infection (593). Finally, Treg cells have also 
been shown to play a role in C57BL/6 with cutaneous leishmaniasis. Indeed, the lack of 
sterile cure observed in C57BL/6 mice infected with L. major was shown to correlate with 
the accumulation of Treg cells within the dermis (46). Consequently, these suppressor cells 
inhibit the dermal effector CD4+ T cells necessary to eliminate the persistent parasites (46). 
This suppression of T cell réponses by the Treg cells was partially mediated by IL-10 (46). 
Finally, the persistence of parasites at the infection site was shown to be responsible for the 
maintenance of an immunological memory (46). 
13.3. CD8+T cells 
CD8+T cells represent an important arm of the adaptive immune response. They 
recognize pathogen-derived antigens expressed by antigen-presenting cells in the context of 
MHC class I. Activated CD8+ T cells can produce cytokines such as IFN-7 and TNF-a that 
stimulate anti-microbial effector functions; they can also induce the cytolysis of their target 
cells by producing perforin (reviewed in (201)). In experimental studies of leishmaniasis, 
most of the interest has focused on the CD4+ T cells, as the phenotype of the CD4+ T cell 
response determines disease outcome. However, there has been evidence that CD8+ T cells 
also have a protective role during both visceral and cutaneous Leishmania infections (378, 
539). 
The priming of mice following L. major infection or vaccination leads to the 
development of parasite-specific CD8+ T cells that are subsequently important for inducing 
resistance upon a secondary challenge (127,155,192,193, 374,451,458). The protective 
role was associated with an expansion and concomitant production of IFN-y (193,376,377). 
The role of CD8+ T cells during the course of a primary L. major infection, using mice 
that lack CD8 or (^-microglobulin or that have been depleted from CD8+ T cells, has been 
less clear and controversial results have been reported (155, 212, 225,411,555,577). For 
example, it appears that in the absence of CD8+ T cells, the outcome of a L. major infection 
depends on the number of promastigotes inoculated. Indeed, when mice lacking CD8+ T 
lymphocytes were infected with a high dose challenge, i.e. 106-107 parasites, they were able 
to control the infection as well as wild-type mice (225,411,555,577). However, CD8+ T 
cells were required for the control of a primary L. major infection when the inoculum was 
composed of a low dose of parasites, i.e. 100 metacyclic promastigotes (47). This was further 
supported by the fact that protection of Leishmania-infected RAG deficient mice, which lack 
T and B cells, was optimally achieved when both CD4+ and CD8+ T cells were adoptively 
transferred (47). This data would suggest that vaccine strategies should be designed to 
activate both CD4+ and CD8+ T cells, as the the sand fly vector generally inoculate low 
numbers of promastigotes to the host. 
After infection with L. mexicana, CD8+ T cells deficient mice are as susceptible as wild 
type mice, suggesting that CD8+ T cells may not have an important role in this experimental 
system (80,411). 
The role of CD8+ T cells L. amazonensis infection has also been investigated. While 
CD8+ T cell-deficient and perforin-deficient mice are as susceptible as wild-type controls, 
there is evidence of a protective role for CD8+ T cells after vaccination ((115), and our 
unpublished observations). Protection following vaccination involved both IFN-y and 
perforin-mediated processes (115). In addition, the low levels of IFN-y detected in the in 
vitro recall response of mice infected with L. amazonensis are significantly reduced if CD8+ 
T cells are depleted (100). However, this production of IFN-y by CD8+ T cells was CD4+ T 
cells-dependent (100). This is consistent with recent data showing that although CD8+ T 
lymphocytes can expand and become cytotoxic in the absence of CD4+ T cells, their 
expansion upon antigen re-encounter is CD4+ T lymphocytes-dependent (230). 
In conclusion, although CD8+ T cells may not be essential for protection to leishmaniasis, 
their role after re-infection and/or vaccination suggest that the goal of future vaccine 
strategies should include the induction of parasite-specific CD8+ T lymphocytes. 
13.4. NK cells 
A role for NK cells during cutaneous and visceral leishmaniasis has been clearly 
demonstrated (266,289, 505). After a L. major infection, NK cells are rapidly recruited at the 
inoculation site (379). In addition, there is evidence that these cells participate in the control 
of the infection as the cytotoxic activity of NK cells from inbred strains of mice early after L. 
major infection positively correlates with the ability of those strains to control parasite 
replication (505). Activation of NK cells can occur directly through the stimulation of their 
TLR2 by Leishmania LPG molecules (43). However, there is also evidence of indirect 
pathways of activation as IL-12 and CD4+ T cells are required for NK cell activation during 
L. major infection (505,506). The main role of NK cells is to provide an early source of IFN-
y that in turn will limit parasite spreading (288,505). In mice depleted from NK cells before 
infection, there is in an enhanced pathology at early timepoints, as determined by an 
increased lesion size and parasite load (289,296); however, in NK cell-deficient mice this is 
not observed (503). Nevertheless, the production of IFN-y by NK cells is not necessary for 
CD4+ T cells to promote resistance to L. major and mice either depleted or deficient in NK 
cells are both able to control a L. major infection (289,503, 575). 
Altogether, this suggests that while NK cells may be important early on, their presence is 
not necessary for the control of a L. major challenge. 
13.5. Polymorphonuclear neutrophils 
Polymorphonuclear neutrophils (PMNs) are part of the first line of immune defense 
against pathogens and as a result interact with Leishmania parasites soon after their 
inoculation (reviewed in (290)). The migration of PMNs can be triggered by different 
Leishmania species in vitro (570) and, in vivo, they are recruited very rapidly at the site of 
infection (306, 379,429,435, 547). In addition, PMNs have been shown to efficiently take 
up and kill Leishmania promastigotes (291,420,473). However, it also appears that some of 
the Leishmania parasites internalized by PMNs can resist killing and increase the survival of 
PMNs (6,291). In particular, live L. major promastigotes have been shown to delay the 
apoptosis of PMNs by reducing the activity of the pro-apoptotic caspase-3 within those cells 
(6). Based on these data, Laskay et al. have elaborated the Trojan horse hypothesis in which 
infected neutrophils serve as carriers for Leishmania to enter macrophages (290). They 
proposed that the delayed apoptosis observed in infected PMNs would give time to 
macrophages to be recruited at the lesion site. Subsequently, these macrophages will clear the 
tissue of apoptotic cells, a process that does not lead to macrophage activation. As a result, 
Leishmania parasites end up within their preferred host cell without any activation of the 
antimicrobial functions of macrophages (290). Interestingly, a recent study has shown that 
co-incubation of inflammatory neutrophils and infected macrophages from resistant or 
susceptible strains of mice promoted parasite killing or replication, respectively (459). 
Finally, depletion studies in mice have also tried to address the role of PMNS in vivo. In 
mice infected with L. infantum, the early, but not late, depletion of neutrophils was associated 
with increased parasite burdens (473)). However, studies in which BALB/c mice were 
depleted from their neutrophils soon before infection with L. major have provided conflicting 
results. In one study, neutrophil depletion was shown to result in increased parasite burden 
(306). However, in another study, it was reported to be protective, characterized by a 
decreased Th2 response, and a maintained IL-12 responsiveness from the CD4+ T cells (547). 
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The discrepancies between these two studies may be accounted for by the use of different 
strains of parasites or depleting antibodies. 
13.6. Eosinophils 
Recruitment and migration of eosinophils can be triggered by Leishmania parasites in 
vitro and in vivo (429,435,495). Although their exact role during a Leishmania infection 
remains undetermined and is likely not crucial, eosinophils can engulf the parasites and 
subsequently release their granule content (421,429,435). Furthermore, it appears that their 
production of nitric oxide may be involved in the anti-leishmanial immune response (408). 
13.7. B cells 
Resistance to Leishmania infection is essentially induced by cell-mediated immunity and 
although it is associated with an antibody response, the role of humoral immunity during 
leishmaniasis appears to be minimal (304,409). Nevertheless, the exact role of antibodies 
and/or B cells has been investigated. Initial studies using C3H mice treated with anti-IgM 
antibodies and infected with L. major provided controversial results; indeed both resistance 
and enhanced susceptibility were reported in these mice (489,516). In contrast, in BALB/c 
mice, the administration of anti-IgM or the lack of B cells is associated with disease control 
after Leishmania spp. infection, suggesting a detrimental role for B cells in this strain of mice 
(112,489). However, more recently, studies using B cell-deficient mice or mice depleted 
from B cells failed to support a role for B cells during Leishmania spp. infections (31,77, 
138,523). In addition, B cell-deficient mice were resistant to a secondary L. major challenge 
despite lower production of IFN-y and reduced DTH response (138). 
The role of antibodies during leishmaniasis has been controversial as well. Although 
antibodies are not necessary for healing a Leishmania infection, lines of mice producing high 
levels of serum antibodies have been shown to be more susceptible to L. major than the ones 
producing low antibodies titers (197). In addition, the exogenous administration of either IgG 
from naïve mice or from mice chronically infected mice with L. mexicana induced different 
disease progression after a subsequent L, mexicana infection in B cell-deficient mice (423). 
Indeed, the mice that received the Leishmania-specific IgG developed lesions faster and 
these contained higher parasite loads (423). Finally, a role for antibodies in disease 
progression was suggested in a study in which mice lacking the FcyR only developed 
minimal lesions after L. amazonensis or L. pifanoi infection (262). This would be consistent 
with a report indicating that the uptake of IgG-opsonized parasites through the Fey receptor 
on the surface of macrophages triggered the production of IL-10, which subsequently 
enhanced parasite survival (246). However, in FcyR-deficient mice infected with L. pifanoi, 
the CD4+ T cells from the draining lymph node produced similar levels of IL-10 as the wild-
type controls, suggesting that in this experimental system IL-10 may not be sufficient to 
maintain the infection (Colmenares 20021AI). Rather, the absence of lesion in these mice has 
been linked to the inability of infected macrophages to activate CD4+ T cells (112). 
13.8. Macrophages 
The two main roles attributed to macrophages during leishmaniasis are antigen 
presentation and parasite killing (263,410,535). Macrophages were considered, for a long 
time, as the main APC. As a result, macrophages were initially thought to be the main host 
cells initiating a Leishmania infection and studies have reported the ability of Leishmania 
parasites to limit antigen-processing and presentation by macrophages (21, 133, 264, 312, 
345,410,443). However, the importance of macrophages as antigen presenting cells during 
murine experimental leishmaniasis has been challenged. Indeed, recent data has indicated 
that while the main function of macrophages is to kill intra-cellular amastigotes, DC likely 
represent the host cells priming the parasite-specific immune response (573). In addition, 
more recently, a study reported that mice in which the expression of MHC class II was 
restricted to DC were able to control a L. major infection (300). This demonstrates that DC 
are sufficient to prime a protective response towards L. major. In addition, it indicates that 
macrophages are likely to kill the parasites in an MHC II-TCR independent fashion. 
Altogether, this suggests that the role of macrophages in presenting Leishmania antigens may 
be of minimal importance for the outcome of the disease. 
Regardless of the relevance of their ability to present antigen, the role of macrophages in 
the killing of engulfed parasites remains undisputed. One of the most potent microbicidal 
molecules produced by macrophages is nitric oxide (NO) (reviewed in (318)). It is 
synthesized by the cytokine-inducible NO synthase (iNOS), which can be triggered by 
cytokines such as IFN-y and TNF-a or inhibited by IL-4, IL-10 and TGF-(3 (reviewed in 
(304)). iNOS catalyzes L-arginine with oxygen to produce NO, and mice lacking iNOS or 
given NO inhibitors are highly susceptible to most Leishmania spp. (80, 387, 538,580). 
Furthermore, a continuous iNOS activity is necessary to maintain a healed phenotype, as the 
administration of iNOS inhibitor to mice that had previously cured their L. major infection 
lead to the reactivation of the disease (538). Although the leishmanicidal effects of NO have 
been extensively studied, how NO mediates parasite killing is still unclear (reviewed in (304) 
and (305). For example, a recent study using L. amazonensis suggested that NO may only be 
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cytostatic but that peroxynitrites, resulting from the association of NO with superoxide, are 
the molecules with cytotoxic activity (309). Finally, although NO is mainly secreted by 
macrophages, it can also be produced by DC. However, while NO has microbicidal activities 
in macrophages, it mediates apoptosis in DC and subsequently inhibits T cell (65). This 
further supports the disctinct roles that DC and macrophages have during leishmaniasis, i.e. 
antigen presentation and parasite killing, respectively. 
Although Leishmania-infected macrophages can become activated and subsequently kill 
intracellular amastigotes, Leishmania spp. have also evolved ways to inhibit several 
macrophages effector functions, including microbicidal activity (517) and IL-12 production 
(86, 335,428,456). In particular, L. amazonensis can resist the microbicidal effects of NO 
(170). In addition, L. amazonensis was also shown to inhibit the production of NO in vitro, 
but not in vivo (34, 308). 
Altogether, this suggests that parasite persistence result from a fine balance between the 
host microbicidal defense mechanisms and the parasites intrinsic ability to evade the host 
immune response. 
13.9. Dendritic cells 
Dendritic cells (DC) are the main antigen-presenting cells (APC) in vivo, inducing both 
tolerance and immunity. DC act as a link between the innate and adaptive immune systems 
by recognizing specific molecular patterns on the surface of pathogens and subsequently 
priming antigen-specific naïve T cells (reviewed in (36) and (35)). Their pivotal role in the 
induction of cellular immune responses has focused attention on DC as a powerful tool for 
eliciting anti-pathogen and/or anti-tumor immunity. 
Dendritic cells are found in primary and secondary lymphoid organs and peripheral 
tissues such as the skin. Several subsets of mouse and human DC have been characterized, 
i.e. myeloid, lymphoid, follicular and plasmacytoid DC (reviewed in (520). These 
characterizations are based on their differential expression of an array of surface markers, 
location, function and/or morphology. The direct lineage relationships between those subsets 
are not fully understood. 
DC arise from bone-marrow progenitor cells that give rise to circulating precursor DC in 
the blood, which can enter tissues as immature DC (e.g. Langerhans cells in the skin). The 
main function of immature DC is antigen capture through pinocytosis, phagocytosis and 
receptor-mediated endocytosis (reviewed in (187)). Upon antigen uptake, DC undergo a 
maturation process triggering their transition from an antigen-capturing cell to an antigen-
presenting cell. This is characterized by the upregulation of their surface expression of MHC 
(both class I and class II) and costimulatory (e.g. CD80/B7.1 & CD86/B7.2) molecules. 
Furthermore, mature DC produce an array of pro-inflammatory cytokines and chemokines. 
Maturation is also associated with the DC leaving the tissues and migrating, via the afferent 
lymphatics, to the T cell-rich area of the draining lymphoid organ. There, DC can present 
peptide antigens to T cells (reviewed in (35). While exogenous antigens acquired by 
phagocytic cells are usually presented on MHC class II molecules, DC also have the ability 
to present such antigens in the context of MHC class I molecules, a process termed cross-
priming (reviewed in (187). This allows DC loaded with exogenous antigens to initiate both 
CD4+ and CD8+ T cell responses. In addition, DC can also present lipid antigens to T cells 
through CD1 molecules, which have a MHC class I like structure (reviewed in (438)). 
Therefore, through their unique ability to prime antigen-specific naïve T cells, DC play a 
crucial role in determining the phenotype (Thl vs Th2) of a developing immune response 
(reviewed in (363)). Finally, because of their strategic role in the induction and outcome of 
cell-mediated immune responses, DC represent a tool for eliciting or modulating anti-
pathogen and/or anti-tumor immune responses. 
Dendritic cells express a variety of Pattern Recognition Receptors (PRR), such as Toll­
like Receptors (TLR), that bind to specific, highly conserved, pathogen-associated molecular 
patterns (PAMP), i.e. lipopolysaccharide (LPS) and peptidoglycans, on the pathogens surface 
(reviewed in (229), (549) and (344)). The interaction of the PRR with a PAMP induces an 
intracellular signaling cascade leading to the maturation of the DC. The specific 
characteristics of the DC stimulation, in terms of what subset of genes is expressed, depends 
on the type of pathogen encountered and the resulting PRR signaling pathway that is 
activated (106,224). Once stimulated, the DC can activate antigen-specific naïve and/or 
memory T cells, turning on the adaptive arm of the immune system. Immature DC express 
high levels of most of the ten TLR that have been described to date. TLR2 has been shown to 
bind to a wide variety of pathogen-derived molecules such as the LPS from Leptospira 
interrogans (581), lipoprotein/lipopeptide from Borrelia burgdorferi, Treponema pallidum 
and Mycoplasma fermentans (302) and glycosylphosphatidylinositol anchors from 
Trypanosoma cruzi (84). There is also evidence that Mycobacterium avium and 
Staphylococcus aureus signal through TLR2 (302, 597). While Leishmania LPG molecules 
have been shown to activate NK cells and transfected cell lines through TLR2, this has not 
been confirmed in dendritic cells (43,134). TLR4 can bind to LPS from gram-negative 
bacteria such as E. coli (220,448) and to other molecules such as lipotechoic acid (550) and 
the fusion protein of respiratory syncitial virus (277). Several mycobacterial species can also 
activate cells through TLR4 (343, 562). Recently, mice deficient in TLR4 were reported to 
be more susceptible to L. major, suggesting a role for TLR4 in the control of this disease 
(272). TLR5 recognizes bacterial flagellin (202). To date, the only ligand for TLR9 has been 
shown to be unmethylated CpG (cytidine linked to a guanosine by a phosphate bond) motifs 
characteristic of bacterial DNA (208). 
In addition to the TLR, DC express a variety of C-lectin type receptors including the 
mannose receptor, DC-SIGN, DEC-205, and Langerin (reviewed in (156)). These receptors 
can bind carbohydrates, lipids and/or peptides and may therefore also act as PRR for the 
specific recognition of pathogens. DC-SIGN, for example, binds ICAM 3 on resting T cells, 
mediates DC-T cell adhesion and is essential for DC-induced T cell proliferation (165). At 
the same time, DC-SIGN has been shown to bind human immunodeficiency virus-1 (HIV-1), 
simian immunodeficiency virus (SIV), cytomegalovirus and Ebola virus (18,164,196,434, 
598) and it plays a role in the transmission of those viruses to permissive cells. DC-SIGN is 
also a receptor for Leishmania amastigotes (116) and Mycobacterium tuberculosis (548). 
Furthermore, DC-SIGN is able to discriminate between different mycobacterial species 
(319). Therefore, DC-SIGN and TLR serve as recognition receptors for the binding and/or 
transmission of many different pathogens. 
There is increasing evidence that DC play a crucial role during the protective immune 
response towards Leishmania parasites (300, 354,460). Although, macrophages were 
initially considered as the main APC, this role is now attributed to DC and recent evidence 
suggest that the major role of macrophages during Leishmania infection is to kill intracellular 
parasites (573). The uptake of Leishmania spp. by DC has been widely reported (52, 62,175, 
355,356,446,573,583). In addition, DC from the skin and draining lymph node harbor the 
parasites in vivo (62, 355, 356). Furthermore, DC are the main APC in the in vitro recall 
response during both acute and chronic L. major infection (355, 356). Finally, Leishmania 
parasites have been shown to modulate DC responses (reviewed in (481) and (514)). Indeed, 
these parasites influence DC migration (30,231,437), surface expression of co-stimulatory 
molecules, and IL-12 production to varying degrees, depending on the species and strain of 
Leishmania (52, 334,446,573). Below is a summary of the different DC functions that 
Leishmania parasites are known to modulate. 
13.9.A. Antigen presentation 
As mentioned earlier, in vitro studies using macrophages have suggested that Leishmania 
parasites, and in particular L. amazonensis, may evade the MHC class II pathway of antigen 
presentation, as both MHC II molecules and H2M colocalized within the engulfed (21,133). 
Similar findings have recently been reported in dendritic cells infected with L. mexicana or L. 
amazonensis (51,442). However, despite the colocalization of MHC II molecules in 
intracellular parasites, L. amazonensis did not seem to inhibit DC activation, especially when 
the parasites were incubated with immune serum before infection (442). Indeed, the uptake 
of opsonized L. amazonensis induced the upregulation of the surface expression of MHC 
class II and co-stimulatory molecules. In contrast, such activation was much less pronounced 
when parasites were not coated with antibodies prior to infection (442). Altogether, this 
suggests that DC taking up L. amazonensis parasites in the absence of antibodies may remain 
immature, and subsequently do not prime efficient T cell responses. 
Finally, whether or not the sub-cellular localization of MHC class II and H2M molecules 
to the PV does impair antigen presentation is unclear. In fact, a recent study indicated that L. 
mexicana-infected DC were not compromised in their ability to present antigen (51). 
13.9.B. Co-stimulation 
13.9.B.1. CD28-B7 
The interaction between CD28 and B7 molecules provides an essential second signal at 
the time of TCR and antigen-MHC complexes interactions (reviewed in (97)). Both B7.1 and 
B7.2 are expressed at low levels on resting DC and are upregulated on activated DC (97,228, 
253,287). The specific roles of B7.1 and B7.2 during Thl and Th2 responses have been 
controversial and seem to be dependent upon the efficiency of T cell priming used 
experimentally (511). In addition, the effect of B7 blockade on T lymphocyte functions will 
vary whether it is a naïve or a primed T cell (512). 
Several studies have investigated the role of B7 molecules during Leishmania infection. 
The surface expression of B7.1 has been shown to be down-regulated on the surface of 
L.donovani-infected macrophages (249). In addition, L. mq/'or-infected Langerhans cells 
from BALB/c mice have a decreased surface expression of B7.1 in comparison to the ones 
from C3H mice (332). Similarly, BMDC infected with L. mexicana do not upregulate their 
surface expression of co-stimulatory molecules, thereby keeping the infection presumably 
silent (52). Furthermore, the blockade of B7.1 and B7.2 in vitro resulted in a decreased 
production of IFN-y, supporting a role for these co-stimualtory molecules for adequate T cell 
activation (75,332). In vivo, although the absence of CD28 does not alter the course of 
infection, the blockade of B.7 molecules using CTLA-4 Ig at the time of L. major infection 
conferred protection to BALB/c mice (118,414). The critical role of B7-mediated co-
stimulation during the early stages of lymphocyte response, i.e. cytokine production and 
proliferation, was further supported recently in both BALB/c and C3H mice infected with L. 
major (152). In particular, the blockade of B7.2, but not B7.1, in BALB/c mice infected with 
L. major was associated with a decreased Th2 response and lower parasite burden (78). This 
was further supported by in vitro data reporting that in the absence of B7.2 signaling, 
Langerhans cells were unable to promote IL-4 secretion by CD4+ T cells (332). In C57BL/6 
mice infected with L. major, the administration of anti-B7.2 similarly led to a decreased 
parasite load without alteration of the cytokine profile (78). Similarly, B7.2 blockade in mice 
infected with L. donovani resulted in decreased parasite load and enhanced IFN-y production 
(382). Altogether, these experiments suggested that B7.2 signaling may play a role in Th2 
responses. However, this was recently challenged by a study reporting that when B7.1 or 
B7.2 are expressed at similar levels, they can equally induce Th2 responses (152). Similarly, 
the fact that the course of L. major infection in CD28-deficient BALB/c mice was unaltered 
suggested that these mice may have developed alternative pathways of Th2 responses 
induction (76). 
Finally, although not all these studies have specifically addressed the role of co-
stimulatory molecules on DC, it is likely that the blockade of B7-mediated co-stimulation has 
affected DC-T cells interactions, as DC play a crucial role during T cell priming. 
13.9.B.2. CTLA-4 
In order to avoid uncontrolled T cell activation and proliferation, the immune system has 
evolved mechanisms to maintain T cell homeostasis. In particular, activated T cells 
upregulate CTLA-4, which binds to both B7.1 and B7.2 with an affinity that is 10 times 
higher than CD28 (310, 568, 576). As a result, CTLA-4 signaling mediates an inhibitory co-
stimulation that is essential for the maintenance of T cell homeostasis (275,576). Indeed, 
mice lacking CTLA-4 display massive T cell proliferation, resulting in lymphadenopathy and 
splenomegaly, and die at 3 to 4 weeks of age (557). 
The role of CTLA-4 during experimental cutaneous and visceral leishmaniasis has been 
recently investigated (reviewed in (172)). During cutaneous disease due to L. major, the 
blocking of CTLA-4 results in an enhanced Th2 response and disease exacerbation (203, 
327,494). This suggests that CTLA-4 signaling may be crucial for the development of a 
protective Thl response. However, in murine studies of visceral leishmaniasis, the blocking 
of CTLA-4 restored T cell responsiveness, increased IFN-y production and enhanced parasite 
clearance both in vitro and in vivo (171, 381). In particular, in this experimental system, 
CTLA-4 engagement was shown to promote CD4+ T cells to secrete TGF-(3, which enhances 
parasite growth (173). 
In conclusion, it appears that the role of CTLA-4 engagement may have opposite effects 
during cutaneous and visceral diseases. In particular, blocking CTLA-4 binding to its 
receptor may be useful in immunotherapeutic strategies to control visceral leishmaniasis. 
13.9.B.4. CD40-CD40L 
The interaction between CD40, expressed on the surface of dendritic cells, and its ligand 
CD40L, expressed on T cells is an important secondary signal that enhances the production 
of IL-12 by the DC and the subsequent Thl response (reviewed in (181)). In particular, 
signaling through CD40 appears important for the production of IL-12p35 the limiting 
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subunit of IL-12 in DC (509). In addition, in the absence of CD40L, Langerhans cells fail to 
migrate to the draining lymph node, further supporting the crucial role of CD40L signaling 
pathways for adequate T cell priming (358). 
The importance of CD40-CD40L interactions during experimental murine leishmaniasis 
has been investigated both in vitro and in vivo. The blockade of CD40-CD40L interactions in 
in vitro co-cultures of L. mo/or-infected macrophages and PBMC induced an inhibition of 
effector cytokine production (75). In addition, CD40 or CD40L-deficient C57BL/6 mice are 
susceptible to a high dose L. major challenge (83,243,414). However, the outcome of the 
disease depends on the size of the inoculum, as CD40L deficient C57BL/6 mice can control a 
low dose L. major challenge, suggesting that in the presence of only few numbers of 
parasites the immune system can be skewed toward a Thl phenotype, even in the absence of 
CD40-CD40L interactions. (413). When CD40L-deficient C57BL/6 mice were infected with 
L. amazonensis, they displayed an exacerbated disease in comparison to wild-type controls, 
indicating that some CD40-CD40L engagement has some protective role in infected control 
mice (527). Finally, vaccination of mice using transfected cells expressing CD40L conferred 
enhanced protection to both L. major and L. amazonensis (107). 
Altogether, this suggests that Leishmania parasites may interfere with CD4O-CD4OL 
signaling and that modulation of this pathway may be useful to promote resistance or 
healing. 
13.9.C. IL-12 production 
As mentioned earlier, IL-12 is an important component of Thl responses and DC have 
been shown to produce IL-12 following Leishmania spp. infection (175,268,447,573,574). 
In addition, the production of bioactive IL-12p70 by infected DC has been reported to be 
CD40-CD40L dependent (321). However, the amplitude of the CD40L-mediated IL-12 
protection varies depending on the genetic background of the host and on the strain or 
species of Leishmania spp. involved (334,446). For example, BMDC infected with L. 
mexicana do not acquire an activated phenotype and their production of IL-12 is not 
upregulated after infection with amastigotes (52). Similarly, there is increasing evidence that 
L. amazonensis may be limiting the production of IL-12 by DC. Indeed, the draining lymph 
nodes from L. amazonensis-'mfected mice contain low numbers of IL-12 producing cells 
(236). Furthermore, in vitro, L. amazonensis-infected DC from BALB/c mice do not up-
regulate their production of IL-12 when stimulated with anti-CD40 (446). This impaired IL-
12 production occurred despite the upregulation of surface MHC II and co-stimulatory 
molecules (446). These data indicate that the maturation stage of L. amazonensis-infected DC 
may lie between the one of an immature and of a mature cell. In fact, a new differentiation 
stage of DC maturation, i.e. semi-mature DC, has been recently identified (317). While semi-
mature DC have a surface phenotype reminiscent of mature DC, they lack the production of 
pro-inflammatory cytokines such as IL-12. Altogether, these data suggest that DC infected 
with L. amazonensis remain in a semi-mature state. 
13.9.D. Migration 
The migration of DC from the peripheral site of antigen uptake to the draining lymphoid 
organ is crucial for the priming of subsequent immune responses. This migration is 
orchestrated by an array of adhesion molecules (441,594), cytokines (26,265), and 
chemokines (reviewed in (94)and (529)). In particular, chemokines are small secreted 
molecules that are involved in leukocyte activation and migration (reviewed in (472)). Four 
classes or families of chemokines have been described so far, namely the alpha (or CXC), 
beta (or CC), gamma and delta families (reviewed in (600)). The biologic effect of 
chemokines is mediated through their binding to 7 transmembrane domain G protein-coupled 
receptors expressed by leukocytes, including DC (reviewed in (346) and (472)). The 
recruitment of immature DC to peripheral tissues or of mature DC to lymphoid organs is 
under the control of various specific chemokines and chemokine receptors (146,528). For 
example, the expression of CCR2 or CCR7 is important for DC migration to secondary 
lymphoid organs (158, 500). In particular, mice that are deficient for CCR7 or its ligands 
display DC migration defects and fail to mount primary T cell responses (158,189). While 
expressed at very low levels on immature DC, CCR7 is rapidly upregulated upon DC 
maturation (419,493,497,528,596). As a result, mature DC display an enhanced migratory 
response to CCR7 ligands (493,497,528). CCR7 ligands include CCL21 (SLC/6Ckine) and 
CCL19 (ELC/MIP-3P). SLC is expressed in the T cell zones of lymphoid organs, by 
lymphatic endothelial cells and in the high endothelial venules of lymph nodes and Peyer's 
patches (190). Blocking of the activity of SLC by neutralizing antibodies has been shown to 
inhibit the migration of skin derived DCs to the draining lymph node (493). Similarly, ELC 
is expressed in high endothelial venules, but also by dendritic cells within the T cell areas of 
secondary lymphoid organs (32, 398,600). 
During experimental leishmaniasis, the importance of chemokine-chemokine receptor 
interactions on the subsequent disease progression has been highlighted in studies using 
knockout mice. For example, CCR2-deficient mice on a resistant background cannot control 
a L. major infection (500). Similarly, when these mice are infected with L. donovani, the 
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resulting granulomas are poorly organized in comparison to the ones from wild type control 
mice (501). In addition, protozoan parasites including Leishmania spp. have evolved 
strategies to exploit or subvert chemokine-mediated responses (reviewed in (71)). For 
example, while L. major infection triggers the overt expression of certain chemokines, it 
appears that the production of chemokines is impaired in L. amazonensis-infected mice (233, 
450). Furthermore, DC from L. donovani-infected mice failed to migrate to the T cell rich 
areas of the spleen and this correlated with a decreased expression of CCR7 (30). Finally, L. 
major parasites themselves have been shown to inhibit DC migration in vitro (231). 
13.9.E. Signal transduction through MyD88 
Myeloid differentiation factor 88 (MyD88) is an adaptor protein that acts as a signaling 
molecule downstream of different Toll-like receptors (TLR), including TLR2 and TLR4, 
leading to the activation of the NF-KB family of transcription factors (reviewed in (242)). DC 
maturation is partly dependent on MyD88 expression and MyD88 has been shown to be 
important for the production of IL-12p40 (223,242, 504). As a result, it was likely that 
MyD88 would play a role in the control of Leishmaniasis. Indeed, when infected with L. 
major, C57BL/6 mice deficient for MyD88 develop an exacerbated clinical disease that is 
associated with the development of a Th2 response (134,135,380). This also correlated with 
undetectable levels of IL-12p40 in the serum of MyD88-deficient mice (380). However, the 
susceptible phenotype observed in the absence of MyD88 could be reversed by the 
exogenous administration of either IL-12 or anti-IL4, suggesting that MyD88 acts as a 
critical switch of Thl responses (135,380). Although these studies have not specifically 
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addressed the role of MyD88 in DC, it is likely that DC responses from MyD88-deficient 
mice were impaired. 
14. The immune response of infected humans 
As in mice, the cellular immune response of humans has been subdivided into two major 
phenotypes, i.e Thl and Th2 (reviewed in (303)). In addition, resistance or susceptibility to 
leishmaniasis in humans has also been shown to correlate with the phenotype of the immune 
response. Indeed, control of the disease has been associated with a potent Thl cell mediated 
immunity, and the enhanced expression or production of IFN-y usually correlates with a 
healing phenotype (64, 89,90, 389,496). Typically, patients with leishmaniasis have a 
defective cellular immunity, especially when during the visceral or diffuse cutaneous form of 
leishmaniasis. These individuals do not develop a DTH reaction in response to the 
Montenegro test, suggesting the presence of an anergic immune response (215,427). In 
patients with cutaneous leishmaniasis, peripheral blood monocytes and cells at the lesion site 
have a mixed Thl/Th2 cytokine profile and/or produce low levels of IFN-y (64, 81,123,432, 
465). In addition, peripheral blood monocytes usually display reduced proliferative response 
to stimulation in vitro, a phenomenon also observed in patients with active visceral 
leishmaniasis (87, 88,90-92,215, 389,427,485). During or after successful treatment 
however, the immune response of patients is characterized by an increased 
lymphoproliferative response in vitro and the cytokine profile of their immune response is of 
the Thl phenotype, i.e. characterized by an increased production of IFN-y (64, 89,91,215, 
350, 389,496). A decrease in the expression of IFN-y mRNA has also been shown during 
clinical relapse (64). Finally, the susceptibility of some patients with active cutaneous 
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leishmaniasis correlated with a state of IL-12 unresponsiveness (66,67). This was 
characterized by a decreased production of IFN-y in response to IL-12 in vitro and by a 
decreased expression of IL12R|32, a marker of human Thl cells, in biopsy samples and 
PBMC (66, 67,467). Furthermore, these studies suggested that the production of the Th2 
cytokine IL-13 was responsible for inhibiting IL-12 responsiveness in patients with active 
cutaneous leishmaniasis (66,67). 
15. Treatment and prevention 
15.1. Chemotherapy 
As vaccines are currently not available for the prevention and/or treatment of 
leishmaniasis, chemotherapy remains the only approach to cure the disease. Systemic, oral 
and topical drugs have been used with variable degrees of success (reviewed in (54) and 
(124)). The efficacy of a drug regimen may vary according to the Leishmania species 
involved, the potential development of drug resistance, and the immune status of the host as 
some drugs have been shown to be less efficient in immunodeficient individuals (124, 388). 
Also, the pharmacokinetic requirements of the drugs to be used to treat cutaneous or visceral 
leishmaniasis are different (124). The current drugs that are recommended include the 
pentavalent antimonials, and different formulations of amphotericin B, a drug also used in 
the treatment of fungal diseases (124). The mechanism of action of antimonial drugs is 
unknown. Amphotericin B creates pores in the leishmanial membranes, resulting in osmotic 
lysis of the parasites (452). 
Systemic injections of pentavalent antimonials (i.e. sodium stibogluconate and 
meglumine antimoniate) were used soon after Leishmania parasites were recognized. The 
typical drug regimen is composed of a daily injection of the drug for 20 to 28 days. The 
clinical response can be rapid but normalization of the clinical parameters can take months. 
In case of treatment failure with those agents, the use of alternative agents is recommended 
as increasing the dose or duration of the treatment with pentavalent antimonials could 
become toxic. Other systemic agents that have been described in the literature include 
pentamidine, paromomycin (aminosidine), cytokines (i.e. IFN-y) and amphotericin B, which 
can also become toxic to the patient. Although amphotericin B has been successfully used in 
patients developing resistance to antimonial drugs, its parenteral administration needs to be 
done for 4 hours and it is also rather toxic (124). However, lipid associated formulations of 
amphotericin B are now available: these have reduced toxicity and increased plasma half-life 
(54,124). Successful combinations of various doses of these systemic agents have been 
reported in the literature (reviewed in (54)). Oral agents that have been used in the treatment 
of leishmaniasis include the anti-fungal imidazoles (i.e. ketoconazole) and triazoles (i.e. 
itraconazole); however, their efficacy was equivocal. In addition, in the mid-1980s, the anti­
cancer drug Miltefosine was shown to have anti-leishmanial activity after oral administration. 
It has been used successfully to treat patients with visceral leishmaniasis (124). Finally, the 
use of topical agents has also been investigated, especially in patients with cutaneous disease, 
as this type of treatment would allow the drug to act directly at the level of the lesion and 
would decrease the likelihood of systemic toxicity. Miconazole, clotrimazole or a 
combination of paromycin and methylbenzethonium chloride have all been tested clinically 
with however equivocal results (reviewed in (54)). It is possible that the local application of 
these agents does not allow the drug to reach the Leishmania parasites present in 
macrophages within the deeper lesion. 
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Alternatively, studies have suggested the use of thermotherapy for the treatment of 
cutaneous leishmaniasis. This method has been successfully used in humans infected with L. 
tropica, L. amazonensis, L. mexicana and L. braziliensis (241, 394, 397). In addition, in both 
humans and mice, thermotherapy was shown to be as effective as antimonial drugs, or better 
(25,132, 394). However, as different species of Leishmania have different thermosensitivity, 
the efficiency of thermotherapy may vary accordingly (397,483). 
Regarding L. amazonensis infection, a recent mouse study has shown that an enhanced 
oral absorption of low doses of pentavalent antimonials could be achieved using |3-
cyclodextrin. This drug regimen was as efficient as parenteral administration of twice as 
much pentavalent antimonials alone (140). In addition, new anti-fungal compounds have 
proven to be equivalent or better than amphotericin B, with decreased toxicity in mice 
infected with L. amazonensis (9,10). Similarly, the topical application of paromomycin and 
gentamycin was recently shown to promote the healing of mice infected with L. amazonensis 
while also limiting the size of the scar (184). 
In conclusion, the diversified panel of drugs currently available for the treatment of 
leishmaniasis gives the practitioners the ability to combine or switch therapies when patients 
show signs of toxicity or resistance to some of the drugs. However, the development of new, 
more efficient and less toxic drugs is needed, especially since there is an increased rate of 
resistance in certain endemic areas. Advancement in genomics, i.e. completion of the 
Leishmania genome, and proteomics will hopefully help identify new drug targets and design 
new therapeutic strategies (129). 
15.2. Sterile cure 
Although clinical cure can be achieved, there is evidence that Leishmania parasites can 
persist in the scar and/or the blood of healed patients (139,349,507, 508). Persistence of 
parasites is also observed in mice that have healed a cutaneous Leishmania infection (132, 
299). In particular, in mice that have healed a L. major infection, parasites are found within 
macrophages, dendritic cells, fibroblasts and necrotic areas of the draining lymph node (63, 
355,538). It is tempting to suggest that fibroblasts may be a major host cell in the scar tissue 
of healed patients. Leishmania parasites, including L. amazonensis, can infect fibroblasts in 
vitro but do not multiply within those cells (63,101,137,510). Furthermore, although some 
amastigotes are degraded within fibroblasts, these cells produce less nitric oxide than 
macrophages and therefore may represent a less hostile environment where parasites can 
persist during the latent phase of infection (63,137, 510). The lack of clinical disease in the 
presence of parasites may suggest that the persistent Leishmania have an attenuated 
virulence. However, the persistent parasites from mice that had healed a L. major infection 
appeared genetically identical to the parent strain and remained virulent (1). In addition, in 
clinically cured mice, the maintenance of the resistant phenotype was dependent upon CD4+ 
T cells, CD8+ T cells, IFN-y, IL-12 and/or iNOS as the inhibition or absence of one of those 
immune factors reactivated the infection (44,375,418,538). Similarly, immunosuppression 
of clinically cured mice caused lesion to reappear, raising some concerns with regards to the 
increased incidence of Leishmania-HÏV co-infected patients (132). Therefore, this has 
implications in human patients co-infected with Leishmania and HIV. 
Finally, it has been demonstrated that IL-10 is required for the establishment of persistent 
parasites: indeed, sterile cure could be achieved in IL-10 deficient mice or in mice treated 
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with blocking antibodies against IL-10 (44). While there is a risk that persistent parasites 
from clinically cured patients or animals may be able to initiate subsequent relapses, they 
may also be important for maintaining an immunological memory in the host (355). Indeed, 
T cell memory has been shown to be short-lived in the absence of antigen (179). 
Furthermore, after sterile cure, IL-10 deficient mice or mice treated with anti-IL-10R are no 
longer immune to reinfection (46). 
15.3. Vaccines 
Leishmanization, i.e. the inoculation of virulent Leishmania promastigotes as a vaccine, 
was initially used with success to protect humans against leishmaniasis in different endemic 
regions of the world (reviewed in (352)). However, due to the development of severe lesions 
in some patients, leishmanization was later discontinued and to date, there is no vaccine 
available for the prevention of leishmaniasis. However, experimental studies of leishmaniasis 
are still actively working on the elaboration of new vaccination strategies (reviewed in (304) 
and in (199)). In particular, these studies have tested the efficacy of vaccines composed of 
killed parasites, attenuated live parasites, recombinant protein, and DNA with or without 
additional adjuvants such as IL-12 (4), Bacillus Calmette Guérin (BCG)(2), Freund 
incomplete or complete adjuvant (56,98), alum (255), CpG-ODN (348,458,534) and/or 
Propionibacterium acnes (formerly Corynebacterium parvum) (526). 
Studies using killed Leishmania parasites as a vaccine have resulted in variable degrees 
of protection. For example, in BALB/c mice, irradiated L. major or L. donovani 
promastigotes were able to confer protection against a subsequent L. major challenge (221, 
222). The route of administration was critical for the subsequent protection; indeed, in 
contrast to the intravenous route, the subcutaneous and intra-peritoneal immunizations were 
ineffective at promoting protection (222). Similarly, radioattenuated L. major increased the 
resistance of CBA mice to a subsequent L. mexicana infection (11). In addition, the 
vaccination of rhesus macaques with heat-killed L. amazonensis, IL-12 and Alum provided 
protection agasint a subsequent L. amazonensis challenge and the protective effect positively 
correlated with the dose of IL-12 used in the vaccine (255). In contrast, when autoclaved L. 
major were administered in combination with IL-12 to vervet monkeys, a protective effect 
could not be observed (168). More recently, the oral administration of freeze-thawed L. 
amazonensis promastigotes to mice allowed them to better control a subsequent infectious 
challenge (431). 
The use of attenuated live parasites in a vaccine is controversial, as it is unconvenient and 
cost-effective to maintain doses of live organisms. In addition, there is always the possibility 
that attenuated pathogens revert to a virulent phenotype. However, these organisms likely 
better mimic a real infection and they are a source of more antigens as a whole. 
Experimentally, avirulent L. major promastigotes lacking DHFR-TS (i.e. a gene encoding for 
a dihydrofolate reductase-thymidylate synthase) have been shown to promote the subsequent 
control of a heterologous challenge with virulent L. amazonensis (571). Similarly, mice that 
had controlled a challenge with cysteine protease-deficient parasites could resist a challenge 
with wild-type virulent organisms (13). Finally, phosphoglycan-deficient L. major parasites, 
which can persist indefinitely in the host without causing pathology, are able to protect 
against a secondary virulent challenge (532,566). As a result, such parasites may become 
candidates for vaccine strategies involving attenuated live parasites. 
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Vaccines composed of recombinant proteins/antigens have the advantage of being easily 
produced, distributed and stored on a large scale. Different degrees of protection toward L. 
amazonensis infection have been shown after vaccination with purified proteins and 
adjuvants (56,98,115,526). However, recombinant protein/antigen-based vaccines may not 
elicit a T cell response that is as diverse as the one induced by whole parasites. For example, 
a mixture of several antigens is usually more protective than each single antigen used 
individually, and different antigenic cocktails also have different effectiveness depending on 
the antigens included in the vaccine (2,359). This suggests that specific antigens may be 
better at specifically expanding certain effector cells. Indeed, for example, the Leishmania 
elongation initiation factor (LeIF) has been shown to preferentially induce the production of 
IL-12 and IFN-y, suggesting that this antigen may be used in vaccine suspension to promote 
Thl responses (522). In all of these vaccination studies, the protective effect was critically 
dependent upon the presence of an adjuvant within the vaccine. Furthermore, the level of 
protection may depend on the site of vaccination relative of that of the infectious challenge 
(461). 
The expression of certain immunogenic proteins within attenuated bacteria or viruses 
represents an alternative to vaccines composed of recombinant proteins/antigens only. For 
example, Leishmania antigens expressed into vaccinia viruses or Salmonella have induced 
protection in different murine models (174, 340, 342). The role of the carrier organisms is to 
serve as an adjuvants and likely to target the antigen of interest to specific subcellular 
location, e.g. the phagolysosomal compartment of dendritic cells. 
Recently, DNA vaccines have emerged as powerful tools to elicit effective immune 
responses against multiple pathogens. The concept implies that the injected plasmid that 
encodes the antigen(s) of choice will reach the nucleus of host cells and subsequently 
transcribed into a messenger RNA. This mRNA will then be translated and the resulting 
antigen be presented to the immune system, which will hopefully mount an effective 
response against this antigen. DMA vaccines encoding for one or several Leishmania 
antigens have reported promising results (8, 82, 85,191,192, 347). Finally, due to the crucial 
role of DC in priming immune responses, their potential as prophylactic vaccine adjuvants 
has been exploited to promote an efficient immune response before infection with L. major 
(53,157,574). Similarly, the direct in vivo expansion of the DC compartment on the 
outcome of a Leishmania infection has been investigated using Flt3-L (270). Pretreatment of 
BALB/c mice with this cytokine promoted resistance to a subsequent L. major infection in 
40% of the mice. 
In conclusion, multiple vaccination strategies aimed at controlling leishmaniasis are 
currently under investigation. The goal of future studies will be to design safe vaccines with 
cross-protecting and long-lasting efficacy. 
16. Concluding remarks 
Experimental murine leishmaniasis shares many similarities with the human disease and 
mouse models of Leishmania spp. infection have helped to uncover some of the immune 
mechanisms associated with resistance and susceptibility to the disease. For example, the 
mouse model of L. major infection has been extensively studied and has been very useful to 
study Thl and Th2 immune responses, which mediate resistance and susceptibility to 
leishmaniasis. In particular, resistance to a L. major infection correlates with the production 
of high levels of IL-12 by antigen-presenting cells, the subsequent priming of Thl CD4+ T 
cells producing IFN-y, and the induction of parasite killing in a NO-dependent manner. In 
contrast, susceptibility to L. major is mediated by Th2 CD4+ T cells producing high levels of 
IL-4 and/or IL-10. In addition, resistance and susceptibility to L. major can usually be easily 
induced or reversed manipulated by exogenous administration of Thl or Th2 cytokines. As a 
result of these studies, it is generally accepted that resistance and/or susceptibility to other 
Leishmania spp. infections follow the same rules. However, there is recent evidence that the 
factors mediating resistance to L. major may not be applicable to parasites belonging to the 
L. mexicana complex, including L. amazonensis. Indeed, mouse strains that are resistant to L. 
major are susceptible to L. amazonensis and this susceptibility does not correlated with a Th2 
phenotype of the host immune reponse. Instead, the associated immune response has been 
characterized by a mixed Thl/Th2 cytokine pattern. Some of the immune defects associated 
with a L. amazonensis infection have been characterized and include defective pro­
inflammatory cytokine and chemokine production, decreased IL-12 production and lower IL-
12 responsiveness, decreased production of IFN-y and enhanced resistance to macrophage 
microbicidal activity (e.g. NO-mediated killing). In addition, the susceptibility to L. 
amazonensis infection could not be reversed by exogenous administration of IL-12 or IFN-y. 
Similarly, mice deficient in IL-4 or IL-10 remained susceptible to a L. amazonensis 
challenge. 
In conclusion, the immune response mounted against L. amazonensis appears very robust 
to any exogenous immunomodulatory factors. Therefore, it would be of interest to 
successfully modulate this mixed immune response towards an effective Thl phenotype. This 
would have implication for both immunotherapeutic and vaccine strategies aimed at curing 
the disease caused by L. amazonensis. Finally, although the Thl immune response of 
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resistant mice infected with L. major is commonly used as a model to characterize the 
immune defects of L. amazonensis-infected mice, it is not known if such promote resistance 
to a L. amazonensis challenge. Indeed, this would confirm that comparisons between the 
immune responses of mice infected with L. major or L. amazonensis is appropriate. The 
present manuscript has attempted to answer some of these questions. 
References 
1. Aebischer, T., S. F. Moody, and E. Handman. 1993. Persistence of virulent 
Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. 
Infect Immun. 61:220-226. 
2. Aebischer, T., M. Wolfram, S. I. Patzer, T. Ilg, M. Wiese, and P. Overath. 2000. 
Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison 
of three proteins expressed in amastigotes and six adjuvants. Infect Immun. 68:1328-
1336. 
3. Afkarian, M., J. R. Sedy, J. Yang, N. G. Jacobson, N. Cereb, S. Y. Yang, T. L. 
Murphy, and K. M. Murphy. 2002. T-bet is a STAT 1-induced regulator of IL-12R 
expression in naive CD4+ T cells. Nat Immunol. 3:549-557. 
4. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. 
Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania 
major. Science. 263:235-237. 
5. Afonso, L. C., and P. Scott. 1993. Immune responses associated with susceptibility 
of C57BL/10 mice to Leishmania amazonensis. Infect Immun. 61:2952-2959. 
6. Aga, E., D. M. Katschinski, G. van Zandbergen, H. Laufs, B. Hansen, K. Muller, 
W. Solbach, and T. Laskay. 2002. Inhibition of the spontaneous apoptosis of 
neutrophil granulocytes by the intracellular parasite Leishmania major. J Immunol. 
169:898-905. 
7. Aguilar Torrentera, F., J. D. Laman, M. Van Meurs, L. Adorini, E. Muraille, 
and Y. Carlier. 2002. Endogenous interleukin-12 is critical for controlling the late 
but not the early stage of Leishmania mexicana infection in C57BL/6 mice. Infect 
Immun. 70:5075-5080. 
8. Ahmed, S. B., C. Bahloul, C. Robbana, S. Askri, and K. Dellagi. 2004. A 
comparative evaluation of different DNA vaccine candidates against experimental 
murine leishmaniasis due to L. major. Vaccine. 22:1631-1639. 
9. Al-Abdely, H. M., J. R. Graybill, R. Bocanegra, L. Najvar, E. Montalbo, S. L. 
Regen, and P. C. Melby. 1998. Efficacies of KY62 against Leishmania amazonensis 
and Leishmania donovani in experimental murine cutaneous leishmaniasis and 
visceral leishmaniasis. Antimicrob Agents Chemother. 42:2542-2548. 
75 
10. Al-Abdely, H. M., J. R. Graybill, D. Loebenberg, and P. C. Melby. 1999. Efficacy 
of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani 
in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents 
Chemother. 43:2910-2914. 
11. Alexander, J. 1982. A radioattenuated Leishmania major vaccine markedly increases 
the resistance of CBA mice to subsequent infection with Leishmania mexicana 
mexicana. Trans R Soc Trop Med Hyg. 76:646-649. 
12. Alexander, J., F. Brombacher, H. A. McGachy, A. N. McKenzie, W. Walker, and 
K. C. Carter. 2002. An essential role for IL-13 in maintaining a non-healing 
response following Leishmania mexicana infection. Eur J Immunol. 32:2923-2933. 
13. Alexander, J., G. H. Coombs, and J. C. Mottram. 1998. Leishmania mexicana 
cysteine proteinase-deficient mutants have attenuated virulence for mice and 
potentiate a Thl response. J Immunol. 161:6794-6801. 
14. Alexander, J., and P. M. Kaye. 1985. Immunoregulatory pathways in murine 
leishmaniasis: different regulatory control during Leishmania mexicana mexicana and 
Leishmania major infections. Clin Exp Immunol. 61:674-682. 
15. Alexander, J., and R. S. Phillips. 1978. Leishmania tropica and Leishmania 
mexicana: cross-immunity in mice. Exp Parasitol. 45:93-100. 
16. Almeida, R. P., M. Barral-Netto, A. M. De Jesus, L. A. De Freitas, E. M. 
Carvalho, and A. Barrai. 1996. Biological behavior of Leishmania amazonensis 
isolated from humans with cutaneous, mucosal, or visceral leishmaniasis in BALB/C 
mice. Am J Trop Med Hyg. 54:178-184. 
17. Alvar, J., R. Molina, M. San Andres, M. Tesouro, J. Nieto, M. Vitutia, F. 
Gonzalez, M. D. San Andres, J. Boggio, F. Rodriguez, A. Sainz, and C. Escacena. 
1994. Canine leishmaniasis: clinical, parasitological and entomological follow-up 
after chemotherapy. Ann Trop Med Parasitol. 88:371-378. 
18. Alvarez, C. P., F. Lasala, J. Carrillo, O. Muniz, A. L. Corbi, and R. Delgado. 
2002. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in 
cis and in trans. J Virol. 76:6841-6844. 
19. Andrade, H. M., P. de Toledo Vde, M. J. Marques, J. C. Franca Silva, W. L. 
Tafuri, W. Mayrink, and O. Genaro. 2002. Leishmania (Leishmania) chagasi is not 
vertically transmitted in dogs. Vet Parasitol. 103:71-81. 
20. Antoine, J. C., C. Jouanne, T. Lang, E. Prina, C. de Chastellier, and C. Frehel. 
1991. Localization of major histocompatibility complex class II molecules in 
phagolysosomes of murine macrophages infected with Leishmania amazonensis. 
Infect Immun. 59:764-775. 
21. Antoine, J. C., T. Lang, E. Prina, N. Courret, and R. Hellio. 1999. H-2M 
molecules, like MHC class II molecules, are targeted to parasitophorous vacuoles of 
Leishmania-infected macrophages and internalized by amastigotes of L. amazonensis 
and L. mexicana. J Cell Sci. 112:2559-2570. 
22. Antoine, J. C., E. Prina, C. Jouanne, and P. Bongrand. 1990. Parasitophorous 
vacuoles of Leishmania amazonensis-infected macrophages maintain an acidic pH. 
Infect Immun. 58:779-787. 
76 
23. Antoine, J. C., E. Prina, T. Lang, and N. Courret. 1998. The biogenesis and 
properties of the parasitophorous vacuoles that harbour Leishmania in murine 
macrophages. Trends Microbiol. 6:392-401. 
24. Appelmelk, B. J., I. Van Die, S. J. Van Vliet, C. M. Vandenbroucke-Grauls, T. B. 
Geijtenbeek, and Y. Van Kooyk. 2003. Cutting Edge: Carbohydrate Profiling 
Identifies New Pathogens That Interact with Dendritic Cell-Specific ICAM-3-
Grabbing Nonintegrin on Dendritic Cells. J Immunol. 170:1635-1639. 
25. Aragort de Rossell, R., O. Rossell, R. de Jesus de Duran, and A. M. Rodriguez. 
1993. Thermotherapy v. antimonials: what happens after the healing of cutaneous 
leishmaniasis lesions? Ann Trop Med Parasitol. 87:23-30. 
26. Arnold:, J., and H. Moll. 1998. Langerhans cell migration in murine cutaneous 
leishmaniasis: regulation by tumor necrosis factor alpha, interleukin-1 beta, and 
macrophage inflammatory protein-1 alpha. Dev Immunol. 6:3-11. 
27. Aseffa, A., A. Gumy, P. Launois, H. R. MacDonald, J. A. Louis, and F. Tacchini-
Cottier. 2002. The early IL-4 response to Leishmania major and the resulting Th2 
cell maturation steering progressive disease in BALB/c mice are subject to the control 
of regulatory CD4+CD25+ T cells. J Immunol. 169:3232-3241. 
28. Ashford, D. A., J. R. David, M. Freire, R. David, I. Sherlock, M. C. Eulalio, D. P. 
Sampaio, and R. Badaro. 1998. Studies on control of visceral leishmaniasis: impact 
of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. 
Am J Trop Med Hyg. 59:53-57. 
29. Ashford, R. W. 1996. Leishmaniasis reservoirs and their significance in control. Clin 
Dermatol. 14:523-532. 
30. Ato, M., S. Stager, C. R. Engwerda, and P. M. Kaye. 2002. Defective CCR7 
expression on dendritic cells contributes to the development of visceral leishmaniasis. 
Nat Immunol. 3:1185-1191. 
31. Babai, B., H. Louzir, P. A. Cazenave, and K. Dellagi. 1999. Depletion of peritoneal 
CD5+ B cells has no effect on the course of Leishmania major infection in 
susceptible and resistant mice. Clin Exp Immunol. 117:123-129. 
32. Baekkevold, E. S., T. Yamanaka, R. T. Palframan, H. S. Carlsen, F. P. Reinholt, 
U. H. von Andrian, P. Brandtzaeg, and G. Haraldsen. 2001. The CCR7 ligand elc 
(CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. 
J Exp Med. 193:1105-1112. 
33. Baldwin, T. M., C. Elso, J. Curtis, L. Buckingham, and E. Handman. 2003. The 
site of Leishmania major infection determines disease severity and immune 
responses. Infect Immun. 71:6830-6834. 
34. Balestieri, F. M., A. R. Queiroz, C. Scavone, V. M. Costa, M. Barral-Netto, and 
A. Abrahamsohn Ide. 2002. Leishmania (L.) amazonensis-induced inhibition of 
nitric oxide synthesis in host macrophages. Microbes Infect. 4:23-29. 
35. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. 
Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu Rev 
Immunol. 18:767-811. 
36. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of 
immunity. Nature. 392:245-252. 
77 
37. Barrai, A., R. Badaro, M. Barral-Netto, G. Grimaldi, Jr., H. Momem, and E. M. 
Carvalho. 1986. Isolation of Leishmania mexicana amazonensis from the bone 
marrow in a case of American visceral leishmaniasis. Am J Trop Med Hyg. 35:732-
734. 
38. Barrai, A., D. Pedral-Sampaio, G. Grimaldi Junior, H. Momen, D. McMahon-
Pratt, A. Ribeiro de Jesus, R. Almeida, R. Badaro, M. Barral-Netto, E. M. 
Carvalho, and et al. 1991. Leishmaniasis in Bahia, Brazil: evidence that Leishmania 
amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg. 
44:536-546. 
39. Barrai, A., E. A. Petersen, D. L. Sacks, and F. A. Neva. 1983. Late metastatic 
Leishmaniasis in the mouse. A model for mucocutaneous disease. Am J Trop Med 
Hyg. 32:277-285. 
40. Barral-Netto, M., A. Barrai, C. E. BrowneU, Y. A. Skeiky, L. R. Ellingsworth, D. 
R. Twardzik, and S. G. Reed. 1992. Transforming growth factor-beta in leishmanial 
infection: a parasite escape mechanism. Science. 257:545-548. 
41. Barral-Netto, M., R. L. Von Sohsten, M. Teixeira, W. L. dos Santos, M. L. 
Pompeu, R. A. Moreira, J. T. Oliveira, B. S. Cavada, E. Falcoff, and A. Barrai. 
1996. In vivo protective effect of the lectin from Canavalia brasiliensis on BALB/c 
mice infected by Leishmania amazonensis. Acta Trop. 60:237-250. 
42. Bebars, M. A., A. O. el Serougi, K. M. Makled, E. M. Mikhael, M. M. Abou 
Gamra, M. el Sherbiny, A. W. Mohareb, and E. A. Mohammed. 2000. An 
experimental vaccine providing heterologous protection for Leishmania species in 
murine model. J Egypt Soc Parasitol. 30:137-156. 
43. Becker, I., N. Salaiza, M. Aguirre, J. Delgado, N. Carrillo-Carrasco, L. G. 
Kobeh, A. Ruiz, R. Cervantes, A. P. Torres, N. Cabrera, A. Gonzalez, C. 
Maldonado, and A. Isibasi. 2003. Leishmania lipophosphoglycan (LPG) activates 
NK cells through toll-like receptor-2. Mol Biochem Parasitol. 130:65-74. 
44. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, 
and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of 
Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 
receptor antibody for sterile cure. J Exp Med. 194:1497-1506. 
45. Belkaid, Y., S. Kamhawi, G. Modi, J. Valenzuela, N. Noben-Trauth, E. Rowton, 
J. Ribeiro, and D. L. Sacks. 1998. Development of a natural model of cutaneous 
leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-
term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med. 
188:1941-1953. 
46. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. 
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. 
Nature. 420:502-507. 
47. Belkaid, Y., E. Von Stebut, S. Mendez, R. Lira, E. Caler, S. Bertholet, M. C. 
Udey, and D. Sacks. 2002. CD8+ T cells are required for primary immunity in 
C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J 
Immunol. 168:3992-4000. 
78 
48. Belli, A., D. Garcia, X. Palacios, B. Rodriguez, S. Valle, E. Videa, E. Tinoco, F. 
Marin, and E. Harris. 1999. Widespread atypical cutaneous Leishmaniasis caused 
by Leishmania (L.) Chagasi in Nicaragua. Am J Trop Med Hyg. 61:380-385. 
49. Belosevic, M., D. S. Finbloom, P. H. Van Der Meide, M. V. Slayter, and C. A. 
Nacy. 1989. Administration of monoclonal anti-IFN-gamma antibodies in vivo 
abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J 
Immunol. 143:266-274. 
50. Benedek, T. 1940. American Leishmaniasis. Report of the first autochtonous case in 
the United States. J Trop Med Hyg. 43:147-155. 
51. Bennett, C. L., L. Colledge, H. E. Richards, P. A. Reay, C. C. Blackburn, and T. 
Aebischer. 2003. Uncompromised generation of a specific H-2DM-dependent 
peptide-MHC class II complex from exogenous antigen in Leishmania mexicana-
infected dendritic cells. Eur J Immunol. 33:3504-3513. 
52. Bennett, C. L., A. Misslitz, L. Colledge, T. Aebischer, and C. C. Blackburn. 2001. 
Silent infection of bone marrow-derived dendritic cells by Leishmania mexicana 
amastigotes. Eur J Immunol. 31:876-883. 
53. Berberich, C., J. R. Ramirez-Pineda, C. Hambrecht, G. Alber, Y. A. Skeiky, and 
H. Moll. 2003. Dendritic cell (DC)-based protection against an intracellular pathogen 
is dependent upon DC-derived IL-12 and can be induced by molecularly defined 
antigens. J Immunol. 170:3171-3179. 
54. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and 
chemotherapeutic developments in the last 10 years. Clin Infect Dis. 24:684-703. 
55. Berrahal, F., C. Mary, M. Roze, A. Berenger, K. Escoffier, D. Lamouroux, and 
S. Dunan. 1996. Canine leishmaniasis: identification of asymptomatic carriers by 
polymerase chain reaction and immunoblotting. Am J Trop Med Hyg. 55:273-277. 
56. Beyrodt, C. G., A. R. Pinto, E. Freymuller, and C. L. Barbieri. 1997. 
Characterization of an antigen from Leishmania amazonensis amastigotes able to 
elicit protective responses in a murine model. Infect Immun. 65:2052-2059. 
57. Bezerra, H. S., and M. J. Teixeira. 2001. Effect of Lutzomyia whitmani (Diptera: 
Psychodidae) salivary gland lysates on Leishmania (Viannia) braziliensis infection in 
BALB/c mice. Mem Inst Oswaldo Cruz. 96:349-351. 
58. Biedermann, T., S. Zimmermann, H. Himmelrich, A. Gumy, O. Egeter, A. K. 
Sakrauski, I. Seegmuller, H. Voigt, P. Launois, A. D. Levine, H. Wagner, K. 
Heeg, J. A. Louis, and M. Rocken. 2001. IL-4 instructs TH1 responses and 
resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol. 2:1054-
1060. 
59. Blackwell, J. M. 1996. Genetic susceptibility to leishmanial infections: studies in 
mice and man. Parasitology. 112:867-74. 
60. Blackwell, J. M. 1983. Leishmania donovani infection in heterozygous and 
recombinant H-2 haplotype mice. Immunogenetics. 18:101-109. 
61. Blackwell, J. M., R. A. Ezekowitz, M. B. Roberts, J. Y. Channon, R. B. Sim, and 
S. Gordon. 1985. Macrophage complement and lectin-like receptors bind Leishmania 
in the absence of serum. J Exp Med. 162:324-331. 
79 
62. Blank, C., H. Fuchs, K. Rappersberger, M. Rollinghoff, and H. Moll. 1993. 
Parasitism of epidermal Langerhans cells in experimental cutaneous leishmaniasis 
with Leishmania major. J Infect Dis. 167:418-425. 
63. Bogdan, C., N. Donhauser, R. Doring, M. Rollinghoff, A. Diefenbach, and M. G. 
Rittig. 2000. Fibroblasts as host cells in latent leishmaniosis. J Exp Med. 191:2121-
2130. 
64. Bomfîm, G., C. Nascimento, J. Costa, E. M. Carvalho, M. Barral-Netto, and A. 
Barrai. 1996. Variation of cytokine patterns related to therapeutic response in diffuse 
cutaneous leishmaniasis. Exp Parasitol. 84:188-194. 
65. Bonham, C. A., L. Lu, R. A. Hoffman, R. L. Simmons, and A. W. Thomson. 
1997. Generation of nitric oxide by mouse dendritic cells and its implications for 
immune response regulation. Adv Exp Med Biol. 417:283-290. 
66. Bourreau, E., G. Prevot, R. Pradinaud, and P. Launois. 2001. Interleukin (IL)-13 
is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and 
renders specific CD4+ T cells unresponsive to IL-12. J Infect Dis. 183:953-959. Epub 
2001 Feb 2009. 
67. Bourreau, E., G. Prevot, R. Pradinaud, and P. Launois. 2001. Unresponsiveness 
of specific T cells to IL-12 is associated with active cutaneous leishmaniasis owing to 
Leishmania guyanensis. Scand J Immunol. 54:335-339. 
68. Bouvier, J., P. Schneider, and R. Etges. 1995. Leishmanolysin: surface 
metalloproteinase of Leishmania. Methods Enzymol. 248:614-633. 
69. Bray, R. S. 1974. Leishmania. Annu Rev Microbiol. 28:189-217. 
70. Bray, R. S. 1983. Leishmania: chemotaxic responses of promastigotes and 
macrophages in vitro. J Protozool. 30:322-329. 
71. Brenier-Pinchart, M., H. Pelloux, D. Derouich-Guergour, and P. Ambroise-
Thomas. 2001. Chemokines in host-protozoan-parasite interactions. Trends Parasitol. 
17:292-296. 
72. Bretscher, P. A., G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann. 1992. 
Establishment of stable, cell-mediated immunity that makes "susceptible" mice 
resistant to Leishmania major. Science. 257:539-542. 
73. Brittingham, A., G. Chen, B. S. McGwire, K. P. Chang, and D. M. Mosser. 1999. 
Interaction of Leishmania gp63 with cellular receptors for fibronectin. Infect Immun. 
67:4477-4484. 
74. Brittingham, A., C. J. Morrison, W. R. McMaster, B. S. McGwire, K. P. Chang, 
and D. M. Mosser. 1995. Role of the Leishmania surface protease gp63 in 
complement fixation, cell adhesion, and resistance to complement-mediated lysis. J 
Immunol. 155:3102-3111. 
75. Brodskyn, C. I., G. K. DeKrey, and R. G. Titus. 2001. Influence of costimulatory 
molecules on immune response to Leishmania major by human cells in vitro. Infect 
Immun. 69:665-672. 
76. Brown, D. R., J. M. Green, N. H. Moskowitz, M. Davis, C. B. Thompson, and S. 
L. Reiner. 1996. Limited role of CD28-mediated signals in T helper subset 
differentiation. J Exp Med. 184:803-810. 
77. Brown, D. R., and S. L. Reiner. 1999. Polarized helper-T-cell responses against 
Leishmania major in the absence of B cells. Infect Immun. 67:266-270. 
80 
78. Brown, J. A., R. G. Titus, N. Nabavi, and L. H. Glimcher. 1996. Blockade of 
CD86 ameliorates Leishmania major infection by down-regulating the Th2 response. 
J Infect Dis. 174:1303-1308. 
79. Buxbaum, L. U., H. Denise, G. H. Coombs, J. Alexander, J. C. Mottram, and P. 
Scott. 2003. Cysteine protease B of Leishmania mexicana inhibits host Thl responses 
and protective immunity. J Immunol. 171:3711-3717. 
80. Buxbaum, L. U., J. E. Uzonna, M. H. Goldschmidt, and P. Scott. 2002. Control of 
New World cutaneous leishmaniasis is IL12-independent but STAT4 dependent. Eur 
J Immunol. 32:3206-3215. 
81. Caceres-Dittmar, G., F. J. Tapia, M. A. Sanchez, M. Yamamura, K. Uyemura, 
R. L. Modlin, B. R. Bloom, and J. Convit. 1993. Determination of the cytokine 
profile in American cutaneous leishmaniasis using the polymerase chain reaction. 
Clin Exp Immunol. 91:500-505. 
82. Campbell, K., H. Diao, J. Ji, and L. Soong. 2003. DNA immunization with the 
gene encoding P4 nuclease of Leishmania amazonensis protects mice against 
cutaneous Leishmaniasis. Infect Immun. 71:6270-6278. 
83. Campbell, K. A., P. J. Ovendale, M. K. Kennedy, W. C. Fanslow, S. G. Reed, 
and C. R. Maliszewski. 1996. CD40 ligand is required for protective cell-mediated 
immunity to Leishmania major. Immunity. 4:283-289. 
84. Campos, M. A., I. C. Almeida, O. Takeuchi, S. Akira, E. P. Valente, D. O. 
Procopio, L. R. Travassos, J. A. Smith, D. T. Golenbock, and R. T. Gazzinelli. 
2001. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors 
from a protozoan parasite. J Immunol. 167:416-423. 
85. Campos-Neto, A., J. R. Webb, K. Greeson, R. N. Coler, Y. A. Skeiky, and S. G. 
Reed. 2002. Vaccination with plasmid DNA encoding TSAZLmSTIl leishmanial 
fusion proteins confers protection against Leishmania major infection in susceptible 
BALB/c mice. Infect Immun. 70:2828-2836. 
86. Carrera, L., R. T. Gazzinelli, R. Badolato, S. Hieny, W. Muller, R. Kuhn, and D. 
L. Sacks. 1996. Leishmania promastigotes selectively inhibit interleukin 12 induction 
in bone marrow-derived macrophages from susceptible and resistant mice. J Exp 
Med. 183:515-526. 
87. Carvalho, E. M., O. Bacellar, C. Brownell, T. Regis, R. L. Coffman, and S. G. 
Reed. 1994. Restoration of IFN-gamma production and lymphocyte proliferation in 
visceral leishmaniasis. J Immunol. 152:5949-5956. 
88. Carvalho, E. M., O. A. Bacellar, S. Reed, A. Barrai, and H. Rocha. 1988. Visceral 
leishmaniasis: a disease associated with inability of lymphocytes to activate 
macrophages to kill leishmania. Braz J Med Biol Res. 21:85-92. 
89. Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson, Jr. 
1985. Absence of gamma interferon and interleukin 2 production during active 
visceral leishmaniasis. J Clin Invest. 76:2066-2069. 
90. Carvalho, E. M., A. Barrai, D. Pedral-Sampaio, M. Barral-Netto, R. Badaro, H. 
Rocha, and W. D. Johnson, Jr. 1992. Immunologic markers of clinical evolution in 
children recently infected with Leishmania donovani chagasi. J Infect Dis. 165:535 
540. 
81 
91. Carvalho, E. M., R. S. Teixeira, and W. D. Johnson, Jr. 1981. Cell-mediated 
immunity in American visceral leishmaniasis: reversible immunosuppression during 
acute infection. Infect Immun. 33:498-500. 
92. Castes, M., A. Agnelli, O. Verde, and A. J. Rondon. 1983. Characterization of the 
cellular immune response in American cutaneous leishmaniasis. Clin Immunol 
Immunopathol. 27:176-186. 
93. Castro-Sousa, F., M. Paranhos-Silva, I. Sherlock, M. S. Paixao, L. C. Pontes-de-
Carvalho, and W. L. dos-Santos. 2001. Dissociation between vasodilation and 
Leishmania infection-enhancing effects of sand fly saliva and maxadilan. Mem Inst 
Oswaldo Cruz. 96:997-999. 
94. Caux, C., S. Ait-Yahia, K. Chemin, O. de Bouteiller, M. C. Dieu-Nosjean, B. 
Homey, C. Massacrier, B. Vanbervliet, A. Zlotnik, and A. Vicari. 2000. Dendritic 
cell biology and regulation of dendritic cell trafficking by chemokines. Springer 
Semin Immunopathol. 22:345-369. 
95. Cavalcante, R. R., M. H. Pereira, and N. F. Gontijo. 2003. Anti-complement 
activity in the saliva of phlebotomine sand flies and other haematophagous insects. 
Parasitology. 127:87-93. 
96. Chakir, H., A. Campos-Neto, M. Mojibian, and J. R. Webb. 2003. IL-12Rbeta2-
deficient mice of a genetically resistant background are susceptible to Leishmania 
major infection and develop a parasite-specific Th2 immune response. Microbes 
Infect. 5:241-249. 
97. Chambers, C. A., and J. P. Allison. 1997. Co-stimulation in T cell responses. Curr 
Opin Immunol. 9:396-404. 
98. Champsi, J., and D. McMahon-Pratt. 1988. Membrane glycoprotein M-2 protects 
against Leishmania amazonensis infection. Infect Immun. 56:3272-3279. 
99. Chan, J., T. Fujiwara, P. Brennan, M. McNeil, S. J. Turco, J. C. Sibille, M. 
Snapper, P. Aisen, and B. R. Bloom. 1989. Microbial glycolipids: possible 
virulence factors that scavenge oxygen radicals. Proc Natl Acad Sci USA. 86:2453-
2457. 
100. Chan, M. M. 1993. T cell response in murine Leishmania mexicana amazonensis 
infection: production of interferon-gamma by CD8+ cells. Eur J Immunol. 23:1181-
1184. 
101. Chang, K. P. 1978. Leishmania infection of human skin fibroblasts in vitro: absence 
of phagolysosomal fusion after induced phagocytosis of promastigotes, and their 
intracellular transformation. Am J Trop Med Hyg. 27:1084-1096. 
102. Chang, K. P., and D. M. Dwyer. 1976. Multiplication of a human parasite 
{Leishmania donovani) in phagolysosomes of hamster macrophages in vitro. Science. 
193:678-680. 
103. Chatelain, R., S. Mauze, and R. L. Coffman. 1999. Experimental Leishmania 
major infection in mice: role of IL-10. Parasite Immunol. 21:211-218. 
104. Chatelain, R., S. Mauze, K. Varkila, and R. L. Coffman. 1999. Leishmania major 
infection in interleukin-4 and interferon-gamma depleted mice. Parasite Immunol. 
21:423-431. 
105. Chatelain, R., K. Varkila, and R. L. Coffman. 1992. IL-4 induces a Th2 response 
in Leishmania major-infected mice. J Immunol. 148:1182-1187. 
82 
106. Chaussabel, D., R. Tolouei Semnani, M. A. McDowell, D. Sacks, A. Sher, and T. 
B. Nutman. 2003. Unique gene expression profiles of human macrophages and 
dendritic cells to phylogenetically distinct parasites. Blood. 27:27. 
107. Chen, G., P. A. Darrah, and D. M. Mosser. 2001. Vaccination against the 
intracellular pathogens Leishmania major and L. amazonensis by directing CD40 
ligand to macrophages. Infect Immun. 69:3255-3263. 
108. Childs, G. E., L. K. Lightner, L. McKinney, M. G. Groves, E. E. Price, and L. D. 
Hendricks. 1984. Inbred mice as model hosts for cutaneous leishmaniasis. I. 
Resistance and susceptibility to infection with Leishmania braziliensis, L. mexicana, 
and L. aethiopica. Ann Trop Med Parasitol. 78:25-34. 
109. Choi, C. M., and E. A. Lemer. 2001. Leishmaniasis as an emerging infection. J 
Investig Dermatol Symp Proc. 6:175-182. 
110. Chulay, J. D., M. A. Adoyo, and J. I. Githure. 1985. Leishmania donovani 
parasitaemia in Kenyan visceral leishmaniasis. Trans R Soc Trop Med Hyg. 79:218-
222. 
111. Coelho, E. A., C. A. Tavares, F. A. Carvalho, K. F. Chaves, K. N. Teixeira, R. C. 
Rodrigues, H. Charest, G. Matlashewski, R. T. Gazzinelli, and A. P. Fernandes. 
2003. Immune responses induced by the Leishmania (Leishmania) donovani A2 
antigen, but not by the LACK antigen, are protective against experimental 
Leishmania (Leishmania) amazonensis infection. Infect Immun. 71:3988-3994. 
112. Colmenares, M., S. L. Constant, P. E. Kima, and D. McMahon-Pratt. 2002. 
Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the 
absence of circulating antibody. Infect Immun. 70:6597-6605. 
113. Colmenares, M., A. L. Corbi, S. J. Turco, and L. Rivas. 2004. The dendritic cell 
receptor DC-SIGN discriminates among species and life cycle forms of Leishmania. J 
Immunol. 172:1186-1190. 
114. Colmenares, M., S. Kar, K. Goldsmith-Pestana, and D. McMahon-Pratt. 2002. 
Mechanisms of pathogenesis: differences amongst Leishmania species. Trans R Soc 
Trop Med Hyg. 96:S3-7. 
115. Colmenares, M., P. E. Kima, E. Samoff, L. Soong, and D. McMahon-Pratt. 2003. 
Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in 
vaccine-induced immunity against Leishmania amazonensis infection. Infect Immun. 
71:3172-3182. 
116. Colmenares, M., A. Puig-Kroger, O. M. Pello, A. L. Corbi, and L. Rivas. 2002. 
Dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing 
nonintegrin (DC-SIGN, CD209), a C-type surface lectin in human DCs, is a receptor 
for Leishmania amastigotes. J Biol Chem. 277:36766-36769. 
117. Colomer-Gould, V., L. Glvao Quintao, J. Keithly, and N. Nogueira. 1985. A 
common major surface antigen on amastigotes and promastigotes of Leishmania 
species. J Exp Med. 162:902-916. 
118. Corry, D. B., S. L. Reiner, P. S. Linsley, and R. M. Locksley. 1994. Differential 
effects of blockade of CD28-B7 on the development of Thl or Th2 effector cells in 
experimental leishmaniasis. J Immunol. 153:4142-4148. 
83 
119. Costa, C. H., H. F. Pereira, F. C. Pereira, J. P. Tavares, M. V. Araujo, and M. J. 
Goncalves. 1999. Is the household dog a risk factor for American visceral 
leishmaniasis in Brazil? Trans R Soc Trop Med Hyg. 93:464. 
120. Courret, N., C. Frehel, N. Gouhier, M. Pouchelet, E. Prina, P. Roux, and J. C. 
Antoine. 2002. Biogenesis of Leisftmam<z-harbouring parasitophorous vacuoles 
following phagocytosis of the metacyclic promastigote or amastigote stages of the 
parasites. J Cell Sci. 115:2303-2316. 
121. Courret, N., C. Frehel, E. Prina, T. Lang, and J. C. Antoine. 2001. Kinetics of the 
intracellular differentiation of Leishmania amazonensis and internalization of host 
MHC molecules by the intermediate parasite stages. Parasitology. 122:263-279. 
122. Courret, N., T. Lang, G. Milon, and J. C. Antoine. 2003. Intradermal inoculations 
of low doses of Leishmania major and Leishmania amazonensis metacyclic 
promastigotes induce different immunoparasitic processes and status of protection in 
BALB/c mice. Int J Parasitol. 33:1373-1383. 
123. Coutinho, S. G., A. M. Da-Cruz, A. L. Bertho, M. A. Santiago, and P. De-Luca. 
1998. Immunologic patterns associated with cure in human American cutaneous 
leishmaniasis. Braz J Med Biol Res. 31:139-142. 
124. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis-current chemotherapy and 
recent advances in the search for novel drugs. Trends Parasitol. 19:502-508. 
125. Cruz, I., M. A. Morales, I. Noguer, A. Rodriguez, and J. Alvar. 2002. Leishmania 
in discarded syringes from intravenous drug users. Lancet. 359:1124-1125. 
126. Cuvillier, A., J. C. Miranda, A. Ambit, A. Barrai, and G. Merlin. 2003. Abortive 
infection of Lutzomyia longipalpis insect vectors by aflagellated LdARL-3A-Q70L 
overexpressing Leishmania amazonensis parasites. Cell Microbiol. 5:717-728. 
127. da Conceicao-Silva, F., B. L. Perlaza, J. A. Louis, and P. Romero. 1994. 
Leishmania major infection in mice primes for specific major histocompatibility 
complex class I-restricted CD8+ cytotoxic T cell responses. Eur J Immunol. 24:2813-
2817. 
128. Da Silva, R. P., B. F. Hall, K. A. Joiner, and D. L. Sacks. 1989. CR1, the C3b 
receptor, mediates binding of infective Leishmania major metacyclic promastigotes to 
human macrophages. J Immunol. 143:617-622. 
129. Davis, A. J., H. W. Murray, and E. Handman. 2004. Drugs against leishmaniasis: a 
synergy of technology and partnerships. Trends Parasitol. 20:73-76. 
130. de Araujo Soares, R. M., A. L. dos Santos, M. C. Bonaldo, A. F. de Andrade, C. 
S. Alviano, J. Angluster, and S. Goldenberg. 2003. Leishmania (Leishmania) 
amazonensis: differential expression of proteinases and cell-surface polypeptides in 
avirulent and virulent promastigotes. Exp Parasitol. 104:104-112. 
131. de Freitas Balanco, J. M., M. E. Costa Moreira, A. Bonomo, P. T. Bozza, G. 
Amarante-Mendes, C. Pirmez, and M. A. Barcinski. 2001. Apoptotic mimicry by 
an obligate intracellular parasite downregulates macrophage microbicidal activity. 
Curr Biol. 11:1870-1873. 
132. de Rossell, R. A., R. J. de Duran, O. Rossell, and A. M. Rodriguez. 1992. Is 
leishmaniasis ever cured? Trans R Soc Trop Med Hyg. 86:251-253. 
84 
133. De Souza Leao, S., T. Lang, E. Prina, R. Hellio, and J. C. Antoine. 1995. 
Intracellular Leishmania amazonensis amastigotes internalize and degrade MHC class 
II molecules of their host cells. J Cell Sci. 108:3219-3231. 
134. de Veer, M. J., J. M. Curtis, T. M. Baldwin, J. A. DiDonato, A. Sexton, M. J. 
McConville, E. Handman, and L. Schofield. 2003. MyD88 is essential for 
clearance of Leishmania major, possible role for lipophosphoglycan and Toll-like 
receptor 2 signaling. Eur J Immunol. 33:2822-2831. 
135. Debus, A., J. Glasner, M. Rollinghoff, and A. Gessner. 2003. High levels of 
susceptibility and T helper 2 response in MyD88-deficient mice infected with 
Leishmania major are interleukin-4 dependent. Infect Immun. 71:7215-7218. 
136. Dedet, J. P., F. Pratlong, G. Lanotte, and C. Ravel. 1999. Cutaneous leishmaniasis. 
The parasite. Clin Dermatol. 17:261-268. 
137. Dedet, J. P., A. Ryter, E. Vogt, P. Hosli, and L. P. da Silva. 1983. Uptake and 
killing of Leishmania mexicana amazonensis amastigotes by human skin fibroblasts. 
Ann Trop Med Parasitol. 77:35-44. 
138. DeKrey, G. K., J. J. Jones, M. L. Mbow, C. I. Brodskyn, and R. G. Titus. 2003. 
Short report: requirement of b cells for delayed type hypersensitivity-like pathology 
after secondary infection with Leishmania major in resistant C57BL/6 mice. Am J 
Trop Med Hyg. 69:481-483. 
139. Delgado, O., P. Guevara, S. Silva, E. Belfort, and J. L. Ramirez. 1996. Follow-up 
of a human accidental infection by Leishmania (Viannia) braziliensis using 
conventional immunologic techniques and polymerase chain reaction. Am J Trop 
Med Hyg. 55:267-272. 
140. Demicheli, C., R. Ochoa, J. B. da Silva, C. A. Falcao, B. Rossi-Bergmann, A. L. 
de Melo, R. D. Sinisterra, and F. Frezard. 2004. Oral delivery of meglumine 
antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob 
Agents Chemother. 48:100-103. 
141. Dent, A. L., T. M. Doherty, W. E. Paul, A. Sher, and L. M. Staudt. 1999. BCL-6-
deficient mice reveal an IL-4-independent, STAT6-dependent pathway that controls 
susceptibility to infection by Leishmania major. J Immunol. 163:2098-2103. 
142. Descoteaux, A., G. Matlashewski, and S. J. Turco. 1992. Inhibition of macrophage 
protein kinase C-mediated protein phosphorylation by Leishmania donovani 
lipophosphoglycan. J Immunol. 149:3008-3015. 
143. Descoteaux, A., S. J. Turco, D. L. Sacks, and G. Matlashewski. 1991. Leishmania 
donovani lipophosphoglycan selectively inhibits signal transduction in macrophages. 
J Immunol. 146:2747-2753. 
144. Desjeux, P. Programme for the surveillance and control of leishmaniasis. 
http://www.who.int/emc/diseases/leish/index.html (Date accessed: June 11,2004). 
145. Dietze, R., G. B. Barros, L. Teixeira, J. Harris, K. Michelson, A. Falqueto, and 
R. Corey. 1997. Effect of eliminating seropositive canines on the transmission of 
visceral leishmaniasis in Brazil. Clin Infect Dis. 25:1240-1242. 
146. Dieu, M. C., B. Vanbervliet, A. Vicari, J. M. Bridon, E. Oldham, S. Ait-Yahia, F. 
Briere, A. Zlotnik, S. Lebecque, and C. Caux. 1998. Selective recruitment of 
immature and mature dendritic cells by distinct chemokines expressed in different 
anatomic sites. J Exp Med. 188:373-386. 
85 
147. Dominguez, M., I. Moreno, C. Aizpurua, and A. Torano. 2003. Early mechanisms 
of Leishmania infection in human blood. Microbes Infect. 5:507-513. 
148. Dominguez, M., I. Moreno, M. Lopez-Trascasa, and A. Torano. 2002. 
Complement interaction with trypanosomatid promastigotes in normal human serum. 
J Exp Med. 195:451-459. 
149. Dominguez, M., and A. Torano. 1999. Immune adherence-mediated 
opsonophagocytosis: the mechanism of Leishmania infection. J Exp Med. 189:25-35. 
150. Dominguez, M., and A. Torano. 2001. Leishmania immune adherence reaction in 
vertebrates. Parasite Immunol. 23:259-265. 
151. Eddlestone, S. M. 2000. Visceral leishmaniasis in a dog from Maryland. J Am Vet 
Med Assoc. 217:1686-1688,1659. 
152. Elloso, M. M., and P. Scott. 1999. Expression and contribution of B7-1 (CD80) and 
B7-2 (CD86) in the early immune response to Leishmania major infection. J 
Immunol. 162:6708-6715. 
153. Eltoum, I. A., E. E. Zijlstra, M. S. Ali, H. W. Ghalib, M. M. Satti, B. Eltoum, and 
A. M. el-Hassan. 1992. Congenital kala-azar and leishmaniasis in the placenta. Am J 
Trop Med Hyg. 46:57-62. 
154. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 
1998. Neutralization of IL-12 demonstrates the existence of discrete organ-specific 
phases in the control of Leishmania donovani. Eur J Immunol. 28:669-680. 
155. Farrell, J. P., I. Muller, and J. A. Louis. 1989. A role for Lyt-2+ T cells in 
resistance to cutaneous leishmaniasis in immunized mice. J Immunol. 142:2052-
2056. 
156. Figdor, C. G., Y. van Kooyk, and G. J. Adema. 2002. C-type lectin receptors on 
dendritic cells and Langerhans cells. Nat Rev Immunol. 2:77-84. 
157. Flohe, S. B., C. Bauer, S. Flohe, and H. Moll. 1998. Antigen-pulsed epidermal 
Langerhans cells protect susceptible mice from infection with the intracellular 
parasite Leishmania major. Eur J Immunol. 28:3800-3811. 
158. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, 
and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing 
functional microenvironments in secondary lymphoid organs. Cell. 99:23-33. 
159. Frame, M. J., J. C. Mottram, and G. H. Coombs. 2000. Analysis of the roles of 
cysteine proteinases of Leishmania mexicana in the host-parasite interaction. 
Parasitology. 121:367-377. 
160. Frankenburg, S., V. Leibovici, N. Mansbach, S. J. Turco, and G. Rosen. 1990. 
Effect of glycolipids of Leishmania parasites on human monocyte activity. Inhibition 
by lipophosphoglycan. J Immunol. 145:4284-4289. 
161. Frommel, D., B. W. Ogunkolade, I. Vouldoukis, and L. Monjour. 1988. Vaccine-
induced immunity against cutaneous leishmaniasis in BALB/c mice. Infect Immun. 
56:843-848. 
162. Gaskin, A. A., P. Schantz, J. Jackson, A. Birkenheuer, L. Tomlinson, M. 
Gramiccia, M. Levy, F. Steurer, E. Kollmar, B. C. Hegarty, A. Ahn, and E. B. 
Breitschwerdt. 2002. Visceral leishmaniasis in a New York foxhound kennel. J Vet 
Intern Med. 16:34-44. 
86 
163. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, 
and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in 
normal and pathologie immune responses. Annu Rev Immunol. 16:495-521. 
164. Geijtenbeek, T. B., D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. van 
Duijnhoven, J. Middel, I. L. Cornelissen, H. S. Nottet, V. N. KewalRamani, D. R. 
Littman, C. G. Figdor, and Y. van Kooyk. 2000. DC-SIGN, a dendritic cell-
specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 
100:587-597. 
165. Geijtenbeek, T. B., R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, G. J. 
Adema, Y. van Kooyk, and C. G. Figdor. 2000. Identification of DC-SIGN, a novel 
dendritic cell-specific ICAM-3 receptor that supports primary immune responses. 
Cell. 100:575-585. 
166. Giannini, M. S. 1986. Sex-influenced response in the pathogenesis of cutaneous 
leishmaniasis in mice. Parasite Immunol. 8:31-37. 
167. Gicheru, M. M., J. O. Olobo, and C. O. Anjili. 1997. Heterologous protection by 
Leishmania donovani for Leishmania major infections in the vervet monkey model of 
the disease. Exp Parasitol. 85:109-116. 
168. Gicheru, M. M., J. O. Olobo, C. O. Anjili, A. S. Orago, F. Modabber, and P. 
Scott. 2001. Vervet monkeys vaccinated with killed Leishmania major parasites and 
interleukin-12 develop a type 1 immune response but are not protected against 
challenge infection. Infect Immun. 69:245-251. 
169. Gifawesen, C., and J. P. Farrell. 1989. Comparison of T-cell responses in self-
limiting versus progressive visceral Leishmania donovani infections in golden 
hamsters. Infect Immun. 57:3091-3096. 
170. Gomes, I. N., A. F. Calabrich, S. Tavares Rda, J. Wietzerbin, L. A. de Freitas, 
and P. S. Veras. 2003. Differential properties of CBA/J mononuclear phagocytes 
recovered from an inflammatory site and probed with two different species of 
Leishmania. Microbes Infect. 5:251-260. 
171. Gomes, N. A., V. Barreto-de-Souza, M. E. Wilson, and G. A. DosReis. 1998. 
Unresponsive CD4+ T lymphocytes from Leishmania chagasi-infected mice increase 
cytokine production and mediate parasite killing after blockade of B7-1/CTLA-4 
molecular pathway. J Infect Dis. 178:1847-1851. 
172. Gomes, N. A., and G. A. DosReis. 2001. The dual role of CTLA-4 in Leishmania 
infection. Trends Parasitol. 17:487-491. 
173. Gomes, N. A., C. R. Gattass, V. Barreto-De-Souza, M. E. Wilson, and G. A. 
DosReis. 2000. TGF-beta mediates CTLA-4 suppression of cellular immunity in 
murine kalaazar. J Immunol. 164:2001-2008. 
174. Gonzalez, C. R., F. R. Noriega, S. Huerta, A. Santiago, M. Vega, J. Paniagua, V. 
Ortiz-Navarrete, A. Isibasi, and M. M. Levine. 1998. Immunogenicity of a 
Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface 
protein gp63 of Leishmania mexicana mexicana. Vaccine. 16:1043-1052. 
175. Gorak, P. M., C. R. Engwerda, and P. M. Kaye. 1998. Dendritic cells, but not 
macrophages, produce IL-12 immediately following Leishmania donovani infection. 
Eur J Immunol. 28:687-695. 
87 
176. Gorczynski, R. M. 1982. Nature of resistance to leishmaniasis in experimental 
rodents. Dev Comp Immunol. 6:199-207. 
177. Gorelik, L., S. Constant, and R. A. Flavell. 2002. Mechanism of transforming 
growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med. 
195:1499-1505. 
178. Gotham, J. D., M. L. Guler, D. Fenoglio, U. Gubler, and K. M. Murphy. 1998. 
Low dose TGF-beta attenuates IL-12 responsiveness in murine Th cells. J Immunol. 
161:1664-1670. 
179. Gray, D. 2002. A role for antigen in the maintenance of immunological memory. Nat 
Rev Immunol. 2:60-65. 
180. Grevelink, S. A., and E. A. Lerner. 1996. Leishmaniasis. J Am Acad Dermatol. 
34:257-272. 
181. Grewal, I. S., and R. A. Flavell. 1998. CD40 and CD 154 in cell-mediated immunity. 
Annu Rev Immunol. 16:111-135. 
182. Grimaldi, G., Jr., M. J. Scares, and P. L. Moriearty. 1984. Tissue eosinophilia and 
Leishmania mexicana mexicana eosinophil interactions in murine cutaneous 
leishmaniasis. Parasite Immunol. 6:397-408. 
183. Grogl, M., J. L. Daugirda, D. L. Hoover, A. J. Magill, and J. D. Berman. 1993. 
Survivability and infectivity of viscerotropic Leishmania tropica from Operation 
Desert Storm participants in human blood products maintained under blood bank 
conditions. Am J Trop Med Hyg. 49:308-315. 
184. Grogl, M., B. G. Schuster, W. Y. Ellis, and J. D. Berman. 1999. Successful topical 
treatment of murine cutaneous leishmaniasis with a combination of paromomycin 
(Aminosidine) and gentamicin. J Parasitol. 85:354-359. 
185. Groux, H., F. Cottrez, M. Rouleau, S. Mauze, S. Antonenko, S. Hurst, T. McNeil, 
M. Bigler, M. G. Roncarolo, and R. L. Coffman. 1999. A transgenic model to 
analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J 
Immunol. 162:1723-1729. 
186. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries, and 
M. G. Roncarolo. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell 
responses and prevents colitis. Nature. 389:737-742. 
187. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena. 2002. 
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 
20:621-667. 
188. Guevara-Mendoza, O., C. Une, P. Franceschi Carreira, and A. Orn. 1997. 
Experimental infection of Balb/c mice with Leishmania panamensis and Leishmania 
mexicana: induction of early IFN-gamma but not IL-4 is associated with the 
development of cutaneous lesions. Scand J Immunol. 46:35-40. 
189. Gunn, M. D., S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L. T. Williams, 
and H. Nakano. 1999. Mice lacking expression of secondary lymphoid organ 
chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp 
Med. 189:451-460. 
190. Gunn, M. D., K. Tangemann, C. Tam, J. G. Cyster, S. D. Rosen, and L. T. 
Williams. 1998. A chemokine expressed in lymphoid high endothelial venules 
88 
promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U 
S A. 95:258-263. 
191. Gurunathan, S., C. Prussia, D. L. Sacks, and R. A. Seder. 1998. Vaccine 
requirements for sustained cellular immunity to an intracellular parasitic infection. 
Nat Med. 4:1409-1415. 
192. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. 
Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the 
immunodominant LACK parasite antigen confers protective immunity to mice 
infected with Leishmania major. J Exp Med. 186:1137-1147. 
193. Gurunathan, S., L. Stobie, C. Prussin, D. L. Sacks, N. Glaichenhaus, A. Iwasaki, 
D. J. Powell, R. M. Locksley, J. T. Chang, C. Y. Wu, and R. A. Seder. 2000. 
Requirements for the maintenance of Thl immunity in vivo following DNA 
vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol. 
165:915-924. 
194. Guy, R. A., and M. Belosevic. 1993. Comparison of receptors required for entry of 
Leishmania major amastigotes into macrophages. Infect Immun. 61:1553-1558. 
195. Hagenbaugh, A., S. Sharma, S. M. Dubinett, S. H. Wei, R. Aranda, H. 
Cheroutre, D. J. Fowell, S. Binder, B. Tsao, R. M. Locksley, K. W. Moore, and 
M. Kronenberg. 1997. Altered immune responses in interleukin 10 transgenic mice. 
J Exp Med. 185:2101-2110. 
196. Halary, F., A. Amara, H. Lortat- Jacob, M. Messerle, T. Delaunay, C. Houles, F. 
Fieschi, F. Arenzana-Seisdedos, J. F. Moreau, and J. Dechanet-Merville. 2002. 
Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection 
and target cell trans-infection. Immunity. 17:653-664. 
197. Hale, C., and J. G. Howard. 1981. Immunological regulation of experimental 
cutaneous leishmaniasis. 2. Studies with Biozzi high and low responder lines of mice. 
Parasite Immunol. 3:45-55. 
198. Handman, E. 1999. Cell biology of Leishmania. Adv Parasitol. 44:1-39. 
199. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin 
Microbiol Rev. 14:229-243. 
200. Handman, E., L. F. Schnur, T. W. Spithill, and G. F. Mitchell. 1986. Passive 
transfer of Leishmania lipopolysaccharide confers parasite survival in macrophages. J 
Immunol. 137:3608-3613. 
201. Harty, J. T., A. R. Tvinnereim, and D. W. White. 2000. CD8+ T cell effector 
mechanisms in resistance to infection. Annu Rev Immunol. 18:275-308. 
202. Hayashi, F., K. D. Smith, A. Ozinsky, T. R. Hawn, E. C. Yi, D. R. Goodlett, J. K. 
Eng, S. Akira, D. M. Underbill, and A. Aderem. 2001. The innate immune 
response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 410:1099-
1103. 
203. Heinzel, F. P., and R. A. Maier, Jr. 1999. Interleukin-4-independent acceleration of 
cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-
CTLA4 antibody. Infect Immun. 67:6454-6460. 
204. Heinzel, F. P., R. M. Rerko, F. Ahmed, and E. Pearlman. 1995. Endogenous IL-12 
is required for control of Th2 cytokine responses capable of exacerbating 
leishmaniasis in normally resistant mice. J Immunol. 155:730-739. 
89 
205. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 
1989. Reciprocal expression of interferon gamma or interleukin 4 during the 
resolution or progression of murine leishmaniasis. Evidence for expansion of distinct 
helper T cell subsets. J Exp Med. 169:59-72; 
206. Heinzel, F. P., M. D. Sadick, S. S. Mutha, and R. M. Locksley. 1991. Production 
of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ 
lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl 
Acad Sci USA. 88:7011-7015. 
207. Heinzel, F. P., D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, and M. K. Gately. 
1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp 
Med. 177:1505-1509. 
208. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, 
K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor 
recognizes bacterial DNA. Nature. 408:740-745. 
209. Herman, R. 1980. Cytophilic and opsonic antibodies in visceral leishmaniasis in 
mice. Infect Immun. 28:585-593. 
210. Herrer, A., and H. A. Christensen. 1975. Implication of Phlebotomus sand flies as 
vectors of bartonellosis and leishmaniasis as early as 1764. Science. 190:154-155. 
211. Herwaldt, B. L. 1999. Leishmaniasis. Lancet. 354:1191-1199. 
212. Hill, J. O., M. Awwad, and R. J. North. 1989. Elimination of CD4+ suppressor T 
cells from susceptible BALB/c mice releases CD8+ T lymphocytes to mediate 
protective immunity against Leishmania. J Exp Med. 169:1819-1827. 
213. Himmelrich, H., P. Launois, I. Maillard, T. Biedermann, F. Tacchini-Cottier, R. 
M. Locksley, M. Rocken, and J. A. Louis. 2000. In BALB/c mice, IL-4 production 
during the initial phase of infection with Leishmania major is necessary and sufficient 
to instruct Th2 cell development resulting in progressive disease. J Immunol. 
164:4819-4825. 
214. Himmelrich, H., C. Parra-Lopez, F. Tacchini-Cottier, J. A. Louis, and P. 
Launois. 1998. The IL-4 rapidly produced in BALB/c mice after infection with 
Leishmania major down-regulates IL-12 receptor beta 2-chain expression on CD4+ T 
cells resulting in a state of unresponsiveness to IL-12. J Immunol. 161:6156-6163. 
215. Ho, M., D. K. Koech, D. W. Iha, and A. D. Bryceson. 1983. Immunosuppression in 
Kenyan visceral leishmaniasis. Clin Exp Immunol. 51:207-214. 
216. Hochrein, H., M. O'Keeffe, T. Luft, S. Vandenabeele, R. J. Grumont, E. 
Maraskovsky, and K. Shortman. 2000. Interleukin (IL)-4 is a major regulatory 
cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J 
Exp Med. 192:823-833. 
217. Hommel, M., C. L. Jaffe, B. Travi, and G. Milon. 1995. Experimental models for 
leishmaniasis and for testing anti-leishmanial vaccines. Ann Trop Med Parasitol. 
89:55-73. 
218. Hondowicz, B. D., A. Y. Park, M. M. EIloso, and P. Scott. 2000. Maintenance of 
IL-12-responsive CD4+ T cells during a Th2 response in Leishmania mayor-infected 
mice. Eur J Immunol. 30:2007-2014. 
90 
219. Hondowicz, B. D., T. M. Scharton-Kersten, D. E. Jones, and P. Scott. 1997. 
Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do 
not maintain a Th2 response. J Immunol. 159:5024-5031. 
220. Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, 
and S. Akira. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are 
hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J 
Immunol. 162:3749-3752. 
221. Howard, J. G., F. Y. Liew, C. Hale, and S. Nicklin. 1984. Prophylactic 
immunization against experimental leishmaniasis. II. Further characterization of the 
protective immunity against fatal Leishmania tropica infection induced by irradiated 
promastigotes. J Immunol. 132:450-455. 
222. Howard, J. G., S. Nicklin, C. Hale, and F. Y. Liew. 1982. Prophylactic 
immunization against experimental leishmaniasis: I. Protection induced in mice 
genetically vulnerable to fatal Leishmania tropica infection. J Immunol. 129:2206-
2212. 
223. Huang, L. Y., J. Aliberti, C. A. Leifer, D. M. Segal, A. Sher, D. T. Golenbock, 
and B. Golding. 2003. Heat-killed Brucella abortus induces TNF and IL-12p40 by 
distinct MyD88-dependent pathways: TNF, unlike IL-12p40 secretion, is Toll-like 
receptor 2 dependent. J Immunol. 171:1441-1446. 
224. Huang, Q., D. Liu, P. Majewski, L. C. Schulte, J. M. Korn, R. A. Young, E. S. 
Lander, and N. Hacohen. 2001. The plasticity of dendritic cell responses to 
pathogens and their components. Science. 294:870-875. 
225. Huber, M., E. Timms, T. W. Mak, M. Rollinghoff, and M. Lohoff. 1998. Effective 
and long-lasting immunity against the parasite Leishmania major in CD8-deficient 
mice. Infect Immun. 66:3968-3970. 
226. Ilg, T. 2000. Lipophosphoglycan is not required for infection of macrophages or mice 
by Leishmania mexicana. Embo J. 19:1953-1962. 
227. Ilg, T., M. Fuchs, V. Gnau, M. Wolfram, D. Harbecke, and P. Overath. 1994. 
Distribution of parasite cysteine proteinases in lesions of mice infected with 
Leishmania mexicana amastigotes. Mol Biochem Parasitol. 67:193-203. 
228. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. 
Yagita, K. Okumura, P. S. Linsley, S. Ikehara, and et al. 1994. The tissue 
distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells 
in situ and during maturation in vitro. J Exp Med. 180:1849-1860. 
229. Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu 
Rev Immunol. 20:197-216. 
230. Janssen, E. M., E. E. Lemmens, T. Wolfe, U. Christen, M. G. von Herrath, and 
S. P. Schoenberger. 2003. CD4+ T cells are required for secondary expansion and 
memory in CD8+ T lymphocytes. Nature. 421:852-856. 
231. Jebbari, H., A. J. Stagg, R. N. Davidson, and S. C. Knight. 2002. Leishmania 
major promastigotes inhibit dendritic cell motility in vitro. Infect Immun. 70:1023-
1026. 
232. Ji, J., J. Sun, H. Qi, and L. Soong. 2002. Analysis of T helper cell responses during 
infection with Leishmania amazonensis. Am J Trop Med Hyg. 66:338-345. 
91 
233. Ji, J., J. Sun, and L. Soong. 2003. Impaired expression of inflammatory cytokines 
and chemokines at early stages of infection with Leishmania amazonensis. Infect 
Immun. 71:4278-4288. 
234. Jones, D., M. M. Elloso, L. Showe, D. Williams, G. Trinchieri, and P. Scott. 1998. 
Differential regulation of the interleukin-12 receptor during the innate immune 
response to Leishmania major. Infect Immun. 66:3818-3824. 
235. Jones, D. E., M. R. Ackermann, U. Wille, C. A. Hunter, and P. Scott. 2002. Early 
enhanced Thl response after Leishmania amazonensis infection of C57BL/6 
interleukin-10-deficient mice does not lead to resolution of infection. Infect Immun. 
70:2151-2158. 
236. Jones, D. E., L. U. Buxbaum, and P. Scott. 2000. IL-4-independent inhibition of IL-
12 responsiveness during Leishmania amazonensis infection. J Immunol. 165:364-
372. 
237. Jones, D. E., M. M. Elloso, and P. Scott. 1998. Host susceptibility factors to 
cutaneous leishmaniasis. Front Biosci. 3:D1171-1180. 
238. Jonuleit, H., E. Schmitt, G. Schuler, J. Knop, and A. H. Enk. 2000. Induction of 
interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties 
by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 
192:1213-1222. 
239. Joshi, P. B., D. L. Sacks, G. Modi, and W. R. McMaster. 1998. Targeted gene 
deletion of Leishmania major genes encoding developmental stage-specific 
leishmanolysin (GP63). Mol Microbiol. 27:519-530. 
240. Julia, V., M. Rassoulzadegan, and N. Glaichenhaus. 1996. Resistance to 
Leishmania major induced by tolerance to a single antigen. Science. 274:421-423. 
241. Junaid, A. J. 1986. Treatment of cutaneous leishmaniasis with infrared heat. Int J 
Dermatol. 25:470-472. 
242. Kaisho, T., and S. Akira. 2001. Dendritic-cell function in Toll-like receptor- and 
MyD88-knockout mice. Trends Immunol. 22:78-83. 
243. Kamanaka, M., P. Yu, T. Yasui, K. Yoshida, T. Kawabe, T. Horii, T. Kishimoto, 
and H. Kikutani. 1996. Protective role of CD40 in Leishmania major infection at 
two distinct phases of cell-mediated immunity. Immunity. 4:275-281. 
244. Kamhawi, S. 2000. The biological and immunomodulatory properties of sand fly 
saliva and its role in the establishment of Leishmania infections. Microbes Infect. 
2:1765-1773. 
245. Kamhawi, S., Y. Belkaid, G. Modi, E. Rowton, and D. Sacks. 2000. Protection 
against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science. 
290:1351-1354. 
246. Kane, M. M., and D. M. Mosser. 2001. The role of IL-10 in promoting disease 
progression in leishmaniasis. J Immunol. 166:1141-1147. 
247. Kaye, P. M., and G. J. Bancroft. 1992. Leishmania donovani infection in scid mice: 
lack of tissue response and in vivo macrophage activation correlates with failure to 
trigger natural killer cell-derived gamma interferon production in vitro. Infect Immun. 
60:4335-4342. 
248. Kaye, P. M., A. J. Curry, and J. M. Blackwell. 1991. Differential production of 
Thl- and Th2-derived cytokines does not determine the genetically controlled or 
92 
vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol. 146:2763-
2770. 
249. Kaye, P. M., N. J. Rogers, A. J. Curry, and J. C. Scott. 1994. Deficient expression 
of co-stimulatory molecules on Leishmania-'mïtcità macrophages. Eur J Immunol. 
24:2850-2854. 
250. Kedzierski, L., J. Montgomery, D. Bullen, J. Curtis, E. Gardiner, A. Jimenez-
Ruiz, and E. Handman. 2004. A leucine-rich repeat motif of Leishmania parasite 
surface antigen 2 binds to macrophages through the complement receptor 3. J 
Immunol. 172:4902-4906. 
251. Kelleher, M., A. Bacic, and E. Handman. 1992. Identification of a macrophage-
binding determinant on lipophosphoglycan from Leishmania major promastigotes. 
Proc Natl Acad Sci USA. 89:6-10. 
252. Kelleher, M., S. F. Moody, P. Mirabile, A. H. Osborn, A. Bacic, and E. 
Handman. 1995. Lipophosphoglycan blocks attachment of Leishmania major 
amastigotes to macrophages. Infect Immun. 63:43-50. 
253. Kelleher, P., and S. C. Knight. 1998. IL-12 increases CD80 expression and the 
stimulatory capacity of bone marrow-derived dendritic cells. Int Immunol. 10:749-
755. 
254. Kelly, B. L., D. B. Stetson, and R. M. Locksley. 2003. Leishmania major LACK 
antigen is required for efficient vertebrate parasitization. J Exp Med. 198:1689-1698. 
255. Kenney, R. T., D. L. Sacks, J. P. Sypek, L. Vilela, A. A. Gam, and K. Evans-
Davis. 1999. Protective immunity using recombinant human IL-12 and alum as 
adjuvants in a primate model of cutaneous leishmaniasis. J Immunol. 163:4481-4488. 
256. Kerr, S. F., C. P. McHugh, and N. O. Dronen, Jr. 1995. Leishmaniasis in Texas: 
prevalence and seasonal transmission of Leishmania mexicana in Neotoma micropus. 
Am J Trop Med Hyg. 53:73-77. 
257. Kerr, S. F., C. P. McHugh, and R. Merkelz. 1999. Short report: a focus of 
Leishmania mexicana near Tucson, Arizona. Am J Trop Med Hyg. 61:378-379. 
258. Killick-Kendrick, R. 1990. Phlebotomine vectors of the leishmaniases: a review. 
Med Vet Entomol. 4:1-24. 
259. Killick-Kendrick, R. 1985. Some epidemiological consequences of the evolutionary 
fit between Leishmaniae and their phlebotomine vectors. Bull Soc Pathol Exot 
Filiales. 78:747-755. 
260. Killick-Kendrick, R., A. J. Leaney, P. D. Ready, and D. H. Molyneux. 1977. 
Leishmania in phlebotomid sandflies. IV. The transmission of Leishmania mexicana 
amazonensis to hamsters by the bite of experimentally infected Lutzomyia 
longipalpis. Proc R Soc Lond B Biol Sci. 196:105-115. 
261. Killick-Kendrick, R., D. H. Molyneux, and R. W. Ashford. 1974. Ultrastructural 
observations on the attachment of Leishmania in the sandfly. Trans R Soc Trop Med 
Hyg. 68:269. 
262. Kima, P. E., S. L. Constant, L. Hannum, M. Colmenares, K. S. Lee, A. M. 
Haberman, M. J. Shlomchik, and D. McMahon-Pratt. 2000. Internalization of 
Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain 
infection in murine cutaneous leishmaniasis. J Exp Med. 191:1063-1068. 
93 
263. Kima, P. E., N. H. Ruddle, and D. McMahon-Pratt. 1997. Presentation via the 
class I pathway by Leishmania amazonensis-infected macrophages of an endogenous 
leishmanial antigen to CD8+ T cells. J Immunol. 159:1828-1834. 
264. Kima, P. E., L. Soong, C. Chicharro, N. H. Ruddle, and D. McMahon-Pratt. 
1996. Leishmania-infected macrophages sequester endogenously synthesized parasite 
antigens from presentation to CD4+ T cells. Eur J Immunol. 26:3163-3169. 
265. Kimber, I., M. Cumberbatch, R. J. Dearman, M. Bhushan, and C. E. Griffiths. 
2000. Cytokines and chemokines in the initiation and regulation of epidermal 
Langerhans cell mobilization. Br J Dermatol. 142:401-412. 
266. Kirkpatrick, C. E., J. P. Farrell, J. F. Warner, and G. Denner. 1985. Participation 
of natural killer cells in the recovery of mice from visceral leishmaniasis. Cell 
Immunol. 92:163-171. 
267. Kirkpatrick, C. E., T. J. Nolan, and J. P. Farrell. 1987. Rate of Leishmania-
induced skin-lesion development in rodents depends on the site of inoculation. 
Parasitology. 94:451-465. 
268. Konecny, P., A. J. Stagg, H. Jebbari, N. English, R. N. Davidson, and S. C. 
Knight. 1999. Murine dendritic cells internalize Leishmania major promastigotes, 
produce IL-12 p40 and stimulate primary T cell proliferation in vitro. Eur J Immunol. 
29:1803-1811. 
269. Kopf, M., F. Brombacher, G. Kohler, G. Kienzle, K. H. Widmann, K. Lefrang, 
C. Humborg, B. Ledermann, and W. Solbach. 1996. IL-4-deficient Balb/c mice 
resist infection with Leishmania major. J Exp Med. 184:1127-1136. 
270. Kremer, I. B., M. P. Gould, K. D. Cooper, and F. P. Heinzel. 2001. Pretreatment 
with recombinant Flt3 ligand partially protects against progressive cutaneous 
leishmaniasis in susceptible BALB/c mice. Infect Immun. 69:673-680. 
271. Kreutzer, R. D., M. Grogl, F. A. Neva, D. J. Fryauff, A. J. Magill, and M. M. 
Aleman-Munoz. 1993. Identification and genetic comparison of leishmanial parasites 
causing viscerotropic and cutaneous disease in soldiers returning from Operation 
Desert Storm. Am J Trop Med Hyg. 49:357-363. 
272. Kropf, P., M. A. Freudenberg, M. Modolell, H. P. Price, S. Herath, S. Antoniazi, 
C. Galanos, D. F. Smith, and I. Muller. 2004. Toll-like receptor 4 contributes to 
efficient control of infection with the protozoan parasite Leishmania major. Infect 
Immun. 72:1920-1928. 
273. Kropf, P., S. Herath, V. Weber, M. Modolell, and I. Muller. 2003. Factors 
influencing Leishmania major infection in IL-4-deficient BALB/c mice. Parasite 
Immunol. 25:439-447. 
274. Kropf, P., L. R. Schopf, C. L. Chung, D. Xu, F. Y. Liew, J. P. Sypek, and I. 
Muller. 1999. Expression of Th2 cytokines and the stable Th2 marker ST2L in the 
absence of IL-4 during Leishmania major infection. Eur J Immunol. 29:3621-3628. 
275. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects 
on the response of T cells to stimulation. J Exp Med. 182:459-465. 
276. Kubar, J., J. F. Quaranta, P. Marty, A. Lelievre, Y. Le Fichoux, and J. P. 
Aufeuvre. 1997. Transmission of L. infantum by blood donors. Nat Med. 3:368. 
277. Kurt-Jones, E. A., L. Popova, L. Kwinn, L. M. Haynes, L. P. Jones, R. A. Tripp, 
E. E. Walsh, M. W. Freeman, D. T. Golenbock, L. J. Anderson, and R. W. 
94 
Finberg. 2000. Pattern recognition receptors TLR4 and CD 14 mediate response to 
respiratory syncytial virus. Nat Immunol. 1:398-401. 
278. Kweider, M., J. L. Lemesre, F. Darcy, J. P. Kusnierz, A. Capron, and F. 
Santoro. 1987. Infectivity of Leishmania braziliensis promastigotes is dependent on 
the increasing expression of a 65,000-dalton surface antigen. J Immunol. 138:299-
305. 
279. Lainson, R. 1983. The American leishmaniases: some observations on their ecology 
and epidemiology. Trans R Soc Trop Med Hyg. 77:569-596. 
280. Lainson, R., and R. S. Bray. 1966. Studies on the immunology and serology of 
leishmaniasis. II. Cross-immunity experiments among different forms of American 
cutaneous leishmaniasis in monkeys. Trans R Soc Trop Med Hyg. 60:526-532. 
281. Lainson, R., and R. S. Bray. 1964. Transmission of Leishmania mexicana among 
laboratory hamsters in the absence of an insect vector. Trans R Soc Trop Med Hyg. 
58:287. 
282. Lainson, R., and J. J. Shaw. 1977. Leishmaniasis in Brazil: XII. Observations on 
cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, 
L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b. panamensis. 
J Trop Med Hyg. 80:29-35. 
283. Lainson, R., and J. J. Shaw. 1966. Studies on the immunology and serology of 
leishmaniasis. 3. on the cross-immunity between Panamanian cutaneous leishmaniasis 
and Leishmania mexicana infection in man. Trans R Soc Trop Med Hyg. 60:533-535. 
284. Lainson, R., and B. A. Southgate. 1965. Mechanical transmission of Leishmania 
mexicana by Stomoxys calcitrans. Trans R Soc Trop Med Hyg. 59:716. 
285. Lang, T., C. de Chastellier, C. Frehel, R. Hellio, P. Metezeau, S. Leao Sde, and J. 
C. Antoine. 1994. Distribution of MHC class I and of MHC class II molecules in 
macrophages infected with Leishmania amazonensis. J Cell Sci. 107:69-82. 
286. Lang, T., R. Hellio, P. M. Kaye, and J. C. Antoine. 1994. Leishmania donovani-
infected macrophages: characterization of the parasitophorous vacuole and potential 
role of this organelle in antigen presentation. J Cell Sci. 107:2137-2150. 
287. Larsen, C. P., S. C. Ritchie, R. Hendrix, P. S. Linsley, K. S. Hathcock, R. J. 
Hodes, R. P. Lowry, and T. C. Pearson. 1994. Regulation of immunostimulatory 
function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic 
cells. J Immunol. 152:5208-5219. 
288. Laskay, T., A. Diefenbach, M. Rollinghoff, and W. Solbach. 1995. Early parasite 
containment is decisive for resistance to Leishmania major infection. Eur J Immunol. 
25:2220-2227. 
289. Laskay, T., M. Rollinghoff, and W. Solbach. 1993. Natural killer cells participate in 
the early defense against Leishmania major infection in mice. Eur J Immunol. 
23:2237-2241. 
290. Laskay, T., G. van Zandbergen, and W. Solbach. 2003. Neutrophil granulocytes— 
Trojan horses for Leishmania major and other intracellular microbes? Trends 
Microbiol. 11:210-214. 
291. Laufs, H., K. Muller, J. Fleischer, N. Reiling, N. Jahnke, J. C. Jensenius, W. 
Solbach, and T. Laskay. 2002. Intracellular survival of Leishmania major in 
95 
neutrophil granulocytes after uptake in the absence of heat-labile serum factors. Infect 
Immun. 70:826-835. 
292. Launois, P., A. Gumy, H. Himmelrich, R. M. Locksley, M. Rocken, and J. A. 
Louis. 2002. Rapid IL-4 production by Leishmania homolog of mammalian RACK1-
reactive CD4(+) T cells in resistant mice treated once with anti-IL-12 or -IFN-gamma 
antibodies at the onset of infection with Leishmania major instructs Th2 cell 
development, resulting in nonhealing lesions. J Immunol. 168:4628-4635. 
293. Launois, P., I. Maillard, S. Pingel, K. G. Swihart, I. Xenarios, H. Acha-Orbea, H. 
Diggelmann, R. M. Locksley, H. R. MacDonald, and J. A. Louis. 1997. IL-4 
rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and 
susceptibility to Leishmania major in BALB/c mice. Immunity. 6:541-549. 
294. Launois, P., T. Ohteki, K. Swihart, H. R. MacDonald, and J. A. Louis. 1995. In 
susceptible mice, Leishmania major induce very rapid interleukin-4 production by 
CD4+ T cells which are NK1.1. Eur J Immunol. 25:3298-3307. 
295. Launois, P., K. G. Swihart, G. Milon, and J. A. Louis. 1997. Early production of 
IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 
unresponsiveness. J Immunol. 158:3317-3324. 
296. Laurenti, M. D., M. Gidlund, D. M. Ura, I. L. Sinhorini, C. E. Corbett, and H. 
Goto. 1999. The role of natural killer cells in the early period of infection in murine 
cutaneous leishmaniasis. Braz J Med Biol Res. 32:323-325. 
297. le Fichoux, Y., J. F. Quaranta, J. P. Aufeuvre, A. Lelievre, P. Marty, I. Suffia, D. 
Rousseau, and J. Kubar. 1999. Occurrence of Leishmania infantum parasitemia in 
asymptomatic blood donors living in an area of endemicity in southern France. J Clin 
Microbiol. 37:1953-1957. 
298. Leal, L. M., D. W. Moss, R. Kuhn, W. Muller, and F. Y. Liew. 1993. Interleukin-4 
transgenic mice of resistant background are susceptible to Leishmania major 
infection. Eur J Immunol. 23:566-569. 
299. Leclerc, C., F. Modabber, E. Deriaud, and L. Cheddid. 1981. Systemic infection 
of Leishmania tropica (major) in various strains of mice. Trans R Soc Trop Med Hyg. 
75:851-854. 
300. Lemos, M. P., F. Esquivel, P. Scott, and T. M. Laufer. 2004. MHC Class II 
Expression Restricted to CD8{alpha}+ and CDllb+ Dendritic Cells Is Sufficient for 
Control of Leishmania major. J Exp Med. 199:725-730. 
301. Lepay, D. A., N. Nogueira, and Z. Cohn. 1983. Surface antigens of Leishmania 
donovani promastigotes. J Exp Med. 157:1562-1572. 
302. Lien, E., T. J. Sellati, A. Yoshimura, T. H. Flo, G. Rawadi, R. W. Finberg, J. D. 
Carroll, T. Espevik, R. R. Ingalls, J. D. Radolf, and D. T. Golenbock. 1999. Toll­
like receptor 2 functions as a pattern recognition receptor for diverse bacterial 
products. J Biol Chem. 274:33419-33425. 
303. Liew, F. Y. 2002. T(H)1 and T(H)2 cells: a historical perspective. Nat Rev Immunol. 
2:55-60. 
304. Liew, F. Y., and C. A. O'Donnell. 1993. Immunology of leishmaniasis. Adv 
Parasitai. 32:161 -259. 
96 
305. Liew, F. Y., X. Q. Wei, and L. Proudfoot. 1997. Cytokines and nitric oxide as 
effector molecules against parasitic infections. Philos Trans R Soc Lond B Biol Sci. 
352:1311-1315. 
306. Lima, G. M., A. L. Vallochi, U. R. Silva, E. M. Bevilacqua, M. M. Kiffer, and I. 
A. Abrahamsohn. 1998. The role of polymorphonuclear leukocytes in the resistance 
to cutaneous Leishmaniasis. Immunol Lett. 64:145-151. 
307. Lima, H. C., and R. G. Titus. 1996. Effects of sand fly vector saliva on development 
of cutaneous lesions and the immune response to Leishmania braziliensis in BALB/c 
mice. Infect Immun. 64:5442-5445. 
308. Linares, E., O. Auguste, S. C. Barao, and S. Giorgio. 2000. Leishmania 
amazonensis infection does not inhibit systemic nitric oxide levels elicited by 
lipopolysaccharide in vivo. J Parasitai. 86:78-82. 
309. Linares, E., S. Giorgio, R. A. Mortara, C. X. Santos, A. T. Yamada, and O. 
Augusto. 2001. Role of peroxynitrite in macrophage microbicidal mechanisms in 
vivo revealed by protein nitration and hydroxy lation. Free Radie Biol Med. 30:1234-
1242. 
310. Linsley, P. S., J. L. Greene, P. Tan, J. Bradshaw, J. A. Ledbetter, C. Anasetti, 
and N. K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and 
CD28 on activated T lymphocytes. J Exp Med. 176:1595-1604. 
311. Liu, X., and K. P. Chang. 1992. Extrachromosomal genetic complementation of 
surface metalloproteinase (gp63)-deficient Leishmania increases their binding to 
macrophages. Proc Natl Acad Sci USA. 89:4991-4995. 
312. Locksley, R. M., F. P. Heinzel, J. E. Fankhauser, C. S. Nelson, and M. D. Sadick. 
1988. Cutaneous host defense in leishmaniasis: interaction of isolated dermal 
macrophages and epidermal Langerhans cells with the insect-stage promastigote. 
Infect Immun. 56:336-342. 
313. Locksley, R. M., F. P. Heinzel, B. J. Holaday, S. S. Mutha, S. L. Reiner, and M. 
D. Sadick. 1991. Induction of Thl and Th2 CD4+ subsets during murine Leishmania 
major infection. Res Immunol. 142:28-32. 
314. Love, D. C., J. D. Esko, and D. M. Mosser. 1993. A heparin-binding activity on 
Leishmania amastigotes which mediates adhesion to cellular proteoglycans. J Cell 
Biol. 123:759-766. 
315. Love, D. C., M. Mentink Kane, and D. M. Mosser. 1998. Leishmania amazonensis: 
the phagocytosis of amastigotes by macrophages. Exp Parasitai. 88:161-171. 
316. Low, G. C., and W. E. Cooke. 1926. A congenital case of Kala-Azar. Lancet: 1209-
1211. 
317. Lutz, M., and G. Schuler. 2002. Immature, semi-mature and fully mature dendritic 
cells: which signals induce tolerance or immunity? Trends Immunol. 23:445. 
318. MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage 
function. Annu Rev Immunol. 15:323-350. 
319. Maeda, N., J. Nigou, J. L. Herrmann, M. Jackson, A. Amara, P. H. Lagrange, G. 
Puzo, B. Gicquel, and O. Neyrolles. 2002. The cell surface receptor DC-SIGN 
discriminates between Mycobacterium species through selective recognition of the 
mannose caps on lipoarabinomannan. J Biol Chem. 20:20. 
97 
320. Magill, A. J., M. Grogl, R. A. Gasser, Jr., W. Sun, and C. N. Oster. 1993. Visceral 
infection caused by Leishmania tropica in veterans of Operation Desert Storm. N 
Engl J Med. 328:1383-1387. 
321. Marovich, M. A., M. A. McDowell, E. K. Thomas, and T. B. Nutman. 2000. IL-
12p70 production by Leishmania mayor-harboring human dendritic cells is a 
CD40/CD40 ligand-dependent process. J Immunol. 164:5858-5865. 
322. Marsden, P. D. 1986. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R 
Soc Trop Med Hyg. 80:859-876. 
323. Marsella, R., and R. Ruiz de Gopegui. 1998. Leishmaniasis: a re-emerging 
zoonosis. Int J Dermatol. 37:801-814. 
324. Martinez, E., F. Le Pont, M. Torrez, J. Telleria, F. Vargas, J. C. Dujardin, and J. 
P. Dujardin. 1999. Lutzomyia nuneztovari anglesi (Le pont & Desjeux, 1984) as a 
vector of Leishmania amazonensis in a sub-Andean leishmaniasis focus of Bolivia. 
Am J Trop Med Hyg. 61:846-849. 
325. Martinez, E., S. Mollinedo, M. Torrez, M. Munoz, A. L. Banuls, and F. Le Pont. 
2002. Co-infection by Leishmania amazonensis and L. infantumlL. chagasi in a case 
of diffuse cutaneous leishmaniasis in Bolivia. Trans R Soc Trop Med Hyg. 96:529-
532. 
326. Martinez, J. E., Alba, L. Arias, M. A. Escobar, and N. G. Saravia. 1992. 
Haemoculture of Leishmania ( Viannia) braziliensis from two cases of mucosal 
leishmaniasis: re-examination of haematogenous dissemination. Trans R Soc Trop 
Med Hyg. 86:392-394. 
327. Masteller, E. L., E. Chuang, A. C. Mullen, S. L. Reiner, and C. B. Thompson. 
2000. Structural analysis of CTLA-4 function in vivo. J Immunol. 164:5319-5327. 
328. Matthews, D. J., C. L. Emson, G. J. McKenzie, H. E. Jolin, J. M. Blackwell, and 
A. N. McKenzie. 2000. IL-13 is a susceptibility factor for Leishmania major 
infection. J Immunol. 164:1458-1462. 
329. Mattner, F., K. Di Padova, and G. Alber. 1997. Interleukin-12 is indispensable for 
protective immunity against Leishmania major. Infect Immun. 65:4378-4383. 
330. Mattner, F., J. Magram, J. Ferrante, P. Launois, K. Di Padova, R. Behin, M. K. 
Gately, J. A. Louis, and G. Alber. 1996. Genetically resistant mice lacking 
interleukin-12 are susceptible to infection with Leishmania major and mount a 
polarized Th2 cell response. Eur J Immunol. 26:1553-1559. 
331. Mbow, M. L., J. A. Bleyenberg, L. R. Hall, and R. G. Titus. 1998. Phlebotomus 
papatasi sand fly salivary gland lysate down-regulates a Thl, but up-regulates a Th2, 
response in mice infected with Leishmania major. J Immunol. 161:5571-5577. 
332. Mbow, M. L., G. K. DeKrey, and R. G. Titus. 2001. Leishmania major induces 
differential expression of costimulatory molecules on mouse epidermal cells. Eur J 
Immunol. 31:1400-1409. 
333. McConville, M. J., S. J. Turco, M. A. Ferguson, and D. L. Sacks. 1992. 
Developmental modification of lipophosphoglycan during the differentiation of 
Leishmania major promastigotes to an infectious stage. Embo J. 11:3593-3600. 
334. McDowell, M. A., M. Marovich, R. Lira, M. Braun, and D. Sacks. 2002. 
Leishmania priming of human dendritic cells for CD40 ligand-induced interleukin-
12p70 secretion is strain and species dependent. Infect Immun. 70:3994-4001. 
98 
335. McDowell, M. A., and D. L. Sacks. 1999. Inhibition of host cell signal transduction 
by Leishmania: observations relevant to the selective impairment of IL-12 responses. 
Curr Opin Microbiol. 2:438-443. 
336. McGwire, B., and K. P. Chang. 1994. Genetic rescue of surface metalloproteinase 
(gp63)-deficiency in Leishmania amazonensis variants increases their infection of 
macrophages at the early phase. Mol Biochem Parasitol. 66:345-347. 
337. McGwire, B. S., K. P. Chang, and D. M. Engman. 2003. Migration through the 
extracellular matrix by the parasitic protozoan Leishmania is enhanced by surface 
metalloprotease gp63. Infect Immun. 71:1008-1010. 
338. McHugh, C. P., P. C. Melby, and S. G. LaFon. 1996. Leishmaniasis in Texas: 
epidemiology and clinical aspects of human cases. Am J Trop Med Hyg. 55:547-555. 
339. McHugh, C. P., M. L. Thies, P. C. Melby, L. D. Yantis, Jr., R. W. Raymond, M. 
D. Villegas, and S. F. Kerr. 2003. Short report: a disseminated infection of 
Leishmania mexicana in an eastern woodrat, Neotoma jloridana, collected in Texas. 
Am J Trop Med Hyg. 69:470-472. 
340. McMahon-Pratt, D., D. Rodriguez, J. R. Rodriguez, Y. Zhang, K. Manson, C. 
Bergman, L. Rivas, J. F. Rodriguez, K. L. Lohman, N. H. Ruddle, and et al. 
1993. Recombinant vaccinia viruses expressing GP46/M-2 protect against 
Leishmania infection. Infect Immun. 61:3351-3359. 
341. McNeely, T. B., and S. J. Turco. 1990. Requirement of lipophosphoglycan for 
intracellular survival of Leishmania donovani within human monocytes. J Immunol. 
144:2745-2750. 
342. McSorley, S. J., D. Xu, and F. Y. Liew. 1997. Vaccine efficacy of Salmonella 
strains expressing glycoprotein 63 with different promoters. Infect Immun. 65:171-
178. 
343. Means, T. K., S. Wang, E. Lien, A. Yoshimura, D. T. Golenbock, and M. J. 
Fenton. 1999. Human toll-like receptors mediate cellular activation by 
Mycobacterium tuberculosis. J Immunol. 163:3920-3927. 
344. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat Rev Immunol. 
1:135-145. 
345. Meier, C. L., M. Svensson, and P. M. Kaye. 2003. Leishmania-induced inhibition 
of macrophage antigen presentation analyzed at the single-cell level. J Immunol. 
171:6706-6713. 
346. Mellado, M., J. M. Rodriguez-Frade, S. Manes, and A. C. Martinez. 2001. 
Chemokine signaling and functional responses: the role of receptor dimerization and 
TK pathway activation. Annu Rev Immunol. 19:397-421. 
347. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. Skeiky, 
A. Campos-Neto, S. Reed, R. A. Seder, and D. Sacks. 2001. The potency and 
durability of DNA- and protein-based vaccines against Leishmania major evaluated 
using low-dose, intradermal challenge. J Immunol. 166:5122-5128. 
348. Mendez, S., K. Tabbara, Y. Belkaid, S. Bertholet, D. Verthelyi, D. Klinman, R. 
A. Seder, and D. L. Sacks. 2003. Coinjection with CpG-containing 
immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine 
against cutaneous Leishmaniasis but maintains its potency and durability. Infect 
Immun. 71:5121-5129. 
99 
349. Mendonca, M. G., M. E. de Brito, E. H. Rodrigues, V. Bandeira, M. L. Jardim, 
and F. G. Abath. 2004. Persistence of leishmania parasites in scars after clinical cure 
of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis. 189:1018-
1023. Epub 2004 Mar 1012. 
350. Mendonca, S. C., S. G. Coutinho, R. R. Amendoeira, M. C. Marzochi, and C. 
Pirmez. 1986. Human american cutaneous leishmaniasis (Leishmania b. braziliensis) 
in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol. 
64:269-276. 
351. Mitchell, G. F., and E. Handman. 1987. Heterologous protection in murine 
cutaneous leishmaniasis. Immunol Cell Biol. 65:387-392. 
352. Modabber, F. 1989. Experiences with vaccines against cutaneous leishmaniasis: of 
men and mice. Parasitology. 98:849-60. 
353. Mohrs, M., B. Ledermann, G. Kohler, A. Dorfmuller, A. Gessner, and F. 
Brombacher. 1999. Differences between IL-4- and IL-4 receptor alpha-deficient 
mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J 
Immunol. 162:7302-7308. 
354. Moll, H. 2000. The role of dendritic cells at the early stages of Leishmania infection. 
Adv Exp Med Biol. 479:163-173. 
355. Moll, H., S. Flohe, and M. Rollinghoff. 1995. Dendritic cells in Leishmania major-
immune mice harbor persistent parasites and mediate an antigen-specific T cell 
immune response. Eur J Immunol. 25:693-699. 
356. Moll, H., H. Fuchs, C. Blank, and M. Rollinghoff. 1993. Langerhans cells transport 
Leishmania major from the infected skin to the draining lymph node for presentation 
to antigen-specific T cells. Eur J Immunol. 23:1595-1601. 
357. Molyneux, D. H., R. Killick-Kendrick, and R. W. Ashford. 1975. Leishmania in 
phlebotomid sandflies. III. The ultrastructure of Leishmania mexicana amazonensis in 
the midgut and pharynx of Lutzomyia longipalpis. Proc R Soc Lond B Biol Sci. 
190:341-357. 
358. Moodycliffe, A. M., V. Shreedhar, S. E. Ullrich, J. Walterscheid, C. Bucana, M. 
L. Kripke, and L. Flores-Romo. 2000. CD40-CD40 ligand interactions in vivo 
regulate migration of antigen-bearing dendritic cells from the skin to draining lymph 
nodes. J Exp Med. 191:2011-2020. 
359. Mora, A. M., W. Mayrink, R. T. Costa, C. A. Costa, O. Genaro, and E. 
Nascimento. 1999. Protection of C57BL/10 mice by vaccination with association of 
purified proteins from Leishmania (Leishmania) amazonensis. Rev Inst Med Trop 
Sao Paulo. 41:243-248. 
360. Moreno, J., and J. Alvar. 2002. Canine leishmaniasis: epidemiological risk and the 
experimental model. Trends Parasitol. 18:399-405. 
361. Moriearty, P. L., and G. Grimaldi Junior. 1983. Host factors influencing outcome 
of Leishmania mexicana mexicana infection in mice. Mem Inst Oswaldo Cruz. 78:49-
59. 
362. Morris, R. V., C. B. Shoemaker, J. R. David, G. C. Lanzaro, and R. G. Titus. 
2001. Sandfly maxadilan exacerbates infection with Leishmania major and 
vaccinating against it protects against L. major infection. J Immunol. 167:5226-5230. 
100 
363. Moser, M., and K. M. Murphy. 2000. Dendritic cell regulation of TH1-TH2 
development. Nat Immunol. 1:199-205. 
364. Mosser, D. M. 1994. Receptors on phagocytic cells involved in microbial 
recognition. Immunol Ser. 60:99-114. 
365. Mosser, D. M., and A. Brittingham. 1997. Leishmania, macrophages and 
complement: a tale of subversion and exploitation. Parasitology. 115:89-23. 
366. Mosser, D. M., S. K. Burke, E. E. Coutavas, J. F. Wedgwood, and P. J. Edelson. 
1986. Leishmania species: mechanisms of complement activation by five strains of 
promastigotes. Exp Parasitol. 62:394-404. 
367. Mosser, D. M., and P. J. Edelson. 1984. Activation of the alternative complement 
pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages. 
J Immunol. 132:1501-1505. 
368. Mosser, D. M., and P. J. Edelson. 1987. The third component of complement (C3) 
is responsible for the intracellular survival of Leishmania major. Nature. 327:329-
331. 
369. Mosser, D. M., and L. A. Rosenthal. 1993. Lm/zmama-macrophage interactions: 
multiple receptors, multiple ligands and diverse cellular responses. Semin Cell Biol. 
4:315-322. 
370. Mosser, D. M., T. A. Springer, and M. S. Diamond. 1992. Leishmania 
promastigotes require opsonic complement to bind to the human leukocyte integrin 
Mac-1 (CDllb/CD18). J Cell Biol. 116:511-520. 
371. Mottram, J. C., D. R. Brooks, and G. H. Coombs. 1998. Roles of cysteine 
proteinases of trypanosomes and Leishmania in host-parasite interactions. Curr Opin 
Microbiol. 1:455-460. 
372. Mottram, J. C., A. E. Souza, J. E. Hutchison, R. Carter, M. J. Frame, and G. H. 
Coombs. 1996. Evidence from disruption of the lmcpb gene array of Leishmania 
m e x i c a n a  t h a t  c y s t e i n e  p r o t e i n a s e s  a r e  v i r u l e n c e  f a c t o r s .  P r o c  N a t l  A c a d  S c i  U S A .  
93:6008-6013. 
373. Mullen, A. C., F. A. High, A. S. Hutchins, H. W. Lee, A. V. Villarino, D. M. 
Livingston, A. L. Kung, N. Cereb, T. P. Yao, S. Y. Yang, and S. L. Reiner. 2001. 
Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 
292:1907-1910. 
374. Muller, I. 1992. Role of T cell subsets during the recall of immunologic memory to 
Leishmania major. Eur J Immunol. 22:3063-3069. 
375. Muller, I., J. A. Garcia-Sanz, R. Titus, R. Behin, and J. Louis. 1989. Analysis of 
the cellular parameters of the immune responses contributing to resistance and 
susceptibility of mice to infection with the intracellular parasite, Leishmania major. 
Immunol Rev. 112:95-113. 
376. Muller, I., P. Kropf, R. J. Etges, and J. A. Louis. 1993. Gamma interferon response 
in secondary Leishmania major infection: role of CD8+ T cells. Infect Immun. 
61:3730-3738. 
377. Muller, I., P. Kropf, J. A. Louis, and G. Milon. 1994. Expansion of gamma 
interferon-producing CD8+ T cells following secondary infection of mice immune to 
Leishmania major. Infect Immun. 62:2575-2581. 
101 
378. Muller, I., T. Pedrazzini, P. Kropf, J. Louis, and G. Milon. 1991. Establishment of 
resistance to Leishmania major infection in susceptible BALB/c mice requires 
parasite-specific CD8+ T cells. Int Immunol. 3:587-597. 
379. Muller, K., G. van Zandbergen, B. Hansen, H. Laufs, N. Jahnke, W. Solbach, 
and T. Laskay. 2001. Chemokines, natural killer cells and granulocytes in the early 
course of Leishmania major infection in mice. Med Microbiol Immunol (Berl). 
190:73-76. 
380. Muraille, E., C. De Trez, M. Brait, P. De Baetselier, O. Leo, and Y. Carlier. 
2003. Genetically resistant mice lacking MyD88-adapter protein display a high 
susceptibility to Leishmania major infection associated with a polarized Th2 
response. J Immunol. 170:4237-4241. 
381. Murphy, M. L., S. E. Cotterell, P. M. Gorak, C. R. Engwerda, and P. M. Kaye. 
1998. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, 
Leishmania donovani. J Immunol. 161:4153-4160. 
382. Murphy, M. L., C. R. Engwerda, P. M. Gorak, and P. M. Kaye. 1997. B7-2 
blockade enhances T cell responses to Leishmania donovani. J Immunol. 159:4460-
4466. 
383. Murphy, M. L., U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell. 2001. IL-
10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol. 
31:2848-2856. 
384. Murray, H. W., S. M. Carriero, and D. M. Donelly. 1986. Presence of a 
macrophage-mediated suppressor cell mechanism during cell-mediated immune 
response in experimental visceral leishmaniasis. Infect Immun. 54:487-493. 
385. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral 
Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated 
response model. J Exp Med. 185:867-874. 
386. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, and 
R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis 
and IL-10 receptor blockade as immunotherapy. Infect Immun. 70:6284-6293. 
387. Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in 
vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular 
visceral Leishmania donovani. J Exp Med. 189:741-746. 
388. Murray, H. W., M. J. Oca, A. M. Granger, and R. D. Schreiber. 1989. 
Requirement for T cells and effect of lymphokines in successful chemotherapy for an 
intracellular infection. Experimental visceral leishmaniasis. J Clin Invest. 83:1253-
1257. 
389. Murray, H. W., B. Y. Rubin, S. Carriero, and A. M. Acosta. 1984. Reversible 
defect in antigen-induced lymphokine and gamma-interferon generation in cutaneous 
leishmaniasis. J Immunol. 133:2250-2254. 
390. Murray, H. W., K. E. Squires, C. D. Miralles, M. Y. Stoeckle, A. M. Granger, A. 
Granelli-Piperno, and C. Bogdan. 1992. Acquired resistance and granuloma 
formation in experimental visceral leishmaniasis. Differential T cell and lymphokine 
roles in initial versus established immunity. J Immunol. 148:1858-1863. 
391. Murray, H. W., J. J. Stern, K. Welte, B. Y. Rubin, S. M. Carriero, and C. F. 
Nathan. 1987. Experimental visceral leishmaniasis: production of interleukin 2 and 
102 
interferon-gamma, tissue immune reaction, and response to treatment with interleukin 
2 and interferon-gamma. J Immunol. 138:2290-2297. 
392. Nabors, G. S., and J. P. Farrell. 1994. Site-specific immunity to Leishmania major 
in SWR mice: the site of infection influences susceptibility and expression of the 
antileishmanial immune response. Infect Immun. 62:3655-3662. 
393. Nakamura, K., A. Kitani, and W. Strober. 2001. Cell contact-dependent 
immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell 
surface-bound transforming growth factor beta. J Exp Med. 194:629-644. 
394. Navin, T. R., B. A. Arana, F. E. Arana, A. M. de Merida, A. L. Castillo, and J. L. 
Pozuelos. 1990. Placebo-controlled clinical trial of meglumine antimonate 
(glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis 
in Guatemala. Am J Trop Med Hyg. 42:43-50. 
395. Neal, R. A., A. Reeves, and W. Peters. 1990. Leishmania infecting man and wild 
animals in Saudi Arabia. 7. Partial protection of mice against Leishmania major by 
prior infection with L. arabica. Trans R Soc Trop Med Hyg. 84:233-238. 
396. Nelson, R. A., Jr. 1953. The immune-adherence phenomenon. An immunologically 
specific reaction between microorganisms and erythrocytes leading to enhanced 
phagocytosis. Science. 118:733-737. 
397. Neva, F. A., E. A. Petersen, R. Corsey, H. Bogaert, and D. Martinez. 1984. 
Observations on local heat treatment for cutaneous leishmaniasis. Am J Trap Med 
Hyg. 33:800-804. 
398. Ngo, V. N., H. L. Tang, and J. G. Cyster. 1998. Epstein-Barr virus-induced 
molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and 
strongly attracts naive T cells and activated B cells. J Exp Med. 188:181-191. 
399. Nishikomori, R., S. Gurunathan, K. Nishikomori, and W. Strober. 2001. BALB/c 
mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype 
to Leishmania major infection despite intact IL-12 signaling. J Immunol. 166:6776-
6783. 
400. Noben-Trauth, N., P. Kropf, and I. Muller. 1996. Susceptibility to Leishmania 
major infection in interleukin-4-deficient mice. Science. 271:987-990. 
401. Noben-Trauth, N., R. Lira, H. Nagase, W. E. Paul, and D. L. Sacks. 2003. The 
relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to 
Leishmania major. J Immunol. 170:5152-5158. 
402. Noben-Trauth, N., W. E. Paul, and D. L. Sacks. 1999. IL-4- and IL-4 receptor-
deficient BALB/c mice reveal differences in susceptibility to Leishmania major 
parasite substrains. J Immunol. 162:6132-6140. 
403. Norsworthy, N. B., J. Sun, D. Elnaiem, G. Lanzaro, and L. Soong. 2004. Sand Fly 
Saliva Enhances Leishmania amazonensis Infection by Modulating Interleukin-10 
Production. Infect Immun. 72:1240-1247. 
404. Nunes, A. C., F. R. Almeida-Campos, M. F. Horta, and F. J. Ramalho-Pinto. 
1997. Leishmania amazonensis promastigotes evade complement killing by 
interfering with the late steps of the cascade. Parasitology. 115:601-609. 
405. Nunes, A. C., and F. J. Ramalho-Pinto. 1996. Complement resistance of 
Leishmania amazonensis promastigotes is independent of parasite proteases and lysis 
103 
of sensitive forms is not due to natural antibodies in normal human serum. Braz J 
Med Biol Res. 29:1633-1640. 
406. Nuwayri-Salti, N., and H. Fallah Khansa. 1985. Direct non-insect-vector 
transmission of Leishmania parasites in mice. Int J Parasitol. 15:497-500. 
407. Nuwayri-Salti, N., D. Mu'Atassem, S. Salman, N. Izzedine, and A. G. Kibbi. 
1992. Chronic cutaneous leishmaniasis: Leishmania parasites in blood. Int J 
Dermatol. 31:562-564. 
408. Oliveira, S. H., S. G. Fonseca, P. R. Romao, S. H. Ferreira, and F. Q. Cunha. 
1997. Nitric oxide mediates the microbicidal activity of eosinophils. Mem Inst 
Oswaldo Cruz. 92:233-235. 
409. Olobo, J. O., E. Handman, J. M. Curtis, and G. F. Mitchell. 1980. Antibodies to 
Leishmania tropica promastigotes during infection in mice of various genotypes. 
Aust J Exp Biol Med Sci. 58:595-601. 
410. Overath, P., and T. Aebischer. 1999. Antigen presentation by macrophages 
harboring intravesicular pathogens. Parasitol Today. 15:325-332. 
411. Overath, P., and D. Harbecke. 1993. Course of Leishmania infection in beta 2-
microglobulin-deficient mice. Immunol Lett. 37:13-17. 
412. Padigel, U. M., J. Alexander, and J. P. Farrell. 2003. The role of interleukin-10 in 
susceptibility of BALB/c mice to infection with Leishmania mexicana and 
Leishmania amazonensis. J Immunol. 171:3705-3710. 
413. Padigel, U. M., and J. P. Farrell. 2003. CD40-CD40 ligand costimulation is not 
required for initiation and maintenance of a Thl-type response to Leishmania major 
infection. Infect Immun. 71:1389-1395. 
414. Padigel, U. M., P. J. Perrin, and J. P. Farrell. 2001. The Development of a Thl-
Type Response and Resistance to Leishmania major Infection in the Absence of 
CD40-CD40L Costimulation. J Immunol. 167:5874-5879. 
415. Palatnik-de-Sousa, C. B., W. R. dos Santos, J. C. Franca-Silva, R. T. da Costa, 
A. B. Reis, M. Palatnik, W. Mayrink, and O. Genaro. 2001. Impact of canine 
control on the epidemiology of canine and human visceral leishmaniasis in Brazil. 
Am J Trop Med Hyg. 65:510-517. 
416. Paranhos-Silva, M., G. G. Oliveira, E. A. Reis, R. M. de Menezes, O. Fernandes, 
I. Sherlock, R. B. Gomes, L. C. Pontes-de-Carvalho, and W. L. dos-Santos. 2003. 
A follow-up of Beagle dogs intradermally infected with Leishmania chagasi in the 
presence or absence of sand fly saliva. Vet Parasitol. 114:97-111. 
417. Park, A. Y., B. Hondowicz, M. Kopf, and P. Scott. 2002. The role of IL-12 in 
maintaining resistance to Leishmania major. J Immunol. 168:5771-5777. 
418. Park, A. Y., B. D. Hondowicz, and P. Scott. 2000. IL-12 is required to maintain a 
Thl response during Leishmania major infection. J Immunol. 165:896-902. 
419. Parlato, S., S. M. Santini, C. Lapenta, T. Di Pucchio, M. Logozzi, M. Spada, A. 
M. Giammarioli, W. Malomi, S. Fais, and F. Belardelli. 2001. Expression of 
CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived 
dendritic cells: importance for the rapid acquisition of potent migratory and 
functional activities. Blood. 98:3022-3029. 
104 
420. Pearson, R. D., and R. T. Steigbigel. 1981. Phagocytosis and killing of the 
protozoan Leishmania donovani by human polymorphonuclear leukocytes. J 
Immunol. 127:1438-1443. 
421. Pearson, R. D., I. L. Uydess, S. W. Chapman, and R. T. Steigbigel. 1987. 
Interaction of human eosinophils with Leishmania donovani. Ann Trop Med 
Parasitol. 81:735-739. 
422. Perez, H., B. Arredondo, and R. Machado. 1979. Leishmania mexicana and 
Leishmania tropica: cross immunity in C57BL/6 mice. Exp Parasitol. 48:9-14. 
423. Peters, C., T. Aebischer, Y. D. Stierhof, M. Fuchs, and P. Overath. 1995. The role 
of macrophage receptors in adhesion and uptake of Leishmania mexicana 
amastigotes. J Cell Sci. 108:3715-3724. 
424. Peters, C., M. Kawakami, M. Kaul, T. Ilg, P. Overath, and T. Aebischer. 1997. 
Secreted proteophosphoglycan of Leishmania mexicana amastigotes activates 
complement by triggering the mannan binding lectin pathway. Eur J Immunol. 
27:2666-2672. 
425. Peters, C., Y. D. Stierhof, and T. Ilg. 1997. Proteophosphoglycan secreted by 
Leishmania mexicana amastigotes causes vacuole formation in macrophages. Infect 
Immun. 65:783-786. 
426. Peters, W. 1988. "The little sister" - a tale of Arabia. Trans R Soc Trop Med Hyg. 
82:179-184. 
427. Petersen, E. A., F. A. Neva, A. Barrai, R. Correa-Coronas, H. Bogaert-Diaz, D. 
Martinez, and F. E. Ward. 1984. Monocyte suppression of antigen-specific 
lymphocyte responses in diffuse cutaneous leishmaniasis patients from the 
Dominican Republic. J Immunol. 132:2603-2606. 
428. Piedrafita, D., L. Proudfoot, A. V. Nikolaev, D. Xu, W. Sands, G. J. Feng, E. 
Thomas, J. Brewer, M. A. Ferguson, J. Alexander, and F. Y. Liew. 1999. 
Regulation of macrophage IL-12 synthesis by Leishmania phosphoglycans. Eur J 
Immunol. 29:235-244. 
429. Pimenta, P. F., M. A. Dos Santos, and W. De Souza. 1987. Fine structure and 
cytochemistry of the interaction between Leishmania mexicana amazonensis and rat 
neutrophils and eosinophils. J Submicrosc Cytol. 19:387-395. 
430. Pimenta, P. F., E. M. Saraiva, E. Rowton, G. B. Modi, L. A. Garraway, S. M. 
Beverley, S. J. Turco, and D. L. Sacks. 1994. Evidence that the vectorial 
competence of phlebotomine sand flies for different species of Leishmania is 
controlled by structural polymorphisms in the surface lipophosphoglycan. Proc Natl 
Acad Sci USA. 91:9155-9156. 
431. Pinto, E. F., M. de Mello Cortezia, and B. Rossi-Bergmann. 2003. Interferon-
gamma-inducing oral vaccination with Leishmania amazonensis antigens protects 
BALB/c and C57BL/6 mice against cutaneous leishmaniasis. Vaccine. 21:3534-3541. 
432. Pirmez, C., M. Yamamura, K. Uyemura, M. Paes-Oliveira, F. Conceicao-Silva, 
and R. L. Modlin. 1993. Cytokine patterns in the pathogenesis of human 
leishmaniasis. J Clin Invest. 91:1390-1395. 
433. Pleass, R. J., and J. M. Woof. 2001. Fc receptors and immunity to parasites. Trends 
Parasitol. 17:545-551. 
105 
434. Pohlmann, S., F. Baribaud, and R. W. Doms. 2001. DC-SIGN and DC-SIGNR: 
helping hands for HIV. Trends Immunol. 22:643-646. 
435. Pompeu, M. L., L. A. Freitas, M. L. Santos, M. Khouri, and M. Barral-Netto. 
1991. Granulocytes in the inflammatory process of BALB/c mice infected by 
Leishmania amazonensis. A quantitative approach. Acta Trop. 48:185-193. 
436. Ponce, C., E. Ponce, A. Morrison, A. Cruz, R. Kreutzer, D. McMahon-Pratt, and 
F. Neva. 1991. Leishmania donovani chagasi: new clinical variant of cutaneous 
leishmaniasis in Honduras. Lancet. 337:67-70. 
437. Ponte-Sucre, A., D. Heise, and H. Moll. 2001. Leishmania major 
lipophosphoglycan modulates the phenotype and inhibits migration of murine 
Langerhans cells. Immunology. 104:462-467. 
438. Porcelli, S. A., and R. L. Modlin. 1999. The CD1 system: antigen-presenting 
molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol. 
17:297-329. 
439. Poulter, L. W., and C. R. Pandolph. 1982. Mechanisms of immunity to 
leishmaniasis. IV. Significance of lymphatic drainage from the site of infection. Clin 
Exp Immunol. 48:396-402. 
440. Preston, P. M., K. Behbehani, and D. C. Dumonde. 1978. Experimental cutaneous 
leishmaniasis: VI: anergy and allergy in the cellular immune response during non­
healing infection in different strains of mice. J Clin Lab Immunol. 1:207-219. 
441. Price, A. A., M. Cumberbatch, I. Kimber, and A. Ager. 1997. Alpha 6 integrins 
are required for Langerhans cell migration from the epidermis. J Exp Med. 186:1725-
1735. 
442. Prina, E., S. Z. Abdi, M. Lebastard, E. Perret, N. Winter, and J. C. Antoine. 
2004. Dendritic cells as host cells for the promastigote and amastigote stages of 
Leishmania amazonensis: the role of opsonins in parasite uptake and dendritic cell 
maturation. J Cell Sci. 117:315-325. Epub 2003 Dec 2002. 
443. Prina, E., C. Jouanne, S. de Souza Lao, A. Szabo, J. G. Guillet, and J. C. 
Antoine. 1993. Antigen presentation capacity of murine macrophages infected with 
Leishmania amazonensis amastigotes. J Immunol. 151:2050-2061. 
444. Puentes, S. M., D. L. Sacks, R. P. da Silva, and K. A. Joiner. 1988. Complement 
binding by two developmental stages of Leishmania major promastigotes varying in 
expression of a surface lipophosphoglycan. J Exp Med. 167:887-902. 
445. Puig, L., and R. Pradinaud. 2003. Leishmania and HIV co-infection: dermatological 
manifestations. Ann Trop Med Parasitol. 97:107-114. 
446. Qi, H., V. Popov, and L. Soong. 2001. Leishmania amazonensis-Dendritic Cell 
Interactions In Vitro and the Priming of Parasite-Specific CD4(+) T Cells In Vivo. J 
Immunol. 167:4534-4542. 
447. Quinones, M., S. K. Ahuja, P. C. Melby, L. Pate, R. L. Reddick, and S. S. Ahuja. 
2000. Preformed membrane-associated stores of interleukin (IL)-12 are a previously 
unrecognized source of bioactive IL-12 that is mobilized within minutes of contact 
with an intracellular parasite. J Exp Med. 192:507-516. 
448. Qureshi, S. T., L. Lariviere, G. Leveque, S. Clermont, K. J. Moore, P. Gros, and 
D. Malo. 1999. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). 
J Exp Med. 189:615-625. 
106 
449. Rabinovitch, M., V. Zilberfarb, and C. Ramazeilles. 1986. Destruction of 
Leishmania mexicana amazonensis amastigotes within macrophages by 
lysosomotropic amino acid esters. J Exp Med. 163:520-535. 
450. Racoosin, E. L., and S. M. Beverley. 1997. Leishmania major: promastigotes induce 
expression of a subset of chemokine genes in murine macrophages. Exp Parasitol. 
85:283-295. 
451. Rafati, S., A. Kariminia, S. Seyde-Eslami, M. Narimani, T. Taheri, and M. 
Lebbatard. 2002. Recombinant cysteine proteinases-based vaccines against 
Leishmania major in BALB/c mice: the partial protection relies on interferon gamma 
producing CD8(+) T lymphocyte activation. Vaccine. 20:2439-2447. 
452. Ramos, H., E. Valdivieso, M. Gamargo, F. Dagger, and B. E. Cohen. 1996. 
Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to 
small cations and anions. J Membr Biol. 152:65-75. 
453. Read, S., and F. Powrie. 2001. CD4(+) regulatory T cells. Curr Opin Immunol. 
13:644-649. 
454. Reed, S. G., Z. A. Andrade, S. B. Roters, J. A. Inverse, and M. Sadigursky. 1986. 
Leishmania mexicana amazonensis infections in 'resistant' inbred mice following 
removal of the draining lymph node. Clin Exp Immunol. 64:8-13. 
455. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania 
major. Annu Rev Immunol. 13:151-177. 
456. Reiner, S. L., S. Zheng, Z. E. Wang, L. Stowring, and R. M. Locksley. 1994. 
Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages 
and stimulate a broad range of cytokines from CD4+ T cells during initiation of 
infection. J Exp Med. 179:447-456. 
457. Reithinger, R., and C. R. Davies. 1999. Is the domestic dog (Canis familiaris) a 
reservoir host of American cutaneous leishmaniasis? A critical review of the current 
evidence. Am J Trop Med Hyg. 61:530-541. 
458. Rhee, E. G., S. Mendez, J. A. Shah, C. Y. Wu, J. R. Kirman, T. N. Turon, D. F. 
Davey, H. Davis, D. M. Klinman, R. N. Coler, D. L. Sacks, and R. A. Seder. 2002. 
Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein 
and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell 
responses and protection against Leishmania major infection. J Exp Med. 195:1565-
1573. 
459. Ribeiro-Gomes, F. L., A. C. Otero, N. A. Gomes, M. C. Moniz-De-Souza, L. 
Cysne-Finkelstein, A. C. Arnholdt, V. L. Calich, S. G. Coutinho, M. F. Lopes, 
and G. A. DosReis. 2004. Macrophage interactions with neutrophils regulate 
Leishmania major infection. J Immunol. 172:4454-4462. 
460. Ritter, U., A. Meissner, C. Scheidig, and H. Korner. 2004. CDSalpha- and 
Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-
presenting cells in leishmaniasis. Eur J Immunol. 34:1542-1550. 
461. . Rivier, D., P. Bovay, R. Shah, S. Didisheim, and J. Mauel. 1999. Vaccination 
against Leishmania major in a CBA mouse model of infection: role of adjuvants and 
mechanism of protection. Parasite Immunol. 21:461-473. 
107 
462. Rizvi, F. S., M. A. Ouaissi, B. Marty, F. Santoro, and A. Capron. 1988. The major 
surface protein of Leishmania promastigotes is a fibronectin-like molecule. Eur J 
Immunol. 18:473-476. 
463. Roberts, M., J. Alexander, and J. M. Blackwell. 1990. Genetic analysis of 
Leishmania mexicana infection in mice: single gene (Scl-2) controlled predisposition 
to cutaneous lesion development. J Immunogenet. 17:89-100. 
464. Robertson, C. D., and G. H. Coombs. 1992. Stage-specific proteinases of 
Leishmania mexicana mexicana promastigotes. FEMS Microbiol Lett. 73:127-132. 
465. Rocha, P. N., R. P. Almeida, O. Bacellar, A. R. de Jesus, D. C. Filho, A. C. Filho, 
A. Barrai, R. L. Coffman, and E. M. Carvalho. 1999. Down-regulation of Thl type 
of response in early human American cutaneous leishmaniasis. J Infect Dis. 
180:1731-1734. 
466. Rodriguez-Sosa, M., G. M. Monteforte, and A. R. Satoskar. 2001. Susceptibility 
to Leishmania mexicana infection is due to the inability to produce IL-12 rather than 
lack of IL-12 responsiveness. Immunol Cell Biol. 79:320-322. 
467. Rogge, L., L. Barberis-Maino, M. Biffi, N. Passini, D. H. Presky, U. Gubler, and 
F. Sinigaglia. 1997. Selective expression of an interleukin-12 receptor component by 
human T helper 1 cells. J Exp Med. 185:825-831. 
468. Rosas, L. E., T. Keiser, R. Pyles, J. Durbin, and A. R. Satoskar. 2003. 
Development of protective immunity against cutaneous leishmaniasis is dependent on 
STAT 1-mediated IFN signaling pathway. Eur J Immunol. 33:1799-1805. 
469. Rose, K., J. Curtis, T. Baldwin, A. Mathis, B. Kumar, A. Sakthianandeswaren, 
T. Spurck, J. Low Choy, and E. Handman. 2004. Cutaneous leishmaniasis in red 
kangaroos: isolation and characterisation of the causative organisms. Int J Parasitol. 
34:655-664. 
470. Rosenthal, L. A., F. S. Sutterwala, M. E. Kehrli, and D. M. Mosser. 1996. 
Leishmania major-human macrophage interactions: cooperation between Mac-1 
(CD1 lb/CD 18) and complement receptor type 1 (CD35) in promastigote adhesion. 
Infect Immun. 64:2206-2215. 
471. Rosypal, A. C., Z. A. M., and L. D. S. 2003. Canine visceral leishmaniasis and its 
emergence in the United States. Vet Clin Small Anim. 33:921-937. 
472. Rot, A., and U. H. Von Andrian. 2004. Chemokines in Innate and Adaptive Host 
Defense: Basic Chemokinese Grammar for Immune Cells. Annu Rev Immunol. 
22:891-928. 
473. Rousseau, D., S. Demartino, B. Ferrua, J. F. Michiels, F. Anjuere, K. Fragaki, Y. 
Le Fichoux, and J. Kubar. 2001. In vivo involvement of polymorphonuclear 
neutrophils in Leishmania infantum infection. BMC Microbiol. 1:17. Epub 2001 Aug 
2017. 
474. Russell, D. G. 1987. The macrophage-attachment glycoprotein gp63 is the 
predominant C3-acceptor site on Leishmania mexicana promastigotes. Eur J 
Biochem. 164:213-221. 
475. Russell, D. G., P. Talamas-Rohana, and J. Zelechowski. 1989. Antibodies raised 
against synthetic peptides from the Arg-Gly-Asp-containing region of the Leishmania 
surface protein gp63 cross-react with human C3 and interfere with gp63-mediated 
binding to macrophages. Infect Immun. 57:630-632. 
108 
476. Russell, D. G., and H. Wilhelm. 1986. The involvement of the major surface 
glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages. J 
Immunol. 136:2613-2620. 
477. Russell, D. G., and S. D. Wright. 1988. Complement receptor type 3 (CR3) binds to 
an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of 
Leishmania promastigotes. J Exp Med. 168:279-292. 
478. Russell, D. G., S. Xu, and P. Chakraborty. 1992. Intracellular trafficking and the 
parasitophorous vacuole of Leishmania mexicana-infected macrophages. J Cell Sci. 
103:1193-1210. 
479. Sacks, D., and S. Kamhawi. 2001. Molecular aspects of parasite-vector and vector-
host interactions in leishmaniasis. Annu Rev Microbiol. 55:453-483. 
480. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and 
resistance to Leishmania major in mice. Nat Rev Immunol. 2:845-858. 
481. Sacks, D., and A. Sher. 2002. Evasion of innate immunity by parasitic protozoa. Nat 
Immunol. 3:1041-1047. 
482. Sacks, D. L. 2001. Leishmania-sand fly interactions controlling species-specific 
vector competence. Cell Microbiol. 3:189-196. 
483. Sacks, D. L., A. Barrai, and F. A. Neva. 1983. Thermosensitivity patterns of Old vs. 
New World cutaneous strains of Leishmania growing within mouse peritoneal 
macrophages in vitro. Am J Trop Med Hyg. 32:300-304. 
484. Sacks, D. L., S. Hieny, and A. Sher. 1985. Identification of cell surface 
carbohydrate and antigenic changes between noninfective and infective 
developmental stages of Leishmania major promastigotes. J Immunol. 135:564-569. 
485. Sacks, D. L., S. L. Lai, S. N. Shrivastava, J. Blackwell, and F. A. Neva. 1987. An 
analysis of T cell responsiveness in Indian kala-azar. J Immunol. 138:908-913. 
486. Sacks, D. L., G. Modi, E. Rowton, G. Spath, L. Epstein, S. J. Turco, and S. M. 
Beverley. 2000. The role of phosphoglycans in Leishmania-sand fly interactions. 
Proc Natl Acad Sci USA. 97:406-411. 
487. Sacks, D. L., and P. V. Perkins. 1985. Development of infective stage Leishmania 
promastigotes within phlebotomine sand flies. Am J Trop Med Hyg. 34:456-459. 
488. Sacks, D. L., and P. V. Perkins. 1984. Identification of an infective stage of 
Leishmania promastigotes. Science. 223:1417-1419. 
489. Sacks, D. L., P. A. Scott, R. Asofsky, and F. A. Sher. 1984. Cutaneous 
leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional 
depletion of a B cell-dependent T cell involved in the suppressor pathway. J 
Immunol. 132:2072-2077. 
490. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. 
Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal 
antibody. Evidence for a T cell-dependent, interferon gamma-independent 
mechanism. J Exp Med. 171:115-127. 
491. Sadick, M. D., R. M. Locksley, C. Tubbs, and H. V. Raff. 1986. Murine cutaneous 
leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in 
response to Leishmania antigens in vitro. J Immunol. 136:655-661. 
109 
492. Sadick, M. D., N. Street, T. R. Mosmann, and R. M. Locksley. 1991. Cytokine 
regulation of murine leishmaniasis: interleukin 4 is not sufficient to mediate 
progressive disease in resistant C57BL/6 mice. Infect Immun. 59:4710-4714. 
493. Saeki, H., A. M. Moore, M. J. Brown, and S. T. Hwang. 1999. Cutting edge: 
secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) 
participate in the emigration pathway of mature dendritic cells from the skin to 
regional lymph nodes. J Immunol. 162:2472-2475. 
494. Saha, B., S. Chattopadhyay, R. Germond, D. M. Harlan, and P. J. Perrin. 1998. 
CTLA4 (CD 152) modulates the Th subset response and alters the course of 
experimental Leishmania major infection. Eur J Immunol. 28:4213-4220. 
495. Saito, S., A. Hamada, N. Watanabe, T. Obata, K. Katakura, and H. Ohtomo. 
1996. Eosinophil chemotactic activity in Leishmania amazonensis promastigotes. 
Parasitol Res. 82:485-489. 
496. Salaiza-Suazo, N., P. Volkow, R. Tamayo, H. Moll, R. Gillitzer, A. Perez-Torres, 
R. Perez-Montfort, J. D. Dominguez, O. Velasco-Castrejon, M. Crippa, and I. 
Becker. 1999. Treatment of two patients with diffuse cutaneous leishmaniasis caused 
by Leishmania mexicana modifies the immunohistological profile but not the disease 
outcome. Trop Med Int Health. 4:801-811. 
497. Sallusto, F., P. Schaerli, P. Loetscher, C. Schaniel, D. Lenig, C. R. Mackay, S. 
Qin, and A. Lanzavecchia. 1998. Rapid and coordinated switch in chemokine 
receptor expression during dendritic cell maturation. Eur J Immunol. 28:2760-2769. 
498. Sampaio, R. N., P. D. Marsden, E. A. Llanos Cuentas, C. A. Cuba Cuba, and G. 
Grimaldi Junior. 1985. Leishmania mexicana amazonensis isolated from a patient 
with fatal mucosal leishmaniasis. Rev Soc Bras Med Trop. 18:273-274. 
499. Samuelson, J., E. Lerner, R. Tesh, and R. Titus. 1991. A mouse model of 
Leishmania braziliensis braziliensis infection produced by coinjection with sand fly 
saliva. J Exp Med. 173:49-54. 
500. Sato, N., S. K. Ahuja, M. Quinones, V. Kostecki, R. L. Reddick, P. C. Melby, W. 
A. Kuziel, and S. S. Ahuja. 2000. CC chemokine receptor (CCR)2 is required for 
langerhans cell migration and localization of T helper cell type 1 (Thl)-inducing 
dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to 
a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained 
neutrophilic inflammation. J Exp Med. 192:205-218. 
501. Sato, N., W. A. Kuziel, P. C. Melby, R. L. Reddick, V. Kostecki, W. Zhao, N. 
Maeda, S. K. Ahuja, and S. S. Ahuja. 1999. Defects in the generation of IFN-
gamma are overcome to control infection with Leishmania donovani in CC 
chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-
deficient mice. J Immunol. 163:5519-5525. 
502. Satoskar, A., H. Bluethmann, and J. Alexander. 1995. Disruption of the murine 
interleukin-4 gene inhibits disease progression during Leishmania mexicana infection 
but does not increase control of Leishmania donovani infection. Infect Immun. 
63:4894-4899. 
503. Satoskar, A. R., L. M. Stamm, X. Zhang, A. A. Satoskar, M. Okano, C. Terhorst, 
J. R. David, and B. Wang. 1999. Mice lacking NK cells develop an efficient Thl 
110 
response and control cutaneous Leishmania major infection. J Immunol. 162:6747-
6754. 
504. Scanga, C. A., J. Aliberti, D. Jankovic, F. Tilloy, S. Bennouna, E. Y. Denkers, R. 
Medzhitov, and A. Sher. 2002. Cutting edge: MyD88 is required for resistance to 
Toxoplasma gondii infection and regulates parasite-induced IL-12 production by 
dendritic cells. J Immunol. 168:5997-6001. 
505. Scharton, T. M., and P. Scott. 1993. Natural killer cells are a source of interferon 
gamma that drives differentiation of CD4+ T cell subsets and induces early resistance 
to Leishmania major in mice. J Exp Med. 178:567-577. 
506. Scharton-Kersten, T., L. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott. 
1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell 
development in experimental leishmaniasis. J Immunol. 154:5320-5330. 
507. Schubach, A., F. Haddad, M. P. Oliveira-Neto, W. Degrave, C. Pirmez, G. 
Grimaldi, Jr., and O. Fernandes. 1998. Detection of Leishmania DNA by 
polymerase chain reaction in scars of treated human patients. J Infect Dis. 178:911-
914. 
508. Schubach, A., M. C. Marzochi, T. Cuzzi-Maya, A. V. Oliveira, M. L. Araujo, A. 
L. Oliveira, R. S. Pacheco, H. Momen, F. Conceicao-Silva, S. G. Coutinho, and 
K. B. Marzochi. 1998. Cutaneous scars in American tegumentary leishmaniasis 
patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven 
years after antimonial therapy and clinical cure. Am J Trop Med Hyg. 58:824-827. 
509. Schulz, O., A. D. Edwards, M. Schito, J. Aliberti, S. Manickasingham, A. Sher, 
and C. Reis e Sousa. 2000. CD40 triggering of heterodimeric IL-12 p70 production 
by dendritic cells in vivo requires a microbial priming signal. Immunity. 13:453-462. 
510. Schwartzman, J. D., and R. D. Pearson. 1985. The interaction of Leishmania 
donovani promastigotes and human fibroblasts in vitro. Am J Trop Med Hyg. 34:850-
855. 
511. Schweitzer, A. N., F. Borriello, R. C. Wong, A. K. Abbas, and A. H. Sharpe. 
1997. Role of costimulators in T cell differentiation: studies using antigen-presenting 
cells lacking expression of CD80 or CD86. J Immunol. 158:2713-2722. 
512. Schweitzer, A. N., and A. H. Sharpe. 1998. Studies using antigen-presenting cells 
lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements 
for B7 molecules during priming versus restimulation of Th2 but not Thl cytokine 
production. J Immunol. 161:2762-2771. 
513. Scott, P. 1991. IFN-gamma modulates the early development of Thl and Th2 
responses in a murine model of cutaneous leishmaniasis. J Immunol. 147:3149-3155. 
514. Scott, P., and C. A. Hunter. 2002. Dendritic cells and immunity to leishmaniasis and 
toxoplasmosis. Curr Opin Immunol. 14:466-470. 
515. Scott, P., P. Natovitz, R. L. Coffman, E. Pearce, and A. Sher. 1988. 
Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective 
immunity or exacerbation belong to different T helper subsets and respond to distinct 
parasite antigens. J Exp Med. 168:1675-1684. 
516. Scott, P., P. Natovitz, and A. Sher. 1986. B lymphocytes are required for the 
generation of T cells that mediate healing of cutaneous leishmaniasis. J Immunol. 
137:1017-1021. 
I l l  
517. Scott, P., and A. Sher. 1986. A spectrum in the susceptibility of leishmanial strains 
to intracellular killing by murine macrophages. J Immunol. 136:1461-1466. 
518. Sellon, R. K., M. M. Menard, D. J. Meuten, E. J. Lengerich, F. J. Steurer, and E. 
B. Breitschwerdt. 1993. Endemic visceral leishmaniasis in a dog from Texas. J Vet 
Intern Med. 7:16-19. 
519. Shevach, E. M. 2002. CD4+ CD25+ suppressor T cells: more questions than 
answers. Nat Rev Immunol. 2:389-400. 
520. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat 
Rev Immunol. 2:151-161. 
521. Shortt, H. E., R. O. A. Smith, C. S. Swaminath, and K. V. Krishnan. 1931. 
Transmission of Indian Kala-azar by the bite of Phlebotomus argentipes. Indian J 
Med Res. 18:1373-1375. 
522. Skeiky, Y. A., M. Kennedy, D. Kaufman, M. M. Borges, J. A. Guderian, J. K. 
Scholler, P. J. Ovendale, K. S. Picha, P. J. Morrissey, K. H. Grabstein, A. 
Campos-Neto, and S. G. Reed. 1998. LeIF: a recombinant Leishmania protein that 
induces an IL-12-mediated Th 1 cytokine profile. J Immunol. 161:6171-6179. 
523. Smelt, S. C., S. E. Cotterell, C. R. Engwerda, and P. M. Kaye. 2000. B cell-
deficient mice are highly resistant to Leishmania donovani infection, but develop 
neutrophil-mediated tissue pathology. J Immunol. 164:3681-3688. 
524. Soares, M. B., J. R. David, and R. G. Titus. 1997. An in vitro model for infection 
with Leishmania major that mimics the immune response in mice. Infect Immun. 
65:2837-2845. 
525. Soong, L., C. H. Chang, J. Sun, B. J. Longley, Jr., N. H. Ruddle, R. A. Flavell, 
and D. McMahon-Pratt. 1997. Role of CD4+ T cells in pathogenesis associated 
with Leishmania amazonensis infection. J Immunol. 158:5374-5383. 
526. Soong, L., S. M. Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania 
pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect 
Immun. 63:3559-3566. 
527. Soong, L., J. C. Xu, I. S. Grewal, P. Kima, J. Sun, B. J. Longley, Jr., N. H. 
Ruddle, D. McMahon-Pratt, and R. A. Flavell. 1996. Disruption of CD40-CD40 
ligand interactions results in an enhanced susceptibility to Leishmania amazonensis 
infection. Immunity. 4:263-273. 
528. Sozzani, S., P. Allavena, G. D'Amico, W. Luini, G. Bianchi, M. Kataura, T. Imai, 
O. Yoshie, R. Bonecchi, and A. Mantovani. 1998. Differential regulation of 
chemokine receptors during dendritic cell maturation: a model for their trafficking 
properties. J Immunol. 161:1083-1086. 
529. Sozzani, S., P. Allavena, A. Vecchi, and A. Mantovani. 2000. Chemokines and 
dendritic cell traffic. J Clin Immunol. 20:151-160. 
530. Spath, G. F., L. Epstein, B. Leader, S. M. Singer, H. A. Avila, S. J. Turco, and S. 
M. Beverley. 2000. Lipophosphoglycan is a virulence factor distinct from related 
glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci U S 
A. 97:9258-9263. 
531. Spath, G. F., L. A. Garraway, S. J. Turco, and S. M. Beverley. 2003. The role(s) 
of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in 
mammalian hosts. Proc Natl Acad Sci USA. 100:9536-9541. Epub 2003 Jul 9517. 
112 
532. Spath, G. F., L. F. Lye, H. Segawa, D. L. Sacks, S. J. Turco, and S. M. Beverley. 
2003. Persistence without pathology in phosphoglycan-deficient Leishmania major. 
Science. 301:1241-1243. 
533. Squires, K. E., R. D. Schreiber, M. J. McElrath, B. Y. Rubin, S. L. Anderson, 
and H. W. Murray. 1989. Experimental visceral leishmaniasis: role of endogenous 
IFN-gamma in host defense and tissue granulomatous response. J Immunol. 
143:4244-4249. 
534. Stacey, K. J., and J. M. Blackwell. 1999. Immunostimulatory DNA as an adjuvant 
in vaccination against Leishmania major. Infect Immun. 67:3719-3726. 
535. Stafford, J. L., N. F. Neumann, and M. Belosevic. 2002. Macrophage-mediated 
innate host defense against protozoan parasites. Crit Rev Microbiol. 28:187-248. 
536. Stamm, L. M., A. Raisanen-Sokolowski, M. Okano, M. E. Russell, J. R. David, 
and A. R. Satoskar. 1998. Mice with STAT6-targeted gene disruption develop a Thl 
response and control cutaneous leishmaniasis. J Immunol. 161:6180-6188. 
537. Stamm, L. M., A. A. Satoskar, S. K. Ghosh, J. R. David, and A. R. Satoskar. 
1999. STAT-4 mediated IL-12 signaling pathway is critical for the development of 
protective immunity in cutaneous leishmaniasis. Eur J Immunol. 29:2524-2529. 
538. Stenger, S., N. Donhauser, H. Thuring, M. Rollinghoff, and C. Bogdan. 1996. 
Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J 
Exp Med. 183:1501-1514. 
539. Stern, J. J., M. J. Oca, B. Y. Rubin, S. L. Anderson, and H. W. Murray. 1988. 
Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol. 
140:3971-3977. 
540. Stetson, D. B., M. Mohrs, V. Mallet-Designe, L. Teyton, and R. M. Locksley. 
2002. Rapid expansion and IL-4 expression by Leishmania-specific naive helper T 
cells in vivo. Immunity. 17:191-200. 
541. Stobie, L., S. Gurunathan, C. Prussin, D. L. Sacks, N. Glaichenhaus, C. Y. Wu, 
and R. A. Seder. 2000. The role of antigen and IL-12 in sustaining Thl memory cells 
in vivo: IL-12 is required to maintain memory/effector Thl cells sufficient to mediate 
protection to an infectious parasite challenge. Proc Natl Acad Sci USA. 97:8427-
8432. 
542. Swenson, C. L., J. Silverman, P. C. Stromberg, S. E. Johnson, D. A. Wilkie, K. 
A. Eaton, and G. J. Kociba. 1988. Visceral leishmaniasis in an English foxhound 
from an Ohio research colony. J Am Vet Med Assoc. 193:1089-1092. 
543. Swihart, K., U. Fruth, N. Messmer, K. Hug, R. Behin, S. Huang, G. Del Giudice, 
M. Aguet, and J. A. Louis. 1995. Mice from a genetically resistant background 
lacking the interferon gamma receptor are susceptible to infection with Leishmania 
major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med. 
181:961-971. 
544. Sypek, J. P., C. L. Chung, S. E. Mayor, J. M. Subramanyam, S. J. Goldman, D. 
S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous 
leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J 
Exp Med. 177:1797-1802. 
113 
545. Szabo, S. J., A. S. Dighe, U. Gubler, and K. M. Murphy. 1997. Regulation of the 
interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Thl) and 
Th2 cells. J Exp Med. 185:817-824. 
546. Szabo, S. J., B. M. Sullivan, C. Stemmann, A. R. Satoskar, B. P. Sleckman, and 
L. H. Glimcher. 2002. Distinct effects of T-bet in TH1 lineage commitment and 
IFN-gamma production in CD4 and CD8 T cells. Science. 295:338-342. 
547. Tacchini-Cottier, F., C. Zweifel, Y. Belkaid, C. Mukankundiye, M. Vasei, P. 
Launois, G. Milon, and J. A. Louis. 2000. An immunomodulatory function for 
neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected 
with Leishmania major. J Immunol. 165:2628-2636. 
548. Tailleux, L., O. Schwartz, J. L. Herrmann, E. Pivert, M. Jackson, A. Amara, L. 
Legres, D. Dreher, L. P. Nicod, J. C. Gluckman, P. H. Lagrange, B. Gicquel, and 
O. Neyrolles. 2003. DC-SIGN is the major Mycobacterium tuberculosis receptor on 
human dendritic cells. J Exp Med. 197:121-127. 
549. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-Like Receptors. Annu Rev 
Immunol. 9:9. 
550. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. 
Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of 
gram-negative and gram-positive bacterial cell wall components. Immunity. 11:443-
451. 
551. Talamas-Rohana, P., S. D. Wright, M. R. Lennartz, and D. G. Russell. 1990. 
Lipophosphoglycan from Leishmania mexicana promastigotes binds to members of 
the CR3, pi50,95 and LFA-1 family of leukocyte integrins. J Immunol. 144:4817-
4824. 
552. Taylor, A. P., and H. W. Murray. 1997. Intracellular antimicrobial activity in the 
absence of interferon-gamma: effect of interleukin-12 in experimental visceral 
leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med. 185:1231-1239. 
553. Theodos, C. M., J. M. Ribeiro, and R. G. Titus. 1991. Analysis of enhancing effect 
of sand fly saliva on Leishmania infection in mice. Infect Immun. 59:1592-1598. 
554. Thornton, A. M., and E. M. Shevach. 1998. CD4+CD25+ immunoregulatory T 
cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 
production. J Exp Med. 188:287-296. 
555. Titus, R. G., G. Milon, G. Marchai, P. Vassalli, J. C. Cerottini, and J. A. Louis. 
1987. Involvement of specific Lyt-2+ T cells in the immunological control of 
experimentally induced murine cutaneous leishmaniasis. Eur J Immunol. 17:1429-
1433. 
556. Titus, R. G., and J. M. Ribeiro. 1988. Salivary gland lysates from the sand fly 
Lutzomyia longipalpis enhance Leishmania infectivity. Science. 239:1306-1308. 
557. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. 
H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal 
multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. 
Immunity. 3:541-547. 
558. Tobin, J. F., S. L. Reiner, F. Hatam, S. Zheng, C. L. Leptak, D. F. Wirth, and R. 
M. Locksley. 1993. Transfected Leishmania expressing biologically active IFN-
gamma. J Immunol. 150:5059-5069. 
114 
559. Travi, B. L., C, Ferro, H. Cadena, J. Montoya-Lerma, and G. H. Adler. 2002. 
Canine visceral leishmaniasis: dog infectivity to sand flies from non-endemic areas. 
Res Vet Sci. 72:83-86. 
560. Travi, B. L., C. J. Tabares, H. Cadena, C. Ferro, and Y. Osorio. 2001. Canine 
visceral leishmaniasis in Colombia: relationship between clinical and parasitologic 
status and infectivity for sand flies. Am J Trop Med Hyg. 64:119-124. 
561. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and 
adaptive immunity. Nat Rev Immunol. 3:133-146. 
562. Tsuji, S., M. Matsumoto, O. Takeuchi, S. Akira, I. Azuma, A. Hayashi, K. 
Toyoshima, and T. Seya. 2000. Maturation of human dendritic cells by cell wall 
skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like 
receptors. Infect Immun. 68:6883-6890. 
563. Turco, S. J., and A. Descoteaux. 1992. The lipophosphoglycan of Leishmania 
parasites. Annu Rev Microbiol. 46:65-94. 
564. Ueda-Nakamura, T., M. da Conceicao Rocha Sampaio, N. L. Cunha-e-Silva, Y. 
M. Traub-Cseko, and W. de Souza. 2002. Expression and processing of megasome 
cysteine proteinases during Leishmania amazonensis differentiation. Parasitol Res. 
88:332-337. 
565. Uzonna, J. E., and P. A. Bretscher. 2001. Anti-IL-4 antibody therapy causes 
regression of chronic lesions caused by medium-dose Leishmania major infection in 
BALB/c mice. Eur J Immunol. 31:3175-3184. 
566. Uzonna, J. E., G. F. Spath, S. M. Beverley, and P. Scott. 2004. Vaccination with 
phosphoglycan-deficient Leishmania major protects highly susceptible mice from 
virulent challenge without inducing a strong Thl response. J Immunol. 172:3793-
3797. 
567. Valenzuela, J. G., Y. Belkaid, M. K. Garfield, S. Mendez, S. Kamhawi, E. D. 
Rowton, D. L. Sacks, and J. M. Ribeiro. 2001. Toward a defined anti-Leishmania 
vaccine targeting vector antigens: characterization of a protective salivary protein. J 
Exp Med. 194:331-342. 
568. van der Merwe, P. A., D. L. Bodian, S. Daenke, P. Linsley, and S. J. Davis. 1997. 
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and veiy fast kinetics. 
J Exp Med. 185:393-403. 
569. van Kooyk, Y., and T. B. Geijtenbeek. 2003. DC-SIGN: escape mechanism for 
pathogens. Nat Rev Immunol. 3:697-709. 
570. van Zandbergen, G., N. Hermann, H. Laufs, W. Solbach, and T. Laskay. 2002. 
Leishmania promastigotes release a granulocyte chemotactic factor and induce 
interleukin-8 release but inhibit gamma interferon-inducible protein 10 production by 
neutrophil granulocytes. Infect Immun. 70:4177-4184. 
571. Veras, P., C. Brodskyn, F. Balestieri, L. Freitas, A. Ramos, A. Queiroz, A. 
Barrai, S. Beverley, and M. Barral-Netto. 1999. A dhfr-ts- Leishmania major 
knockout mutant cross-protects against Leishmania amazonensis. Mem Inst Oswaldo 
Cruz. 94:491-496. 
572. Vieth, M., A. Will, K. Schroppel, M. Rollinghoff, and A. Gessner. 1994. 
Interleukin-10 inhibits antimicrobial activity against Leishmania major in murine 
macrophages. Scand J Immunol. 40:403-409. 
115 
573. von Stebut, E., Y. Belkaid, T. Jakob, D. L. Sacks, and M. C. Udey. 1998. Uptake 
of Leishmania major amastigotes results in activation and interleukin 12 release from 
murine skin-derived dendritic cells: implications for the initiation of a.nt\-Leishmania 
immunity. J Exp Med. 188:1547-1552. 
574. von Stebut, E., Y. Belkaid, B. V. Nguyen, M. Gushing, D. L. Sacks, and M. C. 
Udey. 2000. Leishmania major-infected murine Langerhans cell-like dendritic cells 
from susceptible mice release IL-12 after infection and vaccinate against 
experimental cutaneous Leishmaniasis. Eur J Immunol. 30:3498-3506. 
575. Wakil, A. E., Z. E. Wang, J. C. Ryan, D. J. Fowell, and R. M. Locksley. 1998. 
Interferon gamma derived from CD4(+) T cells is sufficient to mediate T helper cell 
type 1 development. J Exp Med. 188:1651-1656. 
576. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. 
M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a 
negative regulator of T cell activation. Immunity. 1:405-413. 
577. Wang, Z. E., S. L. Reiner, F. Hatam, F. P. Heinzel, J. Bouvier, C. W. Turck, and 
R. M. Locksley. 1993. Targeted activation of CD8 cells and infection of beta 2-
microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells 
in experimental leishmaniasis. J Immunol. 151:2077-2086. 
578. Wang, Z. E., S. L. Reiner, S. Zheng, D. K. Dalton, and R. M. Locksley. 1994. 
CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice 
infected with Leishmania major. J Exp Med. 179:1367-1371. 
579. Warburg, A., E. Saraiva, G. C. Lanzaro, R. G. Titus, and F. Neva. 1994. Saliva of 
Lutzomyia longipalpis sibling species differs in its composition and capacity to 
enhance leishmaniasis. Philos Trans R Soc Lond B Biol Sci. 345:223-230. 
580. Wei, X. Q., I. G. Charles, A. Smith, J. Ure, G. J. Feng, F. P. Huang, D. Xu, W. 
Muller, S. Moncada, and F. Y. Liew. 1995. Altered immune responses in mice 
lacking inducible nitric oxide synthase. Nature. 375:408-411. 
581. Werts, C., R. I. Tapping, J. C. Mathison, T. H. Chuang, V. Kravchenko, I. Saint 
Girons, D. A. Haake, P. J. Godowski, F. Hayashi, A. Ozinsky, D. M. Underbill, 
C. J. Kirschning, H. Wagner, A. Aderem, P. S. Tobias, and R. J. Ulevitch. 2001. 
Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. 
Nat Immunol. 2:346-352. 
582. WHO. The leishmaniasis and leishmania/HIV co-infections. http://.who.int/inf-
fs/en/factl 16.html (Date accessed: February 2,2004). 
583. Williams, R. O. 1988. Invasion of murine dendritic cells by Leishmania major and L. 
mexicana mexicana. J Parasitol. 74:186-187. 
584. Wilson, M. E., and R. D. Pearson. 1986. Evidence that Leishmania donovani 
utilizes a mannose receptor on human mononuclear phagocytes to establish 
intracellular parasitism. J Immunol. 136:4681-4688. 
585. Wilson, M. E., and R. D. Pearson. 1988. Roles of CR3 and mannose receptors in the 
attachment and ingestion of Leishmania donovani by human mononuclear 
phagocytes. Infect Immun. 56:363-369. 
586. Wilson, M. E., M. Sandor, A. M. Blum, B. M. Young, A. Metwali, D. Elliott, R. 
G. Lynch, and J. V. Weinstock. 1996. Local suppression of IFN-gamma in hepatic 
116 
granulomas correlates with tissue-specific replication of Leishmania chagasi. J 
Immunol. 156:2231-2239. 
587. Wilson, M. E., B. M. Young, B. L. Davidson, K. A. Mente, and S. E. McGowan. 
1998. The importance of TGF-beta in murine visceral leishmaniasis. J Immunol. 
161:6148-6155. 
588. Wincker, P., C. Ravel, C. Blaineau, M. Pages, Y. Jauffret, J. P. Dedet, and P. 
Bastien. 1996. The Leishmania genome comprises 36 chromosomes conserved across 
widely divergent human pathogenic species. Nucleic Acids Res. 24:1688-1694. 
589. Wozencraft, A. O., G. Sayers, and J. M. Blackwell. 1986. Macrophage type 3 
complement receptors mediate serum-independent binding of Leishmania donovani. 
Detection of macrophage-derived complement on the parasite surface by 
immunoelectron microscopy. J Exp Med. 164:1332-1337. 
590. Wright, S. D., and S. C. Silverstein. 1983. Receptors for C3b and C3bi promote 
phagocytosis but not the release of toxic oxygen from human phagocytes. J Exp Med. 
158:2016-2023. 
591. Wyler, D. J., J. P. Sypek, and J. A. McDonald. 1985. In vitro parasite-monocyte 
interactions in human leishmaniasis: possible role of fibronectin in parasite 
attachment. Infect Immun. 49:305-311. 
592. Wynn, T. A. 2003. IL-13 effector functions. Annu Rev Immunol. 21:425-456. Epub 
2001 Dec 2019. 
593. Xu, D., H. Liu, M. Komai-Koma, C. Campbell, C. McSharry, J. Alexander, and 
F. Y. Liew. 2003. CD4+CD25+ regulatory T cells suppress differentiation and 
functions of Thl and Th2 cells, Leishmania major infection, and colitis in mice. J 
Immunol. 170:394-399. 
594. Xu, H., H. Guan, G. Zu, D. Bullard, J. Hanson, M. Slater, and C. A. Elmets. 
2001. The role of ICAM-1 molecule in the migration of Langerhans cells in the skin 
and regional lymph node. Eur J Immunol. 31:3085-3093. 
595. Yadav, T. P., H. Gupta, U. Satteya, R. Kumar, and V. Mittal. 1989. Congenital 
kala-azar. Ann Trop Med Parasitol. 83:535-537. 
596. Yanagihara, S., E. Komura, J. Nagafune, H. Watarai, and Y. Yamaguchi. 1998. 
EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-
regulated upon maturation. J Immunol. 161:3096-3102. 
597. Yoshimura, A., E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, and D. 
Golenbock. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall 
components by the innate immune system occurs via Toll-like receptor 2. J Immunol. 
163:1-5. 
598. Yu Kimata, M. T., M. Cella, J. E. Biggins, C. Rorex, R. White, S. Hicks, J. M. 
Wilson, P. G. Patel, J. S. Allan, M. Colonna, and J. T. Kimata. 2002. Capture and 
transfer of simian immunodeficiency virus by macaque dendritic cells is enhanced by 
DC-SIGN. J Virol. 76:11827-11836. 
599. Zaph, C., and P. Scott. 2003. Interleukin-12 regulates chemokine gene expression 
during the early immune response to Leishmania major. Infect Immun. 71:1587-
1589. 
600. Zlotnik, A., J. Morales, and J. A. Hedrick. 1999. Recent advances in chemokines 
and chemokine receptors. Crit Rev Immunol. 19:1-47. 
117 
CHAPTER 2: CD4+ Thl cells induced by a dendritic cell -based 
immunotherapy in mice chronically infected with L. amazonensis do not 
promote healing 
A paper accepted for publication by the Journal Infection and Immunity 
Yannick F. Vanloubbeeck1, Amanda E. Ramer2, Fei Jie2 and Douglas E. Jones 1,2 
Department of Veterinary Pathology1, College of Veterinary Medicine and Immunobiology 
Program2, Iowa State University, Ames IA 50011-1250. 
Abstract 
The susceptibility of mice to Leishmania amazonensis infection is thought to result from 
an inability to develop a Thl response. Our data show that the low levels of IFN-Y produced 
by the draining lymph node (DLN) cells of chronically infected mice could be enhanced in 
vitro and in vivo with L. amazonensis Ag-pulsed bone marrow-derived dendritic cells (BM-
DC) and the Thl promoting cytokine IL-12. Given intralesionally to chronically infected 
mice, this treatment induced the up-regulation of mRNA levels for IFN-y, T-bet, and IL-
12R|32 in CD4+ T cells from the DLN and an increase in parasite-specific IgG2a in the 
serum. However, this Thl response was not associated with healing and the Ag-specific 
enhancement of IFN-y production remained impaired in the DLN. However, addition of IL-
12 to the in vitro recall response was able to recover this defect, suggesting that APC derived 
IL-12 production may be limited in infected mice. This was supported by the fact that L. 
amazonensis amastigotes limited the production of IL-12p40 from BM-DC in vitro. Taken 
together, our data indicate that the immune response of mice chronically infected with L. 
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amazonensis can be enhanced towards a Thl phenotype, but that the presence of Thl CD4+ T 
cells does not promote healing. This suggests that the phenotype of the CD4+ T cells may not 
always be indicative of protection to L. amazonensis infection. Furthermore, our data support 
growing evidence that APC function, such as IL-12 production, may limit the immune 
response in L. amazonensis infected mice. 
Introduction 
Leishmaniasis is a zoonotic disease caused by intracellular protozoa of the genus 
Leishmania. These parasites are transmitted to the host by a sandfly vector and the resulting 
clinical disease can be categorized into three forms: cutaneous, mucocutaneous and visceral. 
Infection of mice with various Leishmania species has led to an understanding of some of the 
immune mechanisms necessary to control these intracellular protozoa. As in humans, murine 
cutaneous leishmaniasis can have different outcomes depending on the parasite strain/species 
and the genetic background of the host (1,4,10,11,21,37). For example, the outcome of 
murine cutaneous leishmaniasis caused by L. major is determined by the phenotype of the 
CD4+ T cell response: Thl CD4+ T cells producing IFN-y promote resistance while Th2 
CD4+ T cells producing IL-4 induce susceptibility (reviewed in (36, 38)). 
C3HeB/FeJ and C57BL/6 mice are able to control a L. major infection by mounting a 
Thl immune response. This resistant phenotype requires a sustained source of IL-12 and the 
expression of IL-12Rp2 and T-bet, a Thl associated transcription factor (14,15,18, 31,41). 
The associated cutaneous lesion subsequently resolves and contains very low parasite 
numbers (reviewed in (36, 38)). In contrast, when infected with L. amazonensis, C3HeB/FeJ 
and C57BL/6 mice develop chronic cutaneous lesions containing from 105 to 108 parasites. 
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This is associated with low levels of both IFN-Y and IL-4 produced in the in vitro recall 
responses from the draining lymph node (DLN)3 (1,20, 39), which suggests that an antigen 
(Ag)-specific memory/ effector cell population may not develop or persist after infection. In 
addition, there is decreased IL-12R|32 expression in the CD4+ T cells from the DLN and this 
persists even in the absence of IL-4 (17, 20). Also, mice given the Thl promoting cytokines 
IL-12 or IFN-y and mice deficient for the Th2 cytokines IL-4 or IL-10 remain susceptible to 
L. amazonensis (5 , 17,19, 20). Therefore, in addition to the mouse models of visceral 
leishmaniasis caused by L. donovani or L. chagasi, the murine model of cutaneous 
leishmaniasis caused by L. amazonensis is an experimental system in which the Thl response 
is limited without the expansion of Th2 cells, (23,45). 
Dendritic cells (DC) are the main Ag-presenting cells (APC) in vivo and in vitro (3). 
They play an important role in priming naïve T cells toward a Thl or Th2 phenotype 
(reviewed in (30)). Their potential as prophylactic vaccine adjuvants has been exploited to 
promote an efficient immune response before infection with L. major (8,12,44). However, 
DC-based immunotherapies have not been tried in mice with established cutaneous lesions. 
Protection to a L. amazonensis challenge has been achieved in mice by giving parasite Ag, 
DNA or by adoptively transferring a L. amazonensis-specific Thl CD4+ T cell line before the 
infection (9,17, 32, 34,40). This was associated with an increase in IFN-Y production within 
the DLN, suggesting a Thl phenotype of the local immune response. Furthermore, Ji et al. 
showed that CD4+ T cells from the DLN of protected mice had increased expression of 
mRNA levels for IL-12RJ32, further supporting that a Thl response could provide protection 
to L. amazonensis infection (17). 
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Our data show that upon L. amazonensis infection the phenotype of the CD4+ T cells is 
not indicative of disease outcome as the induction of Thl CD4+ T cells expressing T-bet and 
IL-12R(32 in chronically infected mice did not promote healing. This was associated with an 
impaired production of IFN-Y in the DLN, which could be restored by addition of IL-12 in 
the DLN recall response. This suggests that IL-12 may have been a limiting factor in the 
DLN and is further supported by the ability of L. amazonensis amastigotes to limit IL-12p40 
production by BM-DC. 
Materials and methods 
Mice. C3HeB/FeJ mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) 
and bred and maintained in a specific-pathogen-free (SPF) facility. Prkdc.Scid (C3H SCID) 
mice were purchased from the same source and maintained in our SPF facility. The 
Committee on Animal Care at Iowa State University approved all protocols involving 
animals. Five to eight week old C3HeB/FeJ females were inoculated with 5x10* stationary-
phase promastigotes in 50 /d of PBS in the left hind footpad. Lesion size was monitored 
weekly with a dial micrometer (L.S. starrett Co., Athol, MA), and the results were expressed 
as the difference between the footpad thickness for the infected foot and the footpad 
thickness for the uninfected foot. C3H SCID mice were inoculated subcutaneously with 10 to 
20 x 106 stationary-phase promastigotes in 50 pd of PBS in the left hindfoot and later 
sacrificed to harvest tissue-derived amastigotes. 
Parasites. Culture of L. amazonensis (MHOM/BR/OO/LTBOO16) or L. major 
(MHOM/IL/80/Friedlin) parasites and the preparation of parasite Ag were performed as 
previously described (19). For the parasite quantification from cutaneous lesions, the 
infected feet were disinfected with 70% ethanol and the skin was dissected away. The 
remaining subcutaneous lesion was homogenized using a Tenbrock tissue homogenizer, 
washed twice in PBS and resuspended in Grace's insect cell culture medium (Life 
Technologies, Grand Island, NY) supplemented with 20% heat-inactivated FBS, 2 raM 
glutamine, 100U/ml penicillin, and 100 //g/ml streptomycin. A ten-fold serial dilution of the 
parasite suspension was then performed and incubated at 24°C for 8 days before parasite 
quantification was assessed. Amastigotes were directly recovered from the lesion of C3H 
SCID mice. The number of live amastigotes recovered from the footpad tissue was 
determined by flurorescence microscopy using fluorescein diacetate (Acros Organics, Morris 
Plains, NJ) and propidium iodide (Sigma, St Louis, MO). 
Antigen challenge. At 10 weeks post infection, mice were injected with 20 pig of Ag in 50 pil 
of PBS in the right hind footpad. Footpad swelling was measured daily for 72 hours with a 
dial micrometer and the results were expressed as the difference between the footpad 
thickness of the Ag-challenged foot and its thickness before the Ag challenge. 
Histology. Feet from challenged mice were fixed in 10% buffered formalin and routinely 
processed for paraffin embedded sectioning. Five pim thick sections were cut, applied to 
poly-L-lysine-coated slides and stained with H&E. Toluidine blue stains were performed to 
assess the tissue infiltration by basophils and/or mast cells. 
Isolation and culture of BM-DC. BM-DC were cultured in vitro in the presence of 10 ng/ml 
of murine GM-CSF (PeproTech Inc, Rocky Hill, NJ) according to a method from Lutz et al. 
(26). At day 10 of culture, approximately 90% of the BM-DC were positive for the DC 
marker CD1 lc. For in vitro studies, 10 day old BM-DC were incubated 24h at 37°C with 
fresh, tissue-derived, amastigotes at a cell: parasite ratio of 1:3. 
BM-DC immunotherapy. Mice infected with L. amazonensis for 10 weeks or naïve control 
mice were injected every other day for 12 days in their left hindfoot. Each injection consisted 
of 20 pi g L. amazonensis Ag and 0.2 pig murine IL-12 (PeproTech Inc, Rocky Hill, NJ) with 
lxlO6BM-DC resuspended in a total of 25pil of PBS. Control groups were injected with 25//1 
of PBS. The mice were sacrificed three days after the last injection. As a control for the in 
vivo efficacy of murine IL-12, BALB/c mice were infected with L. major and simultaneously 
injected with IL-12, as previously described (31). 
Recall responses. Lymph node cell recall responses (1 x 106 lymph node cells per well) were 
performed as previously described (19). Spleen cells were incubated with a lysing buffer 
(0.15M ammonium chloride, 10 mM potassium bicarbonate, 0.1 mM ethylene diamine tetra-
acetic acid) to lyse the red blood cells and plated as the lymph node cells. Supematants were 
harvested after 72 h or 96h (in experiments in which BM-DC were added to the cultures), 
and IFN-Y and IL-4 levels were determined by ELIS A. Recombinant IFN-Y (Pharmingen, 
San Diego, CA) and IL-4 (PeproTech Inc, Rocky Hill, NJ) were used on each ELISA plate to 
set up a standard curve. The limit of detection of the IFN-y ELISA ranged between 39 and 78 
pg/ml; the limit of detection of the IL-4 ELISA was 78 pg/ml. When BM-DC were added to 
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the cultures, a total of 1 or 2 x 105 BM-DC were co-cultured with 4 times more LN cells in 
200 ]i\ of complete tissue culture medium ± L. amazonensis Ag (50 pig/ml). The 
concentration of murine IL-12 (PeproTech Inc, Rocky Hill, NJ) and anti-murine IL-12p70 
(Pharmingen, San Diego, CA) used were 1 ng/ml and 10^g/ml, respectively. Endotoxin 
levels in culture supernatants were undetectable as determined by the LAL assay (Sigma, St 
Louis, MO). 
Purification of CD4+ T cells. Lymph node cells were incubated with anti-CD4-coupled 
microbeads (Miltenyi Biotec, Auburn, CA) according to the manufacturer's protocol, 
followed by one passage through an autoMACS. Purity of the cell preparation was higher 
than 95%. 
Flow cytometry. Intracellular staining for IFN-y was performed as previously described 
(20). Live events were gated based on forward scatter versus side scatter. 
Amastigote infection of BM-DC. L. amazonensis and L. major amastigotes were harvested 
from C3H SCID mice as indicated above. BM-DC (2 x 106) were incubated 24h with 6 x 106 
live amastigotes (3:1 parasite to BM-DC ratio). The infection rate was determined by 
microscopic examination of Hema 3-stained (Fisher Scientific, Middletown, VA) cytospin 
preparations. Infection rates ranged from 56 to 65%. There were no significant differences in 
the infection rate between the two organisms. 
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IL-12p40 ELISA. Supernatants from BM-DC 24h post-amastigote infection were harvested 
and the IL-12p40 ELISA was performed using commercially available antibodies 
(Pharmingen, San Diego, CA), peroxidase-conjugated streptavidin (Jackson 
ImmunoResearch Laboratories, West Grove, PA) and ABTS microwell peroxidase substrate 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD). 
IgG2a ELISA. ELISA plates were coated with 10/ig/ml of L. amazonensis Ag. The serum 
samples were serially diluted from 1/100 to 1/12800 and the ELISA was performed as 
previously described (19). 
RT-PCR. Total RNA was extracted from CD4+ T cells using the Rapid Total RNA 
Purification System (Marligen Biosciences, Ijamsville, MD) according to the manufacturer's 
protocol. RNA concentration was measured spectrophotometrically; RNA samples were 
then treated with 1.5 U of DNase I (Pierce, Milwaukee, WI) per 1 pig of RNA for 45 min at 
37°C. Two pig of each DNase I-treated RNA sample was reverse transcribed in 80 pil 
reaction volumes using IX M-MLV reaction buffer (Promega, Madison, WI), 200 U M-
MLV reverse transcriptase (Promega, Madison, WI), 40 U RNase inhibitor (Applied 
Biosystems, Foster City, CA), 2.5 piM random hexamers (Amersham Biosciences Corp, 
Piscataway, NJ) and 0.5 mM of each dNTP (USB Corporation, Cleveland, OH). RNA 
samples and random hexamers were incubated together at 70°C for 3 min and room 
temperature for 10 min. The reverse transcription reaction was performed at 42°C for 1 hr; 
samples were then heated at 95°C for 5 min and incubated on ice for 10 min. Real-time PCR 
experiments were run on the ABI PRISM 5700 Sequence Detection System (Applied 
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Biosystems, Foster City, CA). Each 50 y\ reaction contained 1 fil of cDNA and IX 
ABsolute QPCR Mix (Abgene, Surrey, UK). Forward and reverse primers were used at 
either 300 or 350 nM (IDT, Coralville, I A) and TaqMan probes (labeled with the reporter dye 
F AM and the quencher dye TAMRA, Applied Biosystems, Foster City, CA) were used at 
either 75 or 100 nM. Primer pairs and probes were designed using Primer Express 1.5 
software (Applied Biosystems, Foster City, CA) and are listed in Table 1. For quantitative 
analysis of gene expression, normalized to an endogeneous control, we used the standard 
curve method, which was detailed previously (13). Briefly, control cDNA samples were 
serially diluted to obtain standard curves for GAPDH cDNA and each target cDNA. For 
each assay, the resultant cycle threshold (Ct) values were plotted against the log ng input of 
RNA. For all experimental samples, the cDNA quantity for the target of interest was then 
determined from its standard curve and then normalized to the GAPDH control. 
Statistical procedure. Statistical analysis was performed using Statview (SAS, Cary, NC). 
When multiple treatment groups were compared, the data were entered into an ANOVA and 
analyzed with the Fisher's PLSD post-hoc test. When a comparison between 2 groups was 
done, a t-test was performed. Differences were considered significant when p<0.05. 
Results 
Low levels of IFN-Y production in the DLN and spleen from mice chronically infected 
with L. amazonensis. While C3HeB/FeJ mice are able to resolve a L. major infection, they 
develop chronic cutaneous lesions when infected with L. amazonensis (Fig. 1). The 
susceptibility to L. amazonensis is thought to result from an inability to develop a Thl 
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response. Within DLN and splenic recall responses from L. amazonensis-infected mice, the 
absolute amounts of IFN-y detected were low (0.31 ±0.11 and 1.75 + 0.37 ng/ml, 
respectively), and typically 10 to 20 times lower than the ones detected in the recall 
responses from the DLN and spleen from L. major-infected animals (6.79 + 2.59 ng/ml and 
21.57 ± 4.45 ng/ml, respectively). There was no IL-4 detected in the recall responses at 10 
weeks post-infection. However, the low levels of IFN-y detected in vitro, together with the 
absence of IL-4, do suggest that the immune response of mice chronically infected with L. 
amazonensis has some component of a Thl response. 
Antigen-specific footpad swelling upon subcutaneous antigen challenge indicates a 
functional memory response in vivo during the chronic L. amazonensis infection. The 
low levels of effector cytokines within the recall response of mice chronically infected with 
L. amazonensis may reflect an absence of effector/memory response in vivo. To test this, 
mice infected for 10 weeks with L. amazonensis in their left hindfoot were challenged with 
20ftg of L. amazonensis Ag in the contralateral foot, and the associated footpad swelling was 
measured over a 3-day period. Naïve mice challenged with Leishmania Ag were used as 
negative controls. In parallel, as a positive control for the kinetics and histological changes 
of a DTH response, similar experiments were done using L. major-infected mice challenged 
with 20^g of L. major Ag. As shown in Figure 2A, mice chronically infected with L. 
amazonensis developed an Ag-specific footpad swelling, indicating the presence of a 
memory/effector response in vivo. The observed footpad swelling was not as pronounced as 
in L. major infected mice challenged with L. major Ag, but it was significantly higher than in 
uninfected control mice challenged with Leishmania Ag (Fig. 2A). Histologically, the 
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footpad swelling observed in the Ag-challenged feet of mice infected with L. amazonensis or 
L. major was similar and characterized by an infiltrate of lymphocytes with scattered 
neutrophils and rare basophils and/or mast cells (Fig. 2B and data not shown), which is 
consistent with a DTH response. In mice infected with L. amazonensis, the cellular infiltrate 
was found multifocally throughout the dermis and subcutaneous tissue, while it was diffusely 
present in the dermis and subcutis of mice infected with L. major. A cellular infiltrate was 
not present in naïve mice challenged with Leishmania Ag (Fig. 2C). However, a focus of 
neutrophils and few mononuclear cells was occasionally observed in the feet of these mice, 
likely resulting from traumatic injury at the injection site (data not shown). 
Impaired IFN-Y production in the lymph node draining the site of Ag challenge. Since 
Ag-specific memory cells were able to elicit a DTH in vivo we determined if this response 
was associated with increased effector cytokine production, i.e. IFN-Y and IL-4. L. major-
infected mice demonstrated a typical memory response when challenged with L. major Ag in 
the contralateral footpad. The cells from the lymph node draining the site of Ag challenge 
produced two times more IFN-Y than their uninfected controls during the recall response (Fig. 
3). In contrast, L. amazonensis-infected mice had an inhibition of effector cytokine 
production when challenged with L. amazonensis Ag in the contralateral footpad. The cells 
of the lymph node draining the site of Ag challenge had a 75% reduction in IFN-y production 
in comparison to the uninfected mice challenged with L. amazonensis Ag (Fig. 3). The 
IFN-y production was dependent on the presence of leishmanial Ag in all assays, and there 
was no IL-4 detected in any of the recall responses (data not shown). This demonstrates that 
in mice chronically infected with L. amazonensis, the production of IFN-y is also impaired in 
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lymph nodes distant from the site of infection, i.e. the lymph node draining the site of a 
subcutaneous Ag-challenge. 
Ag-pulsed BM-DC enhance IFN-y production from DLN cells in an IL-12 independent 
manner. Dendritic cells have previously been shown to enhance the in vitro production of 
IFN-y by T cells from the DLN of Leishmania-infected mice (6). Therefore, we wanted to 
test the hypothesis that the addition of BM-DC as Ag presenting cells in the in vitro recall 
response would enhance the secretion of IFN-y of DLN cells. Cells from the DLN of mice 
chronically infected with L. amazonensis were co-cultured for 4 days with either BM-DC 
alone (non-pulsed) or L. amazonensis Ag-pulsed BM-DC (see materials and methods) at a 
4:1 ratio. As shown in Figure 4A, L. amazonensis Ag-pulsed BM-DC increased IFN-y levels 
up to 3 to 7 times the level of IFN-y detected in the standard recall response. In addition, 
non-pulsed BM-DC were unable to promote IFN-y production by the lymph node cells, 
demonstrating the Ag-specificity of the response. In our system, IFN-y was not detected 
from cultures containing Ag-pulsed BM-DC alone and IL-4 was not detected in any culture 
condition (data not shown). We then hypothesized that this Ag-specific enhancement of the 
IFN-y production could result from an enhanced IL-12p70 production by the BM-DC, 
skewing the results towards a Thl response. Blocking the bioactive IL-12p70 in the co-
cultures did not result in a significant decrease in the levels of IFN-y recovered in the 
supematants, consistent with a Thl bias of the Ag responsive cells (Fig. 4B). Addition of IL-
12 in the co-cultures significantly enhanced the levels of IFN-y detected, further suggesting 
that the lymphocyte response is skewed towards a Thl response (Fig. 4C). 
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Immunotherapy with Ag-pulsed BM-DC and IL-12 promotes the polarization of CD4+ 
T cells from the DLN towards a Thl phenotype. Since Ag-pulsed BM-DC and IL-12 were 
able to enhance the Thl phenotype of the recall response in vitro, we tested if such treatment 
would promote a Thl response and subsequent healing in vivo. In particular, we determined 
the phenotype of the CD4+ T cells from the DLN. Thl CD4+ T cells have been shown to play 
a major role in resistance to Leishmania major infection (36, 38) and to promote protection to 
a L. amazonensis challenge, after adoptive transfer (17, 34). Therefore, mice chronically 
infected with L. amazonensis were injected in their infected foot every other day for 12 days 
with either PBS or L. amazonensis Ag-pulsed BM-DC +IL-12 (see Material and Methods). 
Naïve mice were included in each treatment group as negative controls. Three days after the 
last injection, the CD4+ T cells from the DLN were purified and their mRNA levels for T-bet, 
GATA-3 (a Th2 associated transcription factor (46)), IFN-y, IL-12R|31 and IL-12R{32 were 
determined by RT-PCR. In comparison to the PBS control, the administration of Ag-pulsed 
BM-DC and IL-12 led to the up-regulation of T-bet, IFN-y and IL-12R|32 mRNA levels in 
both naïve and infected mice (Fig. 5A and data not shown). Furthermore, mRNA levels for 
IL-12R(51 and GATA-3 remained similar between treated and control mice (Fig. 5A), 
indicating that the administration of Ag-pulsed BM-DC and IL-12 led to a specific 
enhancement of a Thl phenotype of the CD4+ T cell population from the DLN. Finally, as 
another indication that the BM-DC immunotherapy induced a Thl response, treated mice had 
increased levels of L. amazonensis-specific IgG2a levels in their serum in comparison to PBS 
control mice (Fig. 5B). 
Specific limitation of the Ag-specific IFN-y production in the DLN of mice chronically 
infected with L. amazonensis. As Ag-pulsed BM-DC and IL-12 induced a Thl response in 
vivo, we hypothesized that it would be accompanied by an enhancement of the IFN-y 
production in the in vitro recall response from the DLN. In the absence of Ag in the recall 
response, DLN cells from treated infected mice produced significantly more IFN-y than DLN 
cells from PBS control mice (6.8 ± 1.6 ng/ml vs 0.5 ± 0.1 ng/ml, respectively). This 
enhanced IFN-y production induced after immunotherapy recapitulated the one previously 
observed in vitro when Ag-pulsed BM-DC and IL-12 were added to the cell cultures (Fig. 
4C). However, the increased levels of IFN-y produced by DLN cells from chronically 
infected mice treated with Ag-pulsed BM-DC +IL-12 were not further enhanced in the 
presence of Ag in vitro, in contrast to what is seen in treated-naïve mice (Fig. 6A). In fact, 
the amount of IFN-y recovered in the recall response of treated naïve mice was significantly 
greater than that of treated infected mice (Fig. 6A). These discrepancies occurred despite 
the presence of similar percentages of IFN-y producing cells within the DLN of both groups 
of mice (Fig. 6B). However, the addition of IL-12 to the cell cultures led to similar levels of 
IFN-y produced by the DLN cells from treated naïve and treated infected mice (59.35 ± 15.94 
ng/ml and 47.41 ± 10.96 ng/ml, respectively; Fig. 6A). This demonstrates that the defective 
Ag-specific IFN-y production of infected mice could be overcome by IL-12 and supports a 
Thl phenotype of the DLN cells. Finally, a limitation of IFN-y production was not observed 
in the spleen, as after immunotherapy with Ag-pulsed BM-DC and IL-12, splenocytes from 
both naïve and infected animals produced comparable levels of Ag-specific IFN-y in the 
recall response (Fig. 6C). Altogether, this indicates that the limitation of Ag-specific IFN-y 
production from the lymphocyte population is confined to the DLN, but not the spleen, of 
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mice chronically infected with L. amazonensis and that it can be overcome by IL-12. 
Consistent with the limitation of the lymphocyte response in the DLN, the immunotherapy 
did not induce a reduction in lesion size 2 weeks after the first BM-DC injection: the mean 
lesion size ± SEM of PBS control and treated mice was 0.99 ±0.11 mm and 0.95 ±0.11 mm, 
respectively. This was further supported by the absence of a significant decrease in the 
parasite numbers in the infected feet at this timepoint (Fig. 6D). Furthermore, to determine if 
a healing response would require more time, in one experiment, lesion size and parasite 
quantification were measured 5 weeks after the first BM-DC injection. At this timepoint, 
lesion size and parasite loads were still similar between treated mice and PBS control (data 
not shown). Taken together, these data demonstrate that the administration of Ag-pulsed 
BM-DC +IL-12 to mice chronically infected with L. amazonensis induced a Thl response in 
vivo; however, this was not associated with lesion resolution. 
L. amazonensis amastigotes limit IL-12p40 production by BM-DC. As the impaired 
production of IFN-y in the DLN of infected mice after treatment was restored by the addition 
of IL-12 in the in vitro recall response, it suggested that the infection with L. amazonensis 
may be limiting the production of IL-12 by APC, i.e. dendritic cells. Therefore, we 
determined the ability of BM-DC to produce IL-12p40 in vitro, after infection with L. 
amazonensis amastigotes. BM-DC were infected, or not, with L. amazonensis amastigotes at 
a 1:3 ratio. As a positive control, BM-DC were infected with L. major amastigotes at a 
similar cell:parasite ratio. The levels of IL-12p40 were determined 24h post-infection by 
ELISA. As shown in Fig. 7, BM-DC infected with L. amazonensis amastigotes produced 
similar levels of IL-12p40 as non-infected BM-DC. In contrast, BM-DC infected with L. 
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major amastigotes produced significantly higher amounts of IL-12p40. Altogether, this 
demonstrates that L. amazonensis amastigotes can limit the production of IL-12p40 by BM-
DC. 
Discussion 
Our data demonstrate that the poor lymphocyte response of mice chronically infected 
with L. amazonensis is not the result of an absence of a memory cell population that can 
recognize parasite Ag, as these mice developed a DTH response after a subcutaneous Ag 
challenge (Fig. 2A and B). However, the elicited DTH reaction is attenuated in comparison 
to that of L. major-mîecteû animals, which have developed a strong Thl response (Fig. 2A). 
In addition, the undetectable levels of IL-4 and the impaired IFN-y production from the 
lymph node draining the site of Ag challenge indicates that the defective Thl response of 
mice chronically infected with L. amazonensis is present at peripheral sites distant from the 
primary infection (Fig. 3). 
It has been recently suggested that defective priming of T cells by DC may be responsible 
for the poor lymphocyte response to L. amazonensis Ag (17). Dendritic cells play a crucial 
role in priming T cells; in particular, IL-12 produced by DC promotes the polarization of the 
T cells towards a Thl phenotype (reviewed in (30) and (25)). During both acute and chronic 
L. major infection, DC are the main APC in the in vitro recall response (28,29). Our data 
show that BM-DC could enhance the Ag-specific production of IFN-y from DLN cells in 
vitro in an IL-12 independent manner (Fig. 4A & B). This enhanced lymphocyte response 
could result from a more efficient DC to T cell ratio, Ag presentation and/or co-stimulation. 
In addition, the levels of IFN-y detected in the DLN recall response were further increased 
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when IL-12 was added to the co-cultures (Fig. 4C). This and the fact that IFN-y, but not IL-
4, were detected in the DLN in vitro recall response indicate a Thl bias of the lymphocyte 
response in mice infected with L. amazonensis. Furthermore, the enhanced production of 
IFN-y in response to IL-12 suggests that cells fully capable of producing IFN-y are present 
within the DLN. Therefore, in addition to the CD4+ T cell defects present during L. 
amazonensis infection (17, 20), it is probable that APC from the DLN are limited 
qualitatively and/or quantitatively, thereby contributing to low effector cytokine production 
in the recall response. This is supported by the low numbers of IL-12 producing cells 
associated with the DLN of L. amazonensis-infected mice (20) and by studies showing that 
Leishmania parasites can modulate the phenotype and functions of APC, i.e. macrophages 
and dendritic cells (2,7,22,24,27,33, 35,43). 
Based on our in vitro results, we hypothesized that giving L. amazonensis Ag-pulsed 
BM-DC +IL-12 as an immunotherapy to mice chronically infected with L. amazonensis 
would promote a Thl response in vivo. Variable degrees of protection towards L. 
amazonensis infection have been achieved in mice by prophylactic administration of Ag (32, 
40), DNA (9), attenuated L. major promastigotes (16,42) or L. amazonensis derived Thl 
CD4+ T cell line (17, 34). DC-based vaccines have successfully been used prophylactically 
in experimental studies of cutaneous leishmaniasis caused by L. major (8,12,44) and 
protection has been linked to the ability of the DC to produce IL-12 (8). However, to our 
knowledge, the present study is the first to use a therapeutic DC-based strategy, in mice with 
established cutaneous lesions. The repeated administration of this treatment led to the 
development of a Thl response in vivo as measured by the upregulation of T-bet, IFN-y, and 
IL-12Rp2 mRNA levels on the CD4+ T cell population from the DLN (Fig. 5A). This is 
different from what was previously observed in BALB/c mice where administration of IL-12 
alone 48h after infection with L. major did not induce a Thl phenotype of the CD4+ T cells 
from the DLN (14). In our study, the presence of a Thl response was further demonstrated 
by the presence of increased levels of L. amazonensis-specific IgG2a in the serum (Fig. 5B). 
As adoptive transfer of Thl CD4+ T cells was recently shown to promote protection to a 
subsequent L. amazonensis infection, a correlation between healing and the vaccine-induced 
Thl CD4+ T cell response was expected (17, 34). This was also supported by a recent study 
of murine visceral leishmaniasis caused by L. donovani in which the administration of BM-
DC alone was associated with decreased parasite burden 7 days later (2). However in the 
present study, despite the Thl response, there was no significant decrease in parasite 
numbers in treated mice, as measured at 2 weeks (Fig. 6D) and 5 weeks after the first BM-
DC injection (data not shown). In addition, although the percentage of IFN-y producing cells 
was similar between treated infected and treated naïve mice, there was no enhancement of 
the IFN-y production when Ag was added to the DLN recall response of infected mice (Fig. 
6A and B). This indicates that the impaired Ag-specific IFN-y production in the DLN of 
mice chronically infected with L. amazonensis does not result from quantitative defects from 
the IFN-y producing cell population, but rather from qualitative defects of these cells, i.e. 
efficiency to produce IFN-y. In addition, it is possible that the qualitative defect affects cells 
other than CD4+ T cells, possibly APC. This is supported by the fact that addition of IL-12 in 
the recall response from the DLN overcomes the defective production of IFN-y by DLN cells 
(Fig. 6A). Furthermore, we tested the hypothesis that L. amazonensis amastigotes, the only 
parasite stage present during chronic infection, could limit IL-12p40 production by BM-DC 
in vitro. Our data provide evidence L. amazonensis amastigotes-infected BMDC do not have 
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enhanced production of IL-12p40 in comparison to non-infected BMDC (Fig. 7), supporting 
previous studies showing that Leishmania parasites can modulate the production of IL-12 by 
DC (7,27,35). Therefore, our data suggest that in chronically infected mice, and even in the 
presence of Thl CD4+ T cells, the production of IFN-y may be limited by insufficient IL-12 
production. This is consistent with studies showing that sustained production of IL-12 is 
critical to promote and maintain resistance to L. major (31). However, we can not rule out 
that the IFN-y production from the DLN cells is actively suppressed by immunomodulatory 
factors produced in the DLN. Finally, our results show that the limitation of the IFN-y 
production in response to Ag was localized to the DLN, as it was not observed in the spleen, 
suggesting a compartmentalization of the immune response (Fig. 6C). As L. amazonensis 
parasites are present in the DLN, but not the spleen of infected animals, it is tempting to 
suggest that such limitation could be specifically mediated by L. amazonensis amastigotes. 
This would be consistent with a very recent study showing that the transfer of a Thl cell line 
prior to infection did confer resistance to a subsequent challenge with L. amazonensis 
promastigotes, but not amastigotes (34). 
Taken together, our data indicate a local impairment of the Ag-specific IFN-y production 
in the DLN of mice chronically infected with L. amazonensis. This defective response 
persists even after the induction of a Thl CD4+ T cells within the DLN, suggesting that the 
phenotype of the CD4+ T cells may not always be indicative of protection to L. amazonensis, 
as it is the case with L. major. Furthermore, our data support growing evidence that in 
addition to CD4+ T cell defects, APC functions such as IL-12 production may be impaired in 
L. amazonensis-infected mice (17). 
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Figure 1. Upon infection with L. amazonensis, C3HeB/FeJ mice develop a chronic cutaneous 
lesion. 5 to 8 week-old C3HeB/FeJ mice were infected in the left hind footpad with 5 x 106 
stationary phase L. amazonensis (open squares) or L. major (closed circles) promastigotes. 
Lesion size was monitored weekly as described in Materials and Methods. The values shown 
are the mean ± standard deviation (12 mice per group). 
Days post antigen stimulation 
Figure 2. Ag-specific footpad swelling consistent with a DTH indicates the presence of a 
memory/effector response in vivo. (A) C3HeB/FeJ mice were infected in the left hind 
footpad with L. amazonensis or L. major as described in Figure 1. Ten weeks post-infection, 
the L. amazonensis-infected mice were challenged subcutaneously with L. amazonensis Ag 
(open squares) and the L. major-infected mice were challenged subcutaneously with L. major 
Ag (closed triangles) in the right hindfoot as described in the Materials and methods. 
Uninfected mice challenged subcutaneously with either L. amazonensis or L. major Ag 
(closed circles) were used as negative controls. The footpad thickness was monitored daily 
over 3 days and was expressed as the difference between the footpad thickness of the 
challenged foot at the time of measurement and its thickness before the Ag challenge. The 
values shown are the mean ± SEM based on 3 separate experiments. (B & C): Two days post 
antigen-challenge, the mice were sacrificed and the antigen-challenged feet were fixed and 
processed for histology (H&E staining). (B) Foot from a mouse infected with L. 
amazonensis and challenged with L. amazonensis Ag: the cellular infiltrate (arrows) within 
the dermis is composed of lymphocytes, scattered neutrophils and rare basophils and/or mast 
cells. (C) Foot from an uninfected mouse challenged with L. amazonensis Ag: there is no 
inflammatory infiltrate within the dermis. 
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Figure 3. Impaired IFN-y production during the memory response of mice infected with L. 
amazonensis. Mice were infected and challenged with Ag as in Figure 2. Three days post-
Ag challenge, the mice were sacrificed and cells from the lymph node draining the Ag-
challenged feet were plated in vitro for 3 days with L. amazonensis or L. major Ag. IFN-y 
levels were detected by ELISA. Results are expressed as a fold increase ± SEM over their 
respective negative controls, that is uninfected mice challenged with L. amazonensis or L. 
major Ag. In parentheses are the mean amounts of IFN-y detected by ELISA for each group. 
Results shown are from 3 separate experiments with 3 mice per group. * Indicates a 
statistically significant difference (p<0.05). 
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Figure 4. Ag-pulsed BM-DC enhance the production of IFN-y by lymph node cells from 
mice chronically infected with L. amazonensis. Ten weeks post-infection with L. 
amazonensis, mice were sacrificed and lymph node cells from the lymph node draining the 
infected foot were plated either (A), in medium alone (no Ag), with L. amazonensis Ag (+ La 
Ag), with BM-DC (+DC), or with L. amazonensis Ag-pulsed BM-DC (+La Ag +DC); (B) 
with L. amazonensis Ag-pulsed BM-DC and an IL-12p70 blocking antibody (+La Ag +DC 
+anti-IL12) or (C) with L. amazonensis Ag-pulsed BM-DC and recombinant murine IL-12 
(+La Ag +DC +IL12). The DLN cells to DC ratio was 4:1. After 4 days of in vitro culture, 
IFN-y levels in the culture supematants were detected by ELISA. The values shown are the 
mean + SEM based on 3 (C) or 4 (A and B) separate experiments. "Indicates a statistically 
significant difference in comparison to the other group(s) (p<0.05). 
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Figure 5. Immunotherapy using Ag-pulsed BM-DC +IL-12 induced a Thl response in 
chronically infected mice. Mice were infected with L. amazonensis as in Fig. 1. Ten weeks 
post-infection, the mice were injected every other day for 12 days in their infected foot with 
L. amazonensis Ag-pulsed BM-DC and IL-12. Negative control mice were injected with 
PBS. Three days after the last injection, the mice were sacrificed. (A) CD4+ T cells from the 
DLN were purified and the expression of GAPDH, T-bet, IFN-y, IL-12R(32, IL-12R(31 and 
GATA-3 determined by RT-PCR as described in Materials and Methods. In each 
experiment, the amount of target cDNA in CD4+ T cells from PBS control mice was given a 
value of 1 (open histogram) and the amount of target cDNA in CD4+ T cells from treated 
mice was expressed as a fold increase (closed histogram). The values shown are the mean 
fold increase ± SEM based on 3 separate experiments. ^Indicates a statistically significant 
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difference with the PBS control mice (p<0.05). (B) Sera from treated (closed squares) and 
PBS control (open circles) mice were collected and the levels of L. amazonensis-specific 
IgG2a were determined by serial dilution as described in Materials and Methods. The data 
shown is the mean O.D. value ± SEM based on 4 separate experiments. 
6. 
OnoAg • + LaAg 
BH+ La Ag +IL-12 
I ™ '  
L
_
P 
|—|T 
Treated Treated 
naive mice infected mice 
Treat ed-naive mice 
2.111.5 
10" 10' 10* 1~03 10' 
t Treated-inlected mice 
1.911.1 
M— 10" 10' 10* 10J 10s. 
CD4 
OnoAg • + LaAg 
Treated Treated 
naive mice infected mice 
PBS control Treated 
147 
Figure 6. BM-DC-based immunotherapy does not promote decreased parasite numbers and 
is still associated with impaired Ag-specific production of IFN-y within the DLN. Naïve and 
L. amazonensis (La)-infected mice were injected every other day with PBS (PBS control) or 
La Ag-pulsed BM-DC +IL-12 (treated) as in Fig. 5. Three days after the last injection, the 
mice were sacrificed. (A) DLN cells from each treatment group were plated for 3 days in 
vitro in medium alone (no Ag) or in medium containing LaAg (+La Ag) or La Ag and IL-12 
(+LaAg +IL-12). The levels of IFN-y were determined in the supematants by ELIS A. The 
values shown are the mean ± SEM based on 5 separate experiments (3 experiments with 
exogenous IL-12 in the cell culture). ^Indicates a statistically significant difference between 
the groups (p<0.05). (B) DLN cells from naïve- and infected- treated mice were plated in 
vitro with La Ag for 24h and the percentage of CD4+ IFN-y producing cells was determined 
by flow cytometry. The data shown is representative of 2 separate experiments. (C) 
Splenocytes from each treatment group were plated for 3 days in vitro in medium alone (no 
Ag) or in medium containing La Ag (+La Ag). The levels of IFN-y were determined in the 
supematants by ELISA. The values shown are the mean + SEM based on 5 separate 
experiments. "Indicates a statistically significant difference between the groups (p<0.05). 
(D) Infected feet from PBS control- and treated- infected mice were collected and parasite 
quantification was determined. The values shown are the mean ± SD based on 5 separate 
experiments. 
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Figure 7. L. amazonensis amastigotes limit IL-12p40 production from BM-DC. Ten day old 
BM-DC were infected or not with L. amazonensis or L. major amastigotes at a parasite:cell 
ratio of 3:1. Culture supematants were harvested 24h later and the levels of IL-12p40 were 
determined by ELIS A. The values shown are the mean ± SEM based on 3 separate 
experiments. ^Indicates a statistically significant difference (p<0.05). 
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Abstract 
One of the goals of vaccine strategies against leishmaniasis is to induce Thl CD4+ T 
cells, which mediate resistance to the disease. However, in the present study, we show that 
although vaccination of naïve C3HeB/FeJ mice with L. amazonensis antigen-pulsed dendritic 
cells and IL-12 induced Thl CD4+ T cells producing IFN-y and expressing high levels of IL-
12R|32 mRNA, vaccinated mice were not protected against a subsequent L. amazonensis 
challenge. Indeed, 10 weeks post-infection, vaccinated mice had similar lesion size and 
parasite loads compared to non-vaccinated control mice. In addition, this correlated with 
decreased production of IFN-y in the in vitro recall response from the draining lymph node 
(DLN) and with reduced expression of IL-12RJ32 mRNA in the CD4+ T cells from the DLN 
of vaccinated mice in comparison to non-vaccinated control mice. Altogether, this data 
indicates that the induction of Thl CD4+ T cells by a vaccine may not be sufficient and/or 
indicative of subsequent protection towards a L. amazonensis infection. 
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Introduction 
Leishmaniasis is a zoonotic disease caused by intracellular protozoan parasites of the 
genus Leishmania spp. Infection occurs through the bite of an infected sand fly vector that 
transmits flagellated Leishmania spp. promastigotes during its blood meal. Within host cells, 
promastigotes transform into non-flagellated amastigotes, which are the only parasite stage 
subsequently found during chronic infection (reviewed in (13)). The phenotype of the host 
immune response after infection is critical for the outcome of the disease and murine studies 
of leishmaniasis have helped determine some of the immune factors necessary for disease 
control. For example, while Thl CD4+ T cells producing IFN-y mediate resistance, Th2 CD4+ 
T cells producing IL-4 and/or IL-10 promote susceptibility (reviewed in (25) and (36)). 
L. amazonensis is prevalent in the New World and the infection with this parasite usually 
results in localized cutaneous leishmaniasis; however, it can also cause diffuse cutaneous and 
mucocutaneous leishmaniasis (4,23, 37). Furthermore it has been sporadically recovered 
from patients with visceral leishmaniasis (3,4). Most inbred strains of mice are susceptible to 
a L. amazonensis infection; for example, when C3H and C57BL/6 mice are subcutaneously 
challenged with L. amazonensis, they develop chronic cutaneous lesions containing up to 10* 
parasites (1,22, 38). The susceptibility of these mice to L. amazonensis is thought to result 
from an inability to mount an effective Thl response, rather than from a Th2 response. 
Indeed, susceptibility is associated with low to undetectable levels of IFN-y in the in vitro 
recall response from the draining lymph node (DLN) (1,22). In addition, the susceptibility to 
L. amazonensis has been shown to correlate with CD4+ T cell defects, i.e. decreased 
expression of pro-inflammatory cytokines and chemokines (19). Furthermore, CD4+ T cells 
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from L. amazonensis-infected mice have a defective expression of IL-12Rf32, a marker of 
Thl responses (19, 22). 
Although there is no vaccine available against leishmaniasis, the availability of a vaccine 
would represent an effective tool in the control of the disease. As a result, the design of 
vaccination strategies that promote safe, effective, long-lasting protection to leishmaniasis 
has been and still is currently investigated (reviewed (14)). In particular, variable degrees of 
protection against a L. amazonensis challenge have been achieved after vaccination with 
Leishmania spp. antigens (Ag) or DNA (6-8,10, 31,39). When determined, the immune 
response associated with protection was characterized by an increased IFN-y production (6, 
7,10,31,39). In addition, more recently, the adoptive transfer of Thl CD4* T cells to naïve 
mice completely protected mice against a subsequent L. amazonensis promastigote challenge 
(19,32). Altogether, these studies suggested that vaccine strategies inducing Thl CD4+ T 
cells should likely promote protection against a subsequent infectious challenge. 
Dendritic cells (DC) are the most potent antigen-presenting cells in vitro and in vivo (2). 
Their critical role in the priming of anti-Leishmania immune responses has been clearly 
demonstrated (24,28,29,35). In addition, in experimental studies of leishmaniasis, DC have 
been successfully used as vaccine adjuvants to promote protective Thl responses (5,11, 34, 
42). However, in mice chronically infected with L. amazonensis, we have recently shown 
that an immunotherapy composed of L. amazonensis antigen-pulsed dendritic cells and IL-12 
was ineffective at promoting healing, despite the induction Thl CD4+ T cells (41). As L. 
amazonensis amastigotes have been shown to limit Thl responses, it is possible that the high 
numbers of amastigotes present during chronic L. amazonensis infection may have been 
partly responsible for the failure of the DC-based immunotherapy to promote healing (33, 
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41). Therefore, we tested the hypothesis that the Thl response induced by the administration 
of L. amazonensis Ag-pulsed DC and IL-12 to naïve mice as a vaccine would promote 
protection against a subsequent L. amazonensis promastigote challenge. 
Our data indicate that while the vaccination of naïve mice with L. amazonensis Ag pulsed 
DC and IL-12 induced Thl CD4+ T cells in vivo, it did not promote resistance to a 
subsequent L. amazonensis promastigote infection. This lack of protection correlated with 
decreased production of IFN-y in the recall response from the DLN and with a reduced 
expression of IL-12R|32 mRNA in CD4+ T cells from the DLN. Altogether, this suggests that 
the presence of Thl CD4+ T cells does not necessarily correlate with protection to a L. 
amazonensis infection. 
Material and Methods 
Mice. C3HeB/FeJ mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) 
and bred and maintained in a specific-pathogen-free facility. The Committee on Animal Care 
at Iowa State University approved all protocols involving animals. Five to eight week old 
C3HeB/FeJ females were inoculated with 5 x 106 stationary-phase promastigotes in the left 
hind footpad (3 to 5 mice per group). Lesion size was monitored weekly with a dial 
micrometer (L.S. Starrett Co., Athol, MA), and the results were expressed as the difference 
between the footpad thickness for the infected foot and the footpad thickness for the 
uninfected foot. 
Parasites. Culture of L. amazonensis promastigotes (MHOM/BR/OO/LTBOOI6) and the 
preparation of parasite Ag were performed as previously described (21). For the parasite 
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quantification from cutaneous lesions, the infected feet were disinfected with 70% ethanol 
and the skin was dissected away. The remaining subcutaneous lesion was homogenized 
using a Tenbrock tissue homogenizer, washed twice in phosphate buffered saline (PBS) and 
resuspended in Grace's insect cell culture medium (Life Technologies, Grand Island, NY) 
supplemented with 20% heat-inactivated FBS, 2 mM glutamine, lOOU/ml penicillin, and 100 
//g/ml streptomycin. A ten-fold serial dilution of the parasite suspension was then performed 
and incubated at 24°C for 8 days before parasite quantification was assessed. 
Vaccine. Bone marrow-derived dendritic cells (BM-DC) were cultured for 10 days in vitro in 
the presence of 10 ng/ml of murine GM-CSF (PeproTech Inc, Rocky Hill, NJ) according to a 
method from Lutz et al. (26). In each experiment, naïve mice were injected every other day 
for 12 days in their left hindfoot. Each injection consisted of 20/tg L. amazonensis Ag, 0.2pi g 
murine IL-12 (PeproTech Inc, Rocky Hill, NJ) and lxl06BM-DC resuspended in a total of 
25/d of PBS. Control mice were injected with 25/d of PBS. Three days after the last vaccine 
injection, some vaccinated mice were killed to determine the phenotype of the immune 
response induced by the vaccine and the remaining mice were infected with L. amazonensis 
as described above. 
Recall responses. Lymph node cell recall responses were performed as previously described 
(21). Supematants were harvested after 72 h, and IFN-y and IL-4 levels were determined by 
ELISA. Recombinant IFN-y (Pharmingen, San Diego, CA) and IL-4 (PeproTech Inc, Rocky 
Hill, NJ) were used on each ELISA plate to set up a standard curve. The lower detection limit 
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of the IFN-y ELISA ranged between 39 and 78 pg/ml; the lower detection limit of the IL-4 
ELISA was 39 pg/ml. 
Purification of CD4+ T cells. Lymph node cells were incubated with anti-CD4-coupled 
microbeads (Miltenyi Biotec, Auburn, CA) according to the manufacturer's protocol, 
followed by one passage through an autoMACS. The average purity of the cell preparation 
was 92%. 
Flow cytometry. Surface staining for CD4 and CD44, and intracellular staining for IFN-y 
were performed using commercially available antiobodies (Pharmingen, San Diego, CA) as 
previously described (22). Live events were gated based on forward scatter versus side 
scatter, and the CD4+ T cells from this live gate were further analyzed for their expression of 
CD44 and production of IFN-y. 
RT-PCR. Total RNA was extracted from CD4+ T cells using the Rapid Total RNA 
Purification System (Marligen Biosciences, Ijamsville, MD) according to the manufacturer's 
protocol. RNA concentration was measured spectrophotometrically; RNA samples were 
then treated with 1.5 U of DNase I (Pierce, Milwaukee, WI) per 1 ng of RNA for 45 min at 
37°C. Two pig of each DNase I-treated RNA sample was reverse transcribed in 80 pi\ 
reaction volumes using IX M-MLV reaction buffer (Promega, Madison, WI), 200 U M-
MLV reverse transcriptase (Promega, Madison, WI), 40 U RNase inhibitor (Applied 
Biosystems, Foster City, CA), 2.5 /iM random hexamers (Amersham Biosciences Corp, 
Piscataway, NJ) and 0.5 mM of each dNTP (USB Corporation, Cleveland, OH). RNA 
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samples and random hexamers were incubated together at 70°C for 3 min and room 
temperature for 10 min. The reverse transcription reaction was performed at 42°C for 1 hr; 
samples were then heated at 95°C for 5 min and incubated on ice for 10 min. Real-time PCR 
experiments were run on the ABI PRISM 5700 Sequence Detection System (Applied 
Biosystems, Foster City, CA). Each 50 /d reaction contained 1 }A of cDNA and IX 
ABsolute QPCR Mix (Abgene, Surrey, UK). Forward and reverse primers were used at 
either 300 or 350 nM (IDT, Coralville, IA) and TaqMan probes (labeled with the reporter dye 
F AM and the quencher dye TAMRA, Applied Biosystems, Foster City, CA) were used at 
either 75 or 100 nM. Primer pairs and probes were designed using Primer Express 1.5 
software (Applied Biosystems, Foster City, CA). The sequences of the Forward (F) and 
Reverse (R) primers for IL-12RJ32 (Genbank accession # U64199) were as follows: F: 
5 ' CTTCACTTCCGCATACGTTCAC3 ' andR:5 GCTCCCAGAAGCATTTAGAAAGTT3. 
The sequence of the IL-12R&2 probe was5 TCCCTCTTCCTCCGTGGGAC ATC A3. The 
sequence of the GAPDH primers (Genbank accession # M32599) were F: 
5 TGTGTCCGTCGTGGATCTGA3 andR:5CCTGCTTCACCACCTTCTTGA3. The 
GAPDH probe sequence was5 CCGCCTGGAGAAACCTGCCAAGTATG3. For 
quantitative analysis of gene expression, normalized to an endogeneous control, we used the 
standard curve method, which was detailed previously (15). Briefly, control cDNA samples 
were serially diluted to obtain standard curves for GAPDH cDNA and each target cDNA. 
For each assay, the resultant cycle threshold (Ct) values were plotted against the log ng input 
of RNA. For all experimental samples, the cDNA quantity for the target of interest was then 
determined from its standard curve and then normalized to the GAPDH control. 
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Statistical analysis. The statistical significance between different groups was determined by 
using a t-test. Differences were considered significant when p<0.05. 
Results 
Vaccination of naïve mice with L. amazonensis antigen-pulsed dendritic cells and IL-12 
induces a Thl response. Naïve female C3HeB/FeJ mice were subcutaneously injected in 
their left hind footpad every other day for 12 days with PBS or a vaccine composed of L. 
amazonensis Ag-pulsed BM-DC and IL-12 as described in Material and Methods. Three days 
after the last injection, some of the vaccinated mice were sacrificed and the cells from the 
popliteal DLN were plated in vitro for 72h with or without L. amazonensis Ag. As shown in 
Figure 1A, there was an antigen-specific production of IFN-y by DLN cells in response to L. 
amazonensis Ag, consistent with a Thl response. Furthermore, as the phenotype of the CD4+ 
T cells has been shown to correlate with the outcome of murine cutaneous leishmaniasis, we 
determined the effect of vaccination on the CD4+ T cell compartment. Although naïve and 
vaccinated mice both had similar percentages of CD4+ T cells in the lymph node draining the 
vaccinated foot, vaccinated mice had an increased percentage of CD4+ T cells expressing the 
memory/effector marker CD44 (Fig IB and data not shown). In addition, vaccinated mice 
had higher percentages of CD4+ CD44+ T cells producing IFN-y in comparison to naïve mice 
(Fig 1C). Furthermore, these CD4+ CD44+ T cells were the only CD4+ T cells producing IFN-
y during the in vitro re-stimulation with L. amazonensis Ag, further supporting their role as 
effector cells (Fig 1C). Finally, as another marker of Thl response, we determined by RT-
PCR the expression of IL-12Rp2 mRNA on the CD4+ T cells from the DLN of vaccinated 
mice in comparison to naïve mice. As shown in Figure ID, the vaccination with L. 
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amazonensis Ag pulsed BM-DC and IL-12 induced an increased expression of mRNA levels 
for IL-12R02 on the CD4+T cells from the DLN in comparison to naïve mice. Altogether, 
this indicates the vaccine induced a Thl response in vivo. 
The Thl response of vaccinated mice does not confer protection to a L. amazonensis 
challenge. Protection to L. amazonensis in mice has been shown to correlate with increased 
level of IFN-y produced in recall responses in vitro (6, 7,10, 31, 39). In addition, the 
adoptive transfer of Thl CD4+ T cells was recently shown to induce resistance to a 
subsequent L. amazonensis promastigote challenge (19, 32). Therefore, we hypothesized that 
the Thl response induced by L. amazonensis Ag-pulsed DC and IL-12 in naïve mice would 
promote protection against a L. amazonensis promastigotes infection. As indicated above, 
naïve mice were subcutaneously vaccinated in their left hind footpad every other day for 12 
days with L. amazonensis Ag-pulsed BM-DC and IL-12 or PBS as a control. Three days after 
the last injection, the mice were infected with 5xl06 L. amazonensis stationary phase 
promastigotes in their left hind footpad and the associated lesion size was measured weekly. 
As shown in Figure 2A, the size of the infected foot from vaccinated mice remained stable 
and significantly smaller than the one from control mice for 4 to 9 weeks. However, between 
week 5 and week 8 post-infection, depending on the experiment, the lesion size of the 
infected feet from vaccinated mice slowly increased to reach the size of infected feet from 
control mice (Fig 2A). In addition, we determined the parasite load of the L. amazonensis-
infected feet 10 weeks post-infection. As shown in Figure 2B, the infected feet of vaccinated 
and control mice contained similar numbers of parasites 10 weeks post-infection. Altogether, 
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this data indicates a failure of the vaccine to protect against a subsequent L. amazonensis 
challenge. 
Vaccine failure correlates with decreased production of IFN-y by DLN cells and 
decreased expression IL-12R(32 by CD4* T cells. Ten weeks post-L. amazonensis infection, 
the mice were sacrificed and the cells from the lymph node draining the infected feet were re-
stimulated in vitro with or without La Ag. While the levels of IL-4 secreted in the in vitro 
recall response from vaccinated and control mice were low to undetectable, DLN cells from 
vaccinated mice produced higher levels of IFN-y than control mice (Figure 3A). However, 
the absolute amounts of IFN-y secreted by the DLN cells of vaccinated mice 10 weeks post­
infection were drastically reduced in comparison to the levels produced before infection (see 
Fig 1A). In addition, the susceptible phenotype of vaccinated mice correlated with decreased 
levels of IL-12RP2 mRNA expression in CD4+ T cells. Indeed, CD4+ T cells from the DLN 
of vaccinated mice expressed levels of IL-12R|32 mRNA that were comparable to the ones of 
purified CD4+ T cells from either naive or L. amazonensis-infected control mice, as 
determined by RT-PCR (Figure 3B). 
Discussion 
Our data shows that the subcutaneous vaccination of naïve mice with L. amazonensis Ag-
pulsed dendritic cells and IL-12 does induce a Thl response in vivo, as evidenced by the Ag-
specific production of IFN-y in the draining lymph node. In addition, within the lymph node 
draining the vaccinated feet, there was an expansion of effector CD4+ T cells producing IFN-
y and expressing IL-12R|32 mRNA, a phenotype consistent with Thl CD4+T cells. However, 
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the vaccine did not mediate resistance to a subsequent L. amazonensis promastigote infection 
and both vaccinated and non-vaccinated control mice had similar lesion size and parasite 
load 10 weeks post-infection. This lack of protection is in contrast to recent data indicating 
that the intravenous adoptive transfer of L. amazonensis-sçecific Thl CD4+ T cells provided 
protection against a L. amazonensis promastigote challenge (19,32). These discrepancies 
may be explained by different numbers of effector CD4+ T cells or by qualitative differences 
in the Thl CD4+ T cells present before infection. In addition, the route of immunization may 
have had an impact on the efficiency of the protection. In particular, intravenous 
immunization has usually resulted in better resistance to a subsequent Leishmania spp. 
challenge (18,27). However, resistance has also been described after subcutaneous 
immunization (6, 8,12) and, in this study, the administration of the vaccine subcutaneously 
did skew the profile of the CD4+ T cells compartment towards a Thl phenotype, indicating 
that the vaccine could influence the immune response locally in the DLN and therefore 
suggesting that protection may have been achieved. 
The susceptibility of mice to L. amazonensis infection is characterized by the production 
of low levels of IFN-y in the in vitro recall response from the DLN (1,22) and the control of 
a L. amazonensis infection after vaccination with parasite Ag or DNA was previously shown 
to correlate with an increased production of IFN-y by DLN cells (6,7,31). This suggested 
that enhanced IFN-y levels in the recall response could be indicative of protection to a L. 
amazonensis challenge. In the present study, vaccinated mice failed to resist a L. 
amazonensis challenge despite an increased Thl response in the DLN 10 weeks post­
infection, as determined by the ratio of IFN-y and IL-4 secreted in the in vitro recall 
response. However, the absolute amounts of IFN-y detected in the in vitro re-stuimulation of 
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DLN from vaccinated mice were significantly decreased in comparison to the ones produced 
before the infection. This indicates that a Thl response, as determined by the ratio of IFN-y 
to IL-4 secreted, may not be indicative of protection during a L. amazonensis infection. 
Finally, the lack of protection after vaccination correlated with a decreased expression of 
the Thl marker IL-12R|32 by the CD4+ T cells from the DLN. Indeed, although the vaccine 
initially up-regulated IL-12R|32 on the CD4+ T cells from the DLN, this expression decreased 
over the 10 week course of infection to reach basal levels. The production of IL-12 and the 
maintenance of IL-12 responsiveness through the expression of IL-12R02 are crucial 
components of the immune response mediating protection to L. major (16,17, 20, 30). The 
sustained production of IL-12 is necessary to maintain effector/memory Thl cells (40) and 
the importance of a persistent source of IL-12 for a successful protection induced by previous 
DC-based vaccination has also been reported (34). Interestingly, there is evidence that L. 
amazonensis can limit the production of IL-12 by dendritic cells in vitro and ex vivo (22,33, 
41). Therefore, it is possible that the loss of IL-12R(52 by the CD4+ T cells and the ultimate 
failure of our vaccine to promote resistance to L. amazonensis infection resulted from a 
suboptimal source of IL-12. 
In conclusion, our study shows that the Thl response induced by a DC-based vaccine was 
not effective at promoting resistance to a L. amazonensis infection. Furthermore, it indicates 
that the presence of Thl CD4+ T cells cannot be considered as a reliable indicator of 
protection to a subsequent L. amazonensis challenge. It reinforces the thought that the 
pathogenesis caused by members of the L. mexicana complex, including L. amazonensis, is 
different from the one induced by L. major and subsequently, that the immune factors 
necessary to promote resistance to one Leishmania sp. may not be applicable to other 
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Leishmania spp. (9). In addition, it is possible, as previously reported, that effector cell types 
other than CD4+ T cells, i.e. CD8+ T cells, are required to induce successful protection to L. 
amazonensis infection (10). This should be taken into consideration when designing future 
vaccine strategies. 
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Figure 1. Vaccination with L. amazonensis antigen-pulsed BM-DC and IL-12 induces Thl 
CD4+ T cells in vivo. Naïve C3H mice were subcutaneously vaccinated with L. amazonensis 
antigen (La Ag) -pulsed BM-DC and IL-12 in their left hindfoot as described in the Materials 
and Methods. Three days after the last vaccination, the mice were sacrificed and the popliteal 
draining lymph nodes (DLN) were harvested. (A): 1 x 106 DLN cells from vaccinated mice 
were plated in vitro with or without La Ag for 72h, and the levels of IFN-y from the culture 
supematants were determined by ELISA. The data shown is the mean ± SEM from 6 
independent experiments. (B) The percentages of CD4+ T cells expressing the 
memory/effector marker CD44 in the DLN from both naïve and vaccinated mice were 
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determined ex vivo by flow cytometry. The data shown is the mean + SEM from 4 
independent experiments. (C) DLN cells were plated with La Ag as in (A) for 24h and then 
surface stained for CD4 and CD44. The cells were subsequently stained for intracellular IFN-
y and analyzed by flow cytometry. Live events were gated based on forward scatter versus 
side scatter and the percentages of CD4+ T cells producing IFN-y were determined (see inset 
quadrant). The data shown is from 1 experiment representative of 2 independent experiments. 
(D) The levels of IL-12Rf32 mRNA expressed in purified CD4+ T cells from the DLN of both 
naïve and vaccinated mice were determined by RT-PCR as described in the Materials and 
Methods. The values shown represent the ratio between of IL-12R|32 mRNA and the 
housekeeping gene mRNA control GAPDH. The data shown is the mean ± SEM from 4 
independent experiments. * Indicates a statistically significant difference between the groups 
(p<0.05). 
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Figure 2. Vaccinated mice are not protected against a subsequent L. amazonensis infection. 
Naive C3H mice were subcutaneously vaccinated with La Ag -pulsed BM-DC and IL-12 in 
their left hindfoot as in Figure 1. (A) Three days after the last vaccination, the mice were 
subcutaneously infected with 5 x 10* stationary phase L. amazonensis promastigotes in their 
left hindfoot (open circles). At the time of infection, naïve C3H mice were also infected with 
5 x 106 stationary phase L. amazonensis promastigotes as controls (closed triangles). Lesion 
size was monitored weekly as described in the Materials and Methods. The data presented is 
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from one experiment representative of 4 independent experiments; the values shown are the 
mean ± standard deviation. (B) Ten weeks post-infection, vaccinated and naïve mice were 
killed and the parasite loads from the infected feet were determined as described in the 
Materials and Methods. The data shown is the mean ± SEM from 4 independent experiments. 
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Figure 3. Vaccine failure occurred despite a Thl cytokine profile in the DLN but decreased 
IL-12R(32 mRNA expression in purified CD4+ T cells from the DLN. C3H mice were 
vaccinated or not and infected with L. amazonensis as in Figure 2. Ten weeks post-infection, 
the mice were killed and the DLN harvested. (A) 1 x 106 DLN cells from vaccinated and 
control mice were plated in vitro with L. amazonensis antigen for 72h, and the levels of IFN-
Y and IL-4 within the culture supernatants were determined by ELISA. The data shown is the 
mean ± SEM from 4 independent experiments. * Indicates a statistically significant 
difference (p<0.05). (B) The levels of IL-12R(32 mRNA expressed in purified CD4+ T cells 
from the DLN of naïve (naïve mice), vaccinated-infected (vaccinated mice) and L. 
amazonensis-infected control (control mice) mice were determined by RT-PCR as described 
in the Materials and Methods. The values shown represent the ratio between of IL-12RJ32 
mRNA and the housekeeping gene mRNA control GAPDH for each group of mice. The data 
shown is the mean ± SEM from 3 independent experiments. 
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Abstract 
The Thl response elicited in mice infected with L. major has been used as a model to 
characterize cellular immune defects associated with L. amazonensis infection. However, it is 
not known if the immune response associated with the infection by virulent L. major 
parasites can promote resistance to a subsequent L. amazonensis infection. Our data 
demonstrate that C3HeB/FeJ mice infected subcutaneously with virulent L. major are 
resistant to a L. amazonensis challenge. The healing phenotype is characterized by a Thl 
response as measured by increased IFN-y production and low levels of IL-4 in the draining 
lymph node. Altogether, this indicates that the Thl response associated with L. major 
infection can promote resistance to L. amazonensis infection and that it can be used as a tool 
to study the immune defects associated with L. amazonensis infection. 
Introduction 
Leishmaniasis is a zoonotic disease caused by protozoa of the genus Leishmania, which 
are transmitted to the host through the bite of an infected sandfly. The disease is 
characterized by a variety of clinical manifestations, depending on the Leishmania species 
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involved and the type of immune response mounted by the host.1-2 Leishmania major and 
Leishmania amazonensis are both associated with the cutaneous form of the disease: the 
lesions induced by L. major are typically localized and self-healing while the ones caused by 
L. amazonensis can become diffuse and chronic, sometimes affecting mucous membranes.1,3 
Mouse models of leishmaniasis have helped to uncover some of the immune factors involved 
with resistance and susceptibility to the disease. For example, while C3H and C57BL/6 mice 
are resistant to L. major, they are susceptible to L. amazonensis. Resistance and susceptibility 
to L. major are mediated by Thl and Th2 immune responses, respectively.4 The susceptibility 
to L. amazonensis is thought to result from an inability to mount a Thl response.5"9 In 
particular, it has been shown that the CD4+ T cells from L. amazonensis-infected mice have 
defective expression of several cytokine and chemokine receptors in comparison to the CD4+ 
T cells from L. mayor-infected mice.6'9 However, while the immune response to L. major 
infection is used as a model in this experimental system of murine cutaneous leishmaniasis, it 
is not known if the Thl response elicited by L. major in vivo would provide protection to a 
subsequent L. amazonensis infection. In fact, it has been reported that even after exogenous 
administration of IL-12 or in the absence IL-10 or IL-4, mice still develop chronic cutaneous 
lesions upon L. amazonensis infection.6,7,9,10 However, in mouse studies using L. major, the 
administration of IL-12 or anti-IL-4 or the absence of IL-10 was associated with disease 
control.11"14 Therefore, it is possible that the immune response necessary to promote 
resistance to L. amazonensis may not be the same as that for L. major. 
Cross-protection between different Leishmania species using either Leishmania antigens, 
attenuated parasites or live Leishmania promastigotes have been previously described in 
mice,15"30 monkeys,31"33 and humans.32,34 However, the effectiveness of cross-protection 
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reported in the literature is variable and several studies have reported its failure, depending 
on the experimental design and/or the Leishmania spp. involved.I5 17-20-32-34-35 Furthermore, the 
cross-protection induced in mice by a previous Leishmania infection does not necessarily 
correlate with complete healing. In contrast, it is sometimes associated with the persistence 
of a smaller lesion or even a slower progressing lesion than the control mice.18,21,29 Finally, 
the route of immunization appears to have an influence on the subsequent protection, and 
subcutaneous immunization has provided variable degrees of resistance.18,25 In particular, one 
mouse study has reported efficient protection to L. amazonensis after a subcutaneous 
infection with an avirulent strain of L. major}5 However, the study did not characterize the 
associated immune response nor was parasite quantification determined. 
Our data indicate that the Thl response developed by C3HeB/FeJ mice after infection 
with wild-type L. major promastigotes does promote resistance to a L. amazonensis 
challenge, as determined by the development of a transient lesion and decreased parasite 
load. To our knowledge, the present report is the first to determine the effectiveness of cross-
protection using an infectious challenge composed of as much as 5x10* L. amazonensis 
promastigotes and using the subcutaneous route of immunization. Altogether, our data also 
confirms that the immune response associated with L. major infection is a good model for the 
study of the immune defects associated with L. amazonensis infection. 
Materials and Methods 
Parasites. Culture of L. amazonensis (MHOM/BR/OO/LTBOO16) or L. major 
(MHOM/IL/80/Friedlin) parasites and the preparation of parasite Ag were performed as 
previously described.7 Parasite quantification was determined when the mice had healed their 
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L. amazonensis infection, i.e. 10 to 12 weeks post-L. amazonensis challenge. For the parasite 
quantification from cutaneous lesions, the infected feet were disinfected with 70% ethanol 
and the skin was dissected away. The remaining subcutaneous lesion was homogenized using 
a Tenbrock tissue homogenizer, washed twice in PBS and resuspended in 2 ml of Grace's 
insect cell culture medium (Life Technologies, Grand Island, NY) supplemented with 20% 
heat-inactivated FBS, 2 mM glutamine, 100U/ml penicillin, and 100 pig/ml streptomycin. A 
ten-fold serial dilution of each parasite suspension was then performed in triplicate and 
incubated at 27°C for 8 days before parasite quantification was assessed. The lower detection 
limit of our quantification assay was 102 parasites per foot, and when parasite numbers were 
lower than the detection limit a value of 10 was given to the sample. 
Mice. C3HeB/FeJ mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) 
and bred in a specific-pathogen-free facility . The Committee on Animal Care at Iowa State 
University approved all protocols involving animals. Five to eight week old mice (3 to 6 
mice per group) were inoculated subcutaneously with 5 x 10* stationary-phase L. major 
promastigotes in their left hindfoot. Eleven to fifteen weeks later, when mice have healed 
their primary L. major infection, the mice were infected subcutaneously with 5 x 106 
stationary-phase L. amazonensis promastigotes in their right hind footpad. Lesion size of the 
footpads was monitored weekly with a dial micrometer (L.S. Starrett Co., Athol, MA), and 
the results were expressed as the difference between the thickness of the right and left hind 
footpads. After infection with L. amazonensis, the thickness of the left feet (those that had 
healed a previous L. major infection) remained stable. 
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Recall responses. The cells from the popliteal lymph node draining the L. amazonensis-
infected feet were obtained at 10 to 12 weeks after L. amazonensis infection and recall 
responses were performed as previously described.7 The cells were incubated with medium 
containing 50 ng of L. amazonensis antigen/ml with or without lng/ml of recombinant 
murine IL-12 (PeproTech Inc, Rocky Hill, NJ). Supematants were harvested after 72 h, and 
IFN-y and IL-4 levels were determined by ELISA. Recombinant IFN-y (Pharmingen, San 
Diego, CA) and IL-4 (PeproTech Inc, Rocky Hill, NJ) were used on each ELISA plate to set 
up a standard curve. The sensitivity of the IFN-Y ELISA ranged between 39 and 78 pg/ml; 
the sensitivity of the IL-4 ELISA was 39 pg/ml. All ELISA were performed with 
commercially available antibodies (Pharmingen, San Diego, CA), peroxidase-conjugated 
streptavidin (Jackson ImmunoResearch Laboratories, West Grove, PA) and ABTS microwell 
peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) following the 
manufacturer instructions. 
Results 
Mice infected with L. major are resistant to a subsequent L. amazonensis infection. 
C3HeB/FeJ mice were infected subcutaneously in their left hind footpad with 5 x 106 L. 
major stationary phase promastigotes. The resulting lesion consisted of a discrete cutaneous 
nodule that occasionally ulcerated and consistently healed over the following 11 to 15 weeks 
(data not shown). At these timepoints, the mice were re-infected subcutaneously with 5 x 106 
L. amazonensis stationary phase promastigotes in their right hind footpad and the associated 
lesion size was measured weekly. As a control, naïve mice were also infected with 5 x 106 L. 
amazonensis stationary phase promastigotes in their right hindfoot. As shown in Figure 1, 
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control mice infected with L. amazonensis developed chronic lesions, whereas in mice 
previously infected with L. major, the L. amazonensis lesion was transient and healed in 10 
to 12 weeks. The chronic lesion of L. amazonensis-infected mice contained an average of 107 
parasites (Fig. 2). In contrast, the healing response of mice infected with L. major and 
subsequently with L. amazonensis was associated with a significant decrease in parasite load 
(Fig. 2). 
Resistance to L. amazonensis infection is associated with an enhanced Thl response 
within the draining lymph node. In each experiment the mice were sacrificed at ten to 
twelve weeks after L. amazonensis infection, a time at which the associated cutaneous lesion 
had resolved. The cells from the draining lymph node were cultured in a 3 day recall 
response with or without L. amazonensis antigens and the levels of IL-4 and IFN-y were 
determined in the culture supematants. While lymph node cells from both groups of mice 
produced low to undetectable amounts of IL-4, mice sequentially infected with L. major and 
L. amazonensis produced significantly higher levels of IFN-y than the L. amazonensis-
infected control mice (Fig. 3A). The levels of IFN-y detected were similar whether L. 
amazonensis or L. major antigens were present during the 3 day recall response (4.5 ±1.0 
ng/ml and 5.9 ±1.5 ng/ml with L. amazonensis and L. major antigens, respectively). To 
further determine the phenotype of the healing immune response, we also determined the IL-
12 responsiveness of the cells from the draining lymph node by measuring the levels of IFN-
y produced in vitro in response to L. amazonensis antigen and recombinant murine IL-12. IL-
12 responsiveness is a marker of Thl responses and as shown in Figure 3B, draining lymph 
node cells from mice sequentially infected with L. major and L. amazonensis produced 
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significantly more IFN-y than the L. amazonensis-infected control in response to IL-12. 
Altogether, these data indicate that the healing phenotype observed in co-infected mice is 
associated with an increased Thl response at the level of the draining lymph node. 
Discussion 
The Thl immune response elicited after L. major infection has been used as a model to 
describe T cell defects associated with L. amazonensis infection.6,9 However, whether the 
immune response of L. major-infected mice represents an appropriate model to study L. 
amazonensis infection, i.e. if the Thl response of mice infected with virulent L. major would 
promote resistance to a subsequent L. amazonensis infection, is not known. Our data indicate 
that mice previously infected with virulent L. major were able to control a L. amazonensis 
infection, characterized by lesion resolution and a decreased parasite load (Fig. 1 & 2). The 
healing phenotype was associated with a Thl response as determined by low levels of IL-4 
and high levels of IFN-y in the in vitro recall response from the draining lymph node (Fig. 
3A). This is consistent with previous studies in which the vaccination of mice with parasite 
antigen or DNA, with or without an adjuvant, was shown to promote resistance to L. 
amazonensis infection.24,27"29,36"38 When determined, the healing response following 
vaccination correlated with increased production of IFN-y in the draining lymph node, the 
spleen or at the lesion site.24,27"29,37 Furthermore, the adoptive transfer of L. amazonensis-
specific Thl cells into C3H mice was recently shown to promote resistance to subsequent L. 
amazonensis infection.9 Altogether, this demonstrates that resistance to L. amazonensis 
infection can be associated with a Thl response. IL-12 responsiveness is another marker of 
Thl responses that was reported to correlate with the potential of mice to heal Leishmania 
infection.39"41 Therefore, the increased IL-12 responsiveness of DLN cells from mice with L. 
major and subsequently with L. amazonensis further supports the Thl phenotype of their 
healing response (Fig. 3B). 
Previous studies have shown that the exogenous administration of the Thl cytokines IL-
12 or IFN-y was not able to promote resistance to L. amazonensis.6'*2 In addition, the 
neutralization or the absence of IL-4 or IL-10, respectively could not restore resistance to L. 
amazonensis.6,7,9,10 Altogether, this suggests that these cytokines are not, by themselves, 
altering the course of L. amazonensis infection. Rather, resistance may require an array of 
immune factors that the L. mayor-induced immune response, as a whole, can provide. This 
would also suggest that some elements of a parasite-specific immune response may be 
needed prior the L. amazonensis challenge in order to provide protection. Our data confirm 
that the immune factors necessary to promote resistance to L. amazonensis are present after a 
L. major infection. Finally, our data also support a previous study suggesting that 
subcutaneous vaccination may be effective in promoting resistance to L. amazonensis 
infection,25 even in an experimental system using a high dose challenge. 
In conclusion, our data show that the Thl response of C3HeB/FeJ mice infected with L. 
major is able to promote protection to a subsequent L. amazonensis challenge. Although 
leishmanization has been currently abandoned, this co-infection model confirms that the 
immune response developed after L. major infection is a good model to study the defects 
associated with L. amazonensis infection. This model will allow us to better understand and 
define the immune factors necessary or sufficient to promote resistance to L. amazonensis. 
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Figure 1. Previous L. major infection provides protection to a subsequent L. amazonensis 
infectious challenge. C3HeB/FeJ mice were infected with 5 x 106 L. major stationary phase 
promastigotes in the left hind footpad. When the mice had healed their L. major infection, 
they were re-infected with 5 x 10* stationary phase L. amazonensis promastigotes in their 
right hind footpad, as described in the Material and Methods. The lesion size of the L. 
amazonensis-infected feet was measured over time after the re-infection. Mice sequentially 
infected with L. major and then L. amazonensis (Lm - La) developed transient lesions in 
comparison to L. amazonensis-infected control mice (La control). The values shown are the 
mean + standard deviation from 1 experiment (5 mice per group) representative of 5 
independent experiments. 
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Figure 2. The healing response of mice sequentially infected with L. major and then L. 
amazonensis (Lm -La) correlated with a significant decrease in parasite load. The number of 
parasites within the L. amazonensis-infected feet of Lm - La mice or L. amazonensis-infected 
controls (La control) was determined 10 to 12 weeks after L. amazonensis infection. * 
Indicates a significant statistical difference (p<0.05, t-test). The values shown are pooled 
from 5 independent experiments and expressed as the mean ± SEM. 
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Figure 3. The cytokine profile of the draining lymph node (DLN) of mice sequentially 
infected with L. major and L. amazonensis (Lm - La) is consistent with a Thl response. Mice 
were infected as described in Material and Methods. Ten to twelve weeks post L. 
amazonensis infection, DLN cells were plated in vitro with L. amazonensis antigens with or 
without IL-12 for 3 days and the total amounts of IFN-y (closed histograms) and IL-4 (open 
histograms) were measured in the culture supematants. A: Both L. amazonensis-infected 
control mice (La control) and Lm-La mice produced low to undetectable levels of IL-4. 
However, Lm-La mice produced significantly more IFN-y than control mice. * Indicates a 
significant statistical difference (p<0.05, t-test). B: When IL-12 is added to the in vitro cell 
cultures, DLN cells from Lm-La mice produced more IFN-y than La control mice. The 
values shown are pooled from 5 independent experiments and expressed as the mean ± SEM. 
187 
CHAPTER 5: General Conclusions 
In experimental studies of L. major, the protective role of Thl CD4+ T cells is widely 
recognized. In mice infected with L. amazonensis, the impaired Thl response has been 
shown to correlate with CD4+ T cells defects such as an impaired expression of IL-12R|32. 
The intravenous adoptive transfer of Thl CD4+ T cells was also recently shown to promote 
protection against a subsequent L. amazonensis promastigote, but not amastigote, challenge. 
We have shown here evidence, under 2 different experimental designs, i.e. 
immunotherapy and vaccine, that the presence of Thl CD4+ T cells is not sufficient to 
mediate protection to L. amazonensis. In our immunotherapy studies, the high numbers of 
amastigotes present during the chronic L. amazonensis infection may have limited the 
effectiveness of the Thl CD4+ T cells induced by the DC-based treatment. Indeed, L. 
amazonensis amastigotes have been shown to impair DC responses, including the production 
of the Thl cytokine IL-12. As a result, although the CD4+ T cells of mice that received the 
immunotherapy did upregulate their expression of the Thl marker IL-12R|32, it is possible 
that the potentially protective immune response was now limited by the lack of available IL-
12. Our data would support this hypothesis and would confirm the thought that during a L. 
amazonensis infection, not only the T cell response is impaired but also the APC response. If 
both T cells and DC are defective, it would be interesting to understand which defect 
occurred first. In fact, it is tempting to hypothesize that during the priming of T cell 
responses, the DC exert some imprinting function on the naïve T cells. As a result, this would 
suggest that if some functional pathways are defective in the DC, the T cells interacting with 
those particular defective DC will subsequently be defective in those same pathways. In fact, 
our immunotherapy studies could support such hypothesis. Indeed, the DC-based 
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immunotherapy contained appropriate APC that could effectively prime T cells toward a Thl 
phenotype. However, the injected DC did not likely persist very long in the draining lymph 
node and T cells subsequently had to interact with the defective, pre-existing host DC again. 
This could explain why the efficiency of the T cell response remained limited. Future studies 
will be needed to better understand what the APC defects are and how they could be 
overcome. Finally, despite the failure to promote protection, the fact that our DC-based 
immunotherapy was able to modulate and polarize the immune response of mice with 
established chronic cutaneous lesions provides hope for future therapeutic strategies aimed at 
modulating the immune response, either in this infectious model or in chronic diseases 
caused by other intra-cellular pathogens. 
Our vaccine studies were designed to test if the failure of the immunotherapy was mainly 
mediated by the high parasite loads present during chronic infection. Our hypothesis was that 
the Thl response elicited by Ag-pulsed BM-DC and IL-12 as a vaccine instead of an 
immunotherapy would promote protection against a subsequent L. amazonensis challenge. 
However, to our surprise, the Thl CD4+T cells induced by the vaccine did not confer 
resistance to a L. amazonensis infection. This is in contrast to a study in which the 
intravenous adoptive transfer of L. amazonensis-sptciTxc Thl CD4+T cell lines promoted 
protection against a subsequent promastigote challenge. Several hypotheses may account for 
these discrepancies. First, it is possible that the DC-based vaccine from our study did not 
prime a central memory response as effectively as the adoptive transfer of CD4+ T cells. This 
seems unlikely as the subcutaneous injection of Ag-pulsed BM-DC and IL-12 did induce a L. 
amazonensis Ag-specific Thl response in the spleen. Second, the numbers of Thl CD4+ T 
cells induced by our vaccine was probably lower than the high numbers that were adoptively 
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transferred i.v. Finally, qualitative differences between the Thl CD4+ T cells from the 
vaccine and the adoptive transfer may explain the different disease outcome observed. In 
particular, in our experimental system, the expression of IL-12R|32 may not be as indicative 
of an efficient Thl response as in the mouse models of L. major infection. In addition, the 
qualitative differences in the Thl CD4+ T cells may account for differences in other cell 
subsets. In particular, it has been recently shown that adequate CD8+ T cell responses 
required the presence of efficient CD4+ T cells. Therefore, it is possible that in our system, 
the Thl CD4+ T cells resulting from vaccination did not stimulate adequate CD8+ T cell 
responses. In conclusion, a more in depth characterization of the CD4+ T cells induced by the 
vaccine is needed. In addition, it would be useful to compare them to Thl CD4+ T cells that 
can mediate protection to a L. amazonensis infection. 
As a result, we thought that it would be useful to design an experimental system 
(different from the artificial intravenous transfer of high numbers of Ag-specific cells) in 
which mice could resist a L. amazonensis challenge. In particular, as the immune response 
elicited by L. major is used as a model to characterize the immune defects associated with a 
L. amazonensis infection, it was of interest to determine if mice infected with L. major could 
resist a L. amazonensis challenge. As shown in our third study, mice that have healed a L. 
major infection can heal a subsequent L. amazonensis infection. This confirms that it is 
appropriate to use the Thl response associated with L. major infection to study the defective 
response of L. amazonensis-infected mice. In addition, this model provides a useful tool to 
determine which immune factors are necessary to promote resistance to L. amazonensis. In 
particular, we are currently undertaking experiments aimed at determining which cell 
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subset(s) from the L. major-infected mice can promote protection to a subsequent L. 
amazonensis challenge. 
In conclusion, our data challenge dogma and indicate that the presence of Thl CD4+ T 
cells is not always indicative of protection to a L. amazonensis infection. It further supports 
the thought that the immune response necessary to heal a L. amazonensis infection may not 
have the same requirements as the one that mediates protection to a L. major challenge. In 
addition, our model of sequential infection with L. amazonensis and L. major will help us 
determine the immune factors that can mediate protection to L. amazonensis infection. 
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